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i 
Abstract 
Cellular therapies targeted at stimulating therapeutic angiogenesis in individuals with critical 
limb ischemia (CLI) have been under intense investigation. Hematopoietic progenitor cells 
(HPC) derived from umbilical cord blood have been previously shown to support limb 
revascularization in animal models of CLI, despite limited cell survival at the site of 
ischemia. This study attempted to improve HPC survival after transplantation and prolong 
pro-angiogenic function using human decellularized adipose tissue (hDAT) as a novel cell 
delivery platform. Compared to HPC conventionally grown on tissue-cultured plastic, hDAT 
scaffolds were shown to promote viability and proliferation of seeded HPC, and had cell-
instructive effects on HPC differentiation through increased expression of cell surface 
markers enriched on the monocyte/macrophage lineage. For in vivo transplantation studies in 
a surgically-induced model of CLI, hDAT-seeded scaffolds promoted an accelerated and 
sustained recovery in limb perfusion, improved functional limb use and increased CD31+ 
capillary density compared to unseeded hDAT controls.  
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ii 
Summary for Lay Audience 
Peripheral artery disease (PAD) caused by the accumulation of atherosclerotic plaque in the 
distal extremities places an immense burden on national healthcare organizations. Individuals 
with large end-stage occlusions typically present with symptoms such as gangrene, pain at 
rest and non-healing ulcers and are commonly diagnosed with the most severe form of PAD 
known as critical limb ischemia (CLI). Due to a lack of effective treatment options, many 
patients require lower limb amputation to relieve symptoms and prevent mortality. 
Fortunately, cellular therapies aimed at stimulating new blood vessel growth and reducing 
amputation rates have been under intense investigation as an alternative treatment for CLI. 
Umbilical cord blood (UCB) has been found to contain a rare population of hematopoietic 
progenitor cells (HPC) that have demonstrated robust regenerative abilities when utilized in 
animal models of CLI. However, due to the harsh environment that the cells were being 
introduced into, cell survival and retention at the site of injection remained low. This project 
aimed to improve HPC survival and retention using a novel cell delivery bioscaffold derived 
from human adipose tissue commonly discarded as surgical waste. The adipose-derived 
bioscaffolds were shown to increase HPC survival and proliferation in vitro, and were shown 
to induce HPC differentiation towards mature cell populations involved in tissue repair. 
When translated into a relevant animal model of CLI, HPC delivered within the adipose 
tissue-derived bioscaffold facilitated increased limb blood flow and improved functional 
metrics of limb use. Overall, these studies aimed to provide pre-clinical proof of concept for 
improved cell therapies harnessing cell supportive biomaterials for CLI. 
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Chapter 1 
1 Introduction 
1.1 Cardiovascular biology 
The human body possesses a complex cardiovascular system consisting of the heart and 
vascular network that delivers essential nutrients, maintains oxygen saturation and removes 
waste products from metabolically active tissues. Oxygenated blood is delivered to all tissues 
in the body through a dynamic vascular system consisting of an intricate hierarchy of 
arteries, capillaries and veins.3, 4 The arterial and venous components of this vascular 
hierarchy have a well-defined and unique histology made up of the tunica adventitia, tunica 
media and tunica intima.3 The tunica adventitia is the outermost layer of the vessel that is 
primarily composed of many fibro-elastic fibers that provide the vessel with structural 
integrity and elasticity.5 The tunica media is the middle layer of the vessel that is comprised 
of highly organized smooth muscle cells (SMCs) and elastin fibers.6 This region is 
responsible for changes in vessel tone and plays an important role in regulating systemic 
blood flow. The tunica intima consists of a single layer of luminal endothelial cells connected 
to a structurally supportive basement membrane.7  
Due to varying blood flow kinetics and the unique physiological roles of different blood 
vessels, the cellular and molecular compositions of all three layers are histologically distinct 
at each level of the vascular hierarchy. The aorta and large arteries contain greater amounts 
of elastic tissue in the tunica adventitia to withstand the large changes in blood volume and 
pressure delivered from the left ventricle.3 As these larger arteries bifurcate into smaller 
arteries and arterioles, the muscular composition of the tunica media increases to moderate 
the velocity of the blood and selectively divert it to fragile capillary beds.8 Returning to the 
heart, deoxygenated blood passes through the capacitive venous system, characterized by the 
presence of flow-directing valves and decreased fibro-connective and muscular tissue in the 
tunica adventitia and tunica media, respectively.3 
1.1.1 The endothelium 
The endothelium is an interconnected single cell layer that lines the lumen of blood vessels 
and is surrounded by stabilizing mural cells. Besides the endothelium’s fundamental role as 
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the interface between the blood and tissue compartments, it has also been shown to be 
centrally involved in the regulation of circulatory hemodynamics through vessel-dependent 
modifications in permeability, vasomotor tone and blood fluidity.9-11 Systemically, the 
endothelium has also been shown to modulate the immune system through the upregulation 
of cell adhesion molecules in response to inflammatory cytokines released by damaged 
tissue.12 Adhesion molecules bind circulating monocytes and initiate a transmigratory 
cascade that leads to the extravasation of monocytes into the extravascular space.13-15 Once 
monocytes are recruited to the damaged tissue, they differentiate into macrophages and 
dendritic cells that mediate the progression or resolution of tissue inflammation.16-18 
There is substantial endothelial heterogeneity in the endothelial cell populations throughout 
the vascular system that accommodate for the diverse roles the endothelium plays in a variety 
of physiologic processes.19 In the arterial system, endothelial cells primarily act to regulate 
blood flow and are structurally capable of withstanding high blood velocities and pressures. 
In particular, endothelial cells in the arterial system are bound together by a higher frequency 
of tight junctions and organize themselves along the longitudinal axis of the vessel.20, 21 To 
mediate changes in vascular tone, endothelial cells actively communicate with smooth 
muscle cells in the tunica media through a variety of secreted molecules and contact-
dependent signals.22, 23 Most prominently, endothelial cells demonstrate the capacity to 
rapidly regulate vasomotor tone in response to high shear stress through nitric oxide (NO) 
synthesis and release.10 In capillaries, the endothelium primarily facilitates the exchange of 
oxygen, nutrients and metabolic waste between the blood and tissue compartments.24 Each 
capillary is made up of a single layer of endothelial cells surrounded by a thin basement 
membrane and specialized support cells, called pericytes.25 Pericytes function to regulate 
capillary blood flow and guide endothelial cell differentiation and proliferation via gap 
junction and paracrine signaling.25-27 Through reciprocal communication between the 
endothelium and surrounding mural cells, vascular homeostasis is maintained in response to 
changing hemodynamic and chemical signals. In the venous system, endothelial cells have 
fewer tight junctions and predominantly function in leukocyte trafficking.28  
In patients with chronic inflammatory diseases affecting the cardiovascular system, elevated 
blood glucose and lipid levels promote systemic endothelial dysfunction via aberrant 
signaling between the endothelium, hematopoietic cells and surrounding mural cells. As a 
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result, monocyte recruitment is accelerated, leading to the pathological accumulation of 
monocyte-derived macrophages, release of pro-inflammatory cytokines and activation of 
apoptotic cascades within the vessel wall.29 
1.2 Cardiovascular disease 
Cardiovascular disease (CVD) is a very common disease classification that encompasses a 
wide range of pathologies affecting the heart and vascular system.30, 31 The most prominent 
forms of CVD are ischemic heart disease, cerebrovascular disease, peripheral vascular 
disease and hypertensive heart disease.31 Despite rapid improvements in prevention, 
diagnosis and treatment, CVD remains the leading cause of premature death globally, 
attributable to over 17 million deaths each year.31 This staggering number accounts for 31% 
of the total global all-cause mortality and is forecasted to grow as CVD frequencies in low 
and middle income countries increase at very high rates, despite decreases in frequencies 
being recorded in higher income countries.31, 32 As a result, CVD places an immense burden 
on national healthcare agencies and is estimated to comprise 17% of all medical expenditures 
in the United States—a total of $270 billion per year.33, 34 
1.2.1 Atherosclerosis 
One of the defining etiologies responsible for CVDs is a chronic inflammatory condition 
affecting blood vessels known as atherosclerosis.30, 31, 35 Atherosclerosis is characterized by 
the chronic accumulation of lipid-laden plaque within the arterial intimal layer leading to 
luminal narrowing of major arteries and drastic reductions in oxygen-rich blood flow to 
target organs. In the most advanced and severe cases of atherosclerosis, fibrous plaques can 
rupture and release prothrombotic material into the circulation. This material rapidly 
coagulates to form an atherothrombotic blockage with the potential to travel distally before 
lodging in a narrower vessel.35 
Risk factors that contribute to atherogenesis within the arterial tree include dyslipidemia, 
hypertension, inflammation, smoking, physical inactivity and diabetes.30, 35 Although the 
exact mechanism regarding atherogenesis initiation remains controversial, it is suggested that 
local hemodynamic forces play a crucial role following observations that atherosclerosis 
predominantly occurs in arterial regions of where laminar flow is disrupted, such as branch 
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points and bifurcations.36 It is hypothesized that endothelial cells in these regions are affected 
by low shear stress and perturbations in the laminar flow that result in poor endothelial cell 
alignment, an increase in the endothelial layer permeability and alterations to the 
subendothelial extracellular matrix (ECM).36-38 
These modifications cumulatively lead to the subendothelial deposition of circulatory low-
density lipoproteins (LDL) in the arterial intima layer.38 Following sustained LDL 
deposition, the LDL particles are modified by myeloperoxidases or lipoxygenases released 
from resident inflammatory cells, or oxidized by reactive oxygen species in the inflammatory 
environment. Oxidized LDL particles aggregate together, forming an immunogenic material 
that induces the release of inflammatory cytokines from tissue resident macrophages and 
subsequently activates adjacent endothelial cells. Activated endothelial cells upregulate the 
expression of adhesion molecules on the luminal surface, which attracts and binds circulating 
leukocytes, such as monocytes and T-cells, facilitating migration into the vessel        
intima.35, 39-41 Following migration, macrophages phagocytose the LDL particles present in 
the intimal matrix and become lipid-laden foam cells.29 
As macrophages and other immune cells continue to migrate into the lesion and amplify 
lipoprotein retention, smooth muscle cells (SMC) from the tunica media migrate to the lesion 
site, proliferate, and secrete large amounts of collagen and elastin to form a fibrous cap.42 
Continued accumulation of LDL particles and mononuclear immune cells ultimately leads to 
the formation of an inflammatory necrotic core, as macrophages become apoptotic and are 
not effectively cleared from the plaque.29, 42, 43 Advanced atherogenic lesions (i.e. vulnerable 
plaques) have the potential to undergo fibrous cap thinning and plaque rupture, leading to 
acute atherothrombotic events such as myocardial infarction or stroke, or may progress into 
stenoses that chronically reduce blood flow to downstream capillary beds.40 
1.2.2 Peripheral artery disease 
Peripheral artery disease (PAD) affects over 200 million people worldwide, and costs 
national healthcare organizations billions of dollars annually.44-46 PAD is initiated by the 
accumulation of atherosclerotic plaque in the peripheral arteries, with severe plaques causing 
narrowing of the arteries and dramatic reductions in blood flow to the distal extremities. 
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Occlusions most frequently occur in the superficial femoral, iliac and/or tibialis posterior 
arteries, reducing the supply of oxygen-rich blood to tissue downstream of the occlusion.47 
Patients typically remain asymptomatic due to the extensive collateral vessel network in the 
distal limbs, with symptoms only appearing when the reduction in collateral blood flow 
surpass the oxygen demands of the downstream tissues.48 This typically occurs when luminal 
occlusion exceeds 50% but varies among patients depending on the location of the plaque 
and extent of vessel collateralization in the limb.48 As the luminal occlusion increases in size, 
collateral arterioles dilate as a compensatory response to limb ischemia. For patients in the 
end stages of PAD, arterioles are at the point of maximal dilation and are not able to respond 
to further vasodilatory stimuli¾a phenomenon known as vasomotor paralysis.49, 50 
Issues regulating vasomotor tone in primary feeder arteries lead to increased capillary 
hydrostatic pressure that, in turn, promotes endothelial cell dysfunction, increased endothelial 
permeability and edema.51 Additionally, endothelial cells in the ischemic environment 
demonstrate increased leukocyte adhesivity leading to further release of pro-inflammatory 
mediators, increased formation of reactive oxygen species (ROS) and improper platelet 
activation.51, 52 As ROS accumulate in the calf muscle tissue, widespread ROS-induced 
mitochondrial dysfunction leads to myocyte apoptosis, lipid accumulation, tissue fibrosis and 
nerve damage.53-55 Overall, aberrant blood flow caused by the formation of atherosclerotic 
plaques in larger arteries disturbs nutrient and oxygen transfer in capillaries, leading to 
widespread inflammation, tissue necrosis, non-healing ulcers and gangrene.50 
In the early stages of PAD, patients present with a myriad of mild symptoms including: 
muscle pain with exercise (intermittent claudication), leg numbness, skin discolouration and 
slow healing sores on the legs or feet.56 Individuals with larger, more diffuse occlusions in 
feeder arteries suffer more severe limb ischemia, resting leg pain, gangrene and non-healing 
ulcers and are typically diagnosed with the most serious form of PAD known as critical limb 
ischemia (CLI).57 CLI is typically diagnosed through clinical examination of ulcers and 
gangrene present on the affected limb and quantification of several objective measures of 
hemodynamic perfusion, such as ankle brachial index (ABI) and transcutaneous oxygen 
(TcPO2).58 
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With few effective treatment options available for CLI, up to 30% of patients will require 
lower limb amputation in the first year due to extensive tissue necrosis and non-healing 
ulcers.57, 59 More importantly, mortality rates are reported as high as 22% at 1 year post 
diagnosis60, and quality of life scores for patients with no-option CLI are up to 2 standard 
deviations below the general population in physical functioning and body pain 
classifications.61 Diabetic patients typically experience more severe PAD, with amputation 
and mortality rates being five-fold and two-fold higher, respectively.62 Unfortunately, the 
prevalence of PAD and CLI is predicted to increase in the future due to the progressively 
aging population and increasing prevalence of risk factors such as diabetes, hypertension and 
obesity in the general population.63 
1.2.3 Current treatments for PAD 
The primary concerns relating to the treatment of PAD and CLI are due to asymptomatic 
progression of the disease, and therefore, a lack of effective late-diagnosis treatment 
options.64 According to the Trans-Atlantic Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II), the primary objectives for the treatment of CLI 
include: relieving resting ischemic leg pain, prolonging amputation-free survival, increasing 
ulcer healing rates, improving patient quality of life and reducing mortality.65 For most 
patients with CLI, surgical revascularization procedures, endovascular catheterization and/or 
pharmaceutical drug interventions are prioritized in an attempt to increase limb blood flow 
and improve primary outcomes.65 While surgical and endovascular revascularization 
procedures have been shown to modestly improve patient quality of life, amputation and 
mortality rates remain high regardless of the surgical treatment intervention employed.66-69 
Additionally, it is estimated that 50% of patients with CLI are not eligible for 
revascularization procedures due to advanced comorbidities, and limb amputation is 
frequently performed to prevent mortality and relieve the patient of severe symptoms.70 
Overall, an effective therapy for the reversal of CLI and other atherosclerotic comorbidities 
has remained elusive.71, 72 
1.3 Mechanisms of vascular regeneration 
In healthy individuals, vessel architecture and development is precisely regulated by the 
oxygen demands of the downstream tissue capillary beds, with adaptive vessel remodeling 
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occurring on a continuous basis.73 For patients with PAD and other occlusive arterial 
conditions, the delivery of oxygen-rich blood to distal capillary beds is impeded and the 
metabolic demands of the tissues are not satisfied.50 As the disease progresses, the body 
attempts to form new and remodel existing blood vessels through the three compensatory 
mechanisms termed angiogenesis, vasculogenesis and arteriogenesis.4  
1.3.1 Angiogenesis 
Angiogenesis, first described by Judah Folkman in 1971, is broadly defined as the formation 
of new capillary networks from pre-existing vessels.74 Angiogenesis encompasses two 
complementary processes (intussusceptive and sprouting angiogenesis) that form new blood 
vessels through distinct mechanisms. Intussusceptive angiogenesis is a dynamic process 
mediated by the formation of transluminal pillars within small vessels and capillaries.75 
These transluminal pillars will typically arrange in parallel along a vessel and will merge 
together to create two separate vessels. Through repetition of this process, capillary networks 
are able to undergo exponential multiplication and can form complex distal vascular trees—a 
process known as intussusceptive arborization.76 Conversely, sprouting angiogenesis is the 
budding and sprouting of endothelial cells from pre-existing vessels followed by continued 
proliferation, migration and capillary stabilization.4 
Angiogenesis is tightly controlled by the balance of stimulatory and inhibitory factors that 
are present in a variety of physiological and pathological environments (Figure 1.1). Of the 
stimulating factors, tissue hypoxia is the main driving force.24 In regions of tissue with low 
oxygen concentrations, inflammatory and connective tissue cells signal regional hypoxia to 
nearby vessels through the heightened activity of the heterodimeric transcription factor 
hypoxia-inducible factor 1 (HIF-1).77 The HIF-1 transcription factor consists of constitutively 
expressed HIF-1b subunit and an oxygen sensitive HIF-1a.78 Under normal oxygen tensions, 
HIF-1a is continually synthesized and degraded based on the hydroxylation status of an 
oxygen-dependent degradation domain. This domain consists of two proline residues that are 
hydroxylated by HIF-1a prolyl hydroxylases using oxygen as a substrate.79 When these 
proline residues are hydroxylated, the HIF-1a subunit is ubiquitinated and subjected to 
degradation by the proteasome. In regions of hypoxia, HIF-1a prolyl hydroxylases become 
inactivated due to a lack of oxygen and the proline residues on the HIF-1a subunit remain 
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dehydroxylated. This increases the half-life of HIF-1a, allowing accumulation within the 
cell.79 Accumulated HIF-1a dimerizes with constitutively expressed HIF-1b, leading to 
translocation into the nucleus and DNA binding. Following binding to hypoxia response 
elements, transcription of genes encoding a variety of proangiogenic cytokines including 
VEGF, placental growth factor (PlGF) and the chemokine stromal derived growth factor-1 
(SDF-1) are rapidly increased.4 
Once the proangiogenic cytokines are produced and secreted, the factors bind to receptors on 
nearby endothelial cells that ultimately results in destabilization of the pericyte-endothelial 
cell layer and changes in vascular permeability.1, 80, 81 These changes are primarily mediated 
by a fine balance between the VEGF/VEGFR and Angiopoietin-1(Ang1)/TIE2 signaling 
axes, where overactivation of either pathway mediates the promotion or inhibition of 
angiogenesis, respectively. While VEGF primarily acts to increase vessel permeability and 
promote vessel sprouting, Ang1 acts in opposition to decrease vascular permeability through 
the TIE2 receptor.82 In regions of vascular remodeling and angiogenesis, angiopoietin-2 
(Ang2) is released and antagonizes Ang1 at the TIE2 receptor. When Ang2 is bound to the 
TIE2 receptor, VEGF signaling predominates over Ang1, resulting in smooth muscle cell 
detachment and increased vessel permeability.83 Simultaneously, disruptions of intracellular 
vascular endothelial cadherin (VE-cadherin) and platelet endothelial cell adhesion molecule 1 
(PECAM-1) junctions lead to the formation of fenestrations in the vessel wall and deposition 
of plasma proteins such as fibrinogen and fibrin into the extravascular space. Migrating 
endothelial cells use these extravasated plasma proteins as a temporary migration scaffold to 
release a variety of proteolytic enzymes including matrix metalloproteinases (MMPs), 
chymases84 and heparanases85 to degrade the surrounding basement membrane and progress 
into the stroma.86 As the ECM is gradually degraded, matrix-bound growth factors such as 
VEGF, basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1) and latent 
transforming growth factor 2 (TGF-2) are liberated and act on sprouting endothelial cells to 
guide vessel morphology.87, 88 
Once the basement membrane surrounding the endothelial cells has been degraded, a single 
endothelial cell adopts the tip cell phenotype.89 The tip cell is characterized by long, dynamic 
filopodia that degrade the surrounding ECM and guide the sprouting vessel towards 
angiogenic signals in the matrix.90 Behind the endothelial tip cell are many stalk cells that are 
 
 
 
9 
phenotypically distinct from the tip cell. These stalk cells have fewer filopodia and rapidly 
proliferate in response to VEGF.89 Initially, the stalk cells assemble as a solid cord and 
subsequently form a lumen following vessel stabilization through upregulation of 
intracellular adhesion molecules such as PECAM-1, various connexins and VE-cadherin.91, 92 
As blood flow begins to exert shear forces on the nascent vessel, complementary platelet 
derived growth factor (PDGF) and Ang1/TIE2 signaling completes the maturation of the 
vessel through recruitment of pericytes and vascular SMCs that stabilize the vessel, stimulate 
the production of ECM, reduce vessel permeability and induce endothelial cell   
quiescence.93, 94   
1.3.2 Vasculogenesis 
Vasculogenesis is the de novo formation of new blood vessels from endothelial precursor 
cells, a process first described in the developing embryo.95 In early embryogenesis, the 
cardiovascular system is one of the first organ systems to form in order to supply developing 
tissues with essential nutrients and oxygen.96 Following gastrulation, early mesodermal cells 
migrate from the epiblast to the extra-embryonic endoderm through the primitive streak 
where they form blood islands consisting of hematopoietic cells surrounded by a layer of 
angioblasts. As blood islands develop, angioblasts differentiate into endothelial cells and 
coalesce to form a vascular plexus. Further vessel development is mediated through 
angiogenesis where new vessels bud and sprout from the existing plexus.95, 97  
The vasculogenic process was believed to be exclusive to embryogenesis until circulating 
bone-marrow derived endothelial precursor cells (EPC) were isolated from human peripheral 
blood by Takayuki Asahara in 1997. 98 Due to the putative belief that endothelial cells and 
hematopoietic cells arise from a common precursor, the hemangioblast, EPC were isolated 
using the primitive hematopoietic cell surface antigens CD34 and the vascular endothelial 
growth factor receptor (VEGFR), Flk1.98 Since then, there has been increasing evidence that 
EPC participate in the neovascularization of damaged or injured tissues through a process 
termed postnatal vasculogenesis.99, 100 Postnatal vasculogenesis occurs when EPC from the 
bone marrow home to damaged tissues in response to hypoxia and other chemoattractants 
such as: VEGF, granulocyte-monocyte colony stimulating factor (GM-CSF), fibroblast 
growth factor-2 (FGF2), IGF-1 and SDF-1.1, 100, 101 Once the EPC have invaded the damaged 
tissue, they form new vessel networks through differentiation into endothelial cells, paracrine 
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modulation of pre-existing endothelial cells or direct inosculation into existing vessel 
networks.102, 103  
1.3.3 Arteriogenesis 
While capillaries deliver small amounts of blood to individual cells, larger arteries facilitate 
the systemic delivery of greater volumes of blood to many capillary beds throughout a vast 
region of tissue. In the event of an arterial occlusion, such as PAD, bulk blood flow to a 
tissue is reduced, leading to significant tissue ischemia.40 Due to redundancy present in the 
vascular system, pre-existing low-flow collateral vessels feeding similar tissue regions are 
actively remodeled and blood flow is diverted into these vessels to compensate for decreases 
in perfusion caused by the occlusion.104, 105  
This vascular remodeling occurs in response to increased flow velocity, and therefore fluid 
shear stress, on endothelial cells within the collateral vessels.106 Endothelial cells in regions 
of high shear stress take on an activated cell phenotype, associated with upregulated 
expression of various adhesion proteins, including intracellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion protein-1 (VCAM-1), and release monocyte chemoattractant 
protein-1 (MCP-1).107-109 Circulating monocytes bind to the endothelium and infiltrate into 
the subendothelial space where they release a variety of growth factors, chemokines and 
cytokines.109, 110 These proteins bind to surrounding endothelial cells and initiate their rapid 
proliferation.106, 111 As the endothelial cells proliferate, they secrete other mitogenic factors 
such as bFGF, PDGF and transforming growth factor beta-1 (TGF-b1) that subsequently 
promote the rapid proliferation of the surrounding SMCs. Simultaneously, monocytes 
produce proteinases, such as plasminogen activator (uPA) and MMPs, to proteolytically 
break down the surrounding ECM to facilitate new vessel growth.112 In the final steps of 
maturation, the SMC arrange in circular and longitudinal layers and deposit extracellular 
elastin and collagen to support to the vessel.109 After remodeling, arteriogenesis can mediate 
up to a 20-fold increase in vessel diameter, leading to increased blood flow to downstream 
tissues within weeks of vessel     occlusion.113, 114 
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Figure 1.1 Mechanisms of vascular regeneration. Existing blood vessels can be remodeled 
or new blood vessels can be formed at varying levels of the vascular hierarchy through three 
complementary processes. Angiogenesis, the formation of new capillary networks from pre-
existing vessels through sprouting or intussusception; Vasculogenesis, the de novo formation 
of new blood vessels from endothelial precursor cells; and Arteriogenesis, the dynamic 
remodeling of pre-existing collateral vessels.1 All acronyms are defined in the main text.  
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1.4 Hematopoietic stem and progenitor cells 
1.4.1 Hematopoietic stem cell development and role in hematopoiesis 
Hematopoietic stem cells (HSC) are extremely rare, pro-regenerative cells responsible for the 
derivation of all blood cells over the course of an organism’s lifetime (Figure 1.2). HSC are 
characterized by their ability to differentiate into all cells in the myeloid and lymphoid 
lineages and their capacity to self-renew for maintenance and/or expansion of the progenitor 
cell pool.115-117 Hematopoiesis is separated into two developmental waves¾called primitive 
and definitive hematopoiesis¾that serve similar yet distinct functions for the developing 
embryo.118 During early embryo development, primitive hematopoiesis first occurs through 
HSC emerging from blood islands in the yolk sac.119 Their purpose is to contribute towards 
the earliest forms of erythropoiesis to supply the growing embryo with red blood cells (RBC) 
for transient tissue oxygenation.120 Definitive hematopoiesis occurs at a later timepoint and 
accounts for the production and homeostasis of all mature cell types in the blood throughout 
life. HSC responsible for definitive hematopoiesis first emerge in the aorta-gonad-
mesonephros (AGM) region before migrating to the fetal liver and bone marrow in the third 
trimester.121  
In the bone marrow, HSC reside in a quiescent state within the endosteal niche surrounded by 
supportive perivascular stromal cells and vascular endothelial cells.122-124 The complex 
physical, cellular and chemical components of the bone marrow microenvironment have been 
highly studied and play an important role in the maintenance of the progenitor cell pool and 
coordinate the generation of a hematopoietic hierarchy.122 During development, quiescent 
HSC (termed long-term HSC or LT-HSC) are believed to give rise to phenotypically distinct 
short-term HSC (ST-HSC) that have a limited capacity for self-renewal. These ST-HSCs 
generate multipotent progenitor cell (MPC) populations that develop into lineage-committed 
progenitors and subsequent mature cells of the lymphoid (e.g. NK, B and T cells), myeloid 
(e.g. granulocytic and monocytic/macrophage cells) and megakaryo-erythroid (e.g. 
megakaryocytes, platelets and erythrocytes) lineages (Figure 1.2).125  
During adult life, LT-HSC are believed to contribute less to steady-state hematopoiesis, with 
ST-HSC being the driving force behind the derivation of mature hematopoietic cell types.126 
However, in response to hematopoietic stressors that deplete mature hematopoietic cell 
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populations, such as systemic infection127, it has been suggested that LT-HSC exit out of 
their quiescent state in response to interferon signaling and produce myeloid and lymphoid 
progenitors that facilitate the replacement of depleted progenitor cell populations and restore 
hematopoietic homeostasis over time.128  
1.4.2 Hematopoietic stem and progenitor cell isolation and 
characterization 
The discovery of HSC by stem cell pioneers Drs. James Till and Ernest McCulloch was 
documented in early bone marrow transplantation studies involving lethally irradiated 
mice.115-117 Drs. Till and McCulloch observed that mice subjected to lethal irradiation would 
survive if they received a syngeneic bone marrow transplant from a non-irradiated animal. 
Following the discovery of donor-derived clonogenic colonies in the spleen of recipient 
animals, they postulated that there were multipotent cells present in the bone marrow that 
were capable of reconstituting the entire hematopoietic system and maintaining 
hematopoiesis (Figure 1.2).115-117  
Since then, prominent research groups around the world have dedicated their life’s work to 
the isolation and characterization of these rare cell populations in the murine and human 
hematopoietic systems. Early attempts to purify murine HSC using density gradients, anti-
mitotic agents and surface glycoprotein molecules demonstrated success in enriching 
multipotent hematopoietic progenitor cells but lacked the ability to distinguish between cells 
that were able to self-renew and cells that were more committed.129, 130 It wasn’t until 1975, 
when Georges Köhler and César Milstein demonstrated the groundbreaking ability to 
formulate and purify monoclonal antibodies,131 that researchers were able to characterize the 
cell surface antigens exclusively found on primitive and mature cell populations in the 
hematopoietic system and enabled the field to identify hematopoietic stem cells capable of 
self-renewal.132  
In humans, hematopoietic stem and progenitor cells (HSPC) can be derived abundantly from 
umbilical cord blood (UCB) 133 and bone marrow134, but can be also found to a lesser extent 
in peripheral blood.135 Traditional isolation of HSPC has focused on the positive and negative 
expression of various cell surface markers, with more stringent panels involving multiple cell 
surface markers being required for the isolation of the extremely rare LT-HSC capable of 
 
 
 
14 
self-renewal. The first cell surface marker found to be highly expressed on HSC was CD34, 
but elevated expression was also exhibited on more committed hematopoietic progenitor 
cells (HPC).136 This finding led researchers to search for additional cell surface markers that 
would allow for the removal of differentiated cell types and enable enrichment of the most 
primitive HSC population. Presently, after decades of research, the most agreed upon cell 
surface marker phenotype for HSC at the top of the hematopoietic hierarchy is a cell that is 
depleted of mature hematopoietic populations (lineage-depleted) and is 
CD34+CD90+CD45R-CD38-.134, 137-139 Otherwise, purification performed on lineage-depleted 
cells based on CD34+CD133+ or CD34+CD38- expression has been shown to broadly select 
for a mixture of both HSC and HPC with moderate long-term hematopoietic reconstitution 
capacity in immunodeficient mice.134, 140  
Paradoxically, there has also been recent evidence showing that there is an extremely small 
population of quiescent LT-HSC at the top of the hematopoietic hierarchy that are 
Lin−CD34−CD38−CD93hi and may upregulate CD34 expression following early HSC 
differentiation.141 Due to the transient expression of many cell surface markers and the need 
for complex immunological stains, recent findings suggest that use of functional markers 
such as aldehyde dehydrogenase (ALDH) activity may also be effective at isolating 
progenitor cells from heterogeneous cell populations based on a primitive cell function rather 
than cell surface phenotype.133, 142 
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Figure 1.2 Overview of human hematopoietic hierarchy. Long-term hematopoietic stem 
cells are at the top of the hierarchy and give rise to all mature hematopoietic cell populations in 
the myeloid and lymphoid lineages. MEP: Megakaryo-erythroid progenitor, LT-HSC: Long-
term hematopoietic stem cell, ST-HSC: Short-term hematopoietic stem cell. 
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1.4.3 Aldehyde dehydrogenase 
The ALDH enzyme superfamily consists of 19 distinct isoforms organized into 11 families 
and 4 subfamilies with varying substrate specificity and tissue distribution.143, 144 Different 
isoforms of ALDH are found throughout the cytosol, mitochondria, nucleus and endoplasmic 
reticulum, and are believed to play an important cytoprotective role by catalyzing the 
oxidation of reactive aldehydes from endogenous and exogenous sources to less toxic 
carboxylic acids.145 Aldehydes are electrophilic compounds that have the potential to 
covalently bond with nucleophilic compounds such as DNA, enzymes, structural proteins 
and other macromolecules. Through the covalent bonding to cellular components, reactive 
aldehydes can extensively damage intracellular components leading to downstream 
mutagenic, cytotoxic and carcinogenic effects.146 Exogenous aldehydes can be derived from 
environmental sources (i.e. cigarette smoke, industrial manufacturing, air and water 
pollution), but are also formed following the ingestion of xenobiotics, food and drugs (i.e. 
ethanol and anti-cancer drug cyclophosphamide).147, 148 Endogenous aldehydes are formed as 
biproducts of many physiological processes involving the metabolism of lipids (i.e. lipid 
peroxidation), amino acids, carbohydrates and vitamins.145, 149    
Besides their ubiquitous role in the reduction of the cytotoxic effects of reactive aldehyde 
species, ALDH enzymes are also crucial for guiding differentiation during embryogenesis 
and are commonly upregulated in multiple stem cell and cancer stem cell populations.150-153 
In stem cells, the ALDH1A1 and ALDH3A1 isoforms have demonstrated particular 
importance towards self-protection, differentiation and self-renewal.154, 155 The protective 
function of both of these isoforms can be seen through their contributions towards mediating 
increased resistance for HSPC against alkylating agents such as cyclophosphamide.154 As for 
the regulation of differentiation and self-renewal in stem cell populations, ALDH1 isoforms 
(i.e. ALDH1A1, ALDH1A2 and ALDH1A3) are the rate-limiting enzyme for the multi-step, 
intracellular conversion of retinol (vitamin A) to retinoic acid.156 Retinoic acid is produced 
through the reversible oxidation of retinol to retinaldehyde by retinoid dehydrogenases 
followed by irreversible oxidation of retinaldehyde to retinoic acid by cytosolic ALDH1A 
isoforms.157 Retinoic acid is a potent morphogen and stimulates cell differentiation through 
its activation of the retinoic acid receptor/retinoid X receptor (RAR/RXR) transcription 
factor complex.157, 158 These morphogenic effects can be measured through experiments 
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inhibiting retinoic acid production through the use of reversible ALDH-inhibitors such as 
diethylaminobenzaldehyde (DEAB). Specifically, studies have found that HSC demonstrated 
blunted differentiation when cultured with DEAB in vitro, leading to the amplification of 
HSC capable of self-renewal when measured in reconstitution assays in non-obese 
diabetic/severe combined immune deficient (NOD/SCID) mice.158 Overall, stem cells must 
maintain a complex balance between ALDH-induced retinoid signaling and retinoic acid-
induced differentiation to ensure the production of mature blood cells without depletion of 
the stem cell pool. 
1.4.4 Aldehyde dehydrogenase as an alternative marker for 
progenitor cell populations 
One benefit to elevated ALDH-activity present in stem and progenitor cells is that it can be 
used to purify primitive cells based on cell function rather than cell surface phenotype. 
Within the hematopoietic hierarchy, ALDH-activity is reduced as HSC differentiate towards 
a mature state. Differential expression of ALDH1 among HSC and more committed lineages 
was first demonstrated in 1990 using flow cytometry with conjugated antibodies that bound 
to intracellular isoforms of ALDH1 and various cell surface markers.159 This study found that 
CD34+ hematopoietic cells also demonstrated elevated ALDH1 levels compared to mature B, 
T and monocytic cells.159  
While these studies were effective in characterizing ALDH expression within the 
hematopoietic hierarchy, the cells needed to be fixed and permeabilized prior to analysis and 
therefore had limited clinical applicability. Five years later, Jones et al. developed the first 
flow cytometric assay for ALDH activity that could be used on viable cells using the 
fluorescent substrate of ALDH, termed dansyl aminoacetaldehyde (DAAA).160 
Unfortunately, due to the polarity of the fluorescent molecule produced following oxidation 
by ALDH1, the substrate would remain in the isolated cells indefinitely, thus leading to 
mutagenic consequences and limiting clinical applications.142 To address this drawback with 
(DAAA), Storms et al. developed a new fluorescent substrate for ALDH, BODIPY-
aminoacetaldehyde (BAAA), that could be washed out of cells following fluorescence 
activated cell sorting (FACS).142 Using this assay, isolation of viable human HSPC from 
bone marrow, umbilical cord blood and peripheral blood were successfully employed in 
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regenerative medicine applications in animal models of hematopoietic reconstitution, acute 
myocardial infarction, liver damage and limb ischemia.161-163  
ALDH-activity was not only successful in purifying hematopoietic cells with a primitive 
phenotype but could also be used to isolate endothelial precursor cells and multipotent 
mesenchymal stromal cell (MSC) populations that could act in concert with host-derived 
cells to accelerate blood vessel regeneration.163-166 In mice with femoral artery ligation 
(FAL), intravenous (IV) or intramuscular (IM) injection of UCB-derived ALDHhi cells 
significantly restored limb perfusion up to day 35, despite limited cell engraftment and 
transient survival in the ischemic muscle (<7 days).165 It was believed that their enhanced 
regenerative capacity was mediated through the secretion of various pro-angiogenic paracrine 
signals, including VEGF, interleukin-8 (IL-8), Ang1 and fibroblast growth factor 16 (FGF-
16), that collectively induced small collateral vessel formation to restore blood flow in the 
ischemic limb.165 Mounting preclinical evidence of the regenerative capacity of human HSPC 
derived from BM or umbilical cord blood in mouse models of limb ischemia has led 
researchers to propose that HSPC transfer may improve patient outcomes for occlusive 
arterial diseases such as PAD.   
1.4.5 Alternative revascularization strategies for patients with PAD 
As mentioned previously, therapeutic interventions for PAD are targeted at relieving the 
severe symptomology of the disease, reducing amputation rates, improving patient quality of 
life and reducing patient mortality.65 Patients with severe CLI that do not qualify for 
traditional surgical revascularization techniques have limited treatment options to reduce 
symptoms, reestablish distal blood flow and restore metabolic homeostasis to the ischemic 
limb. As such, early attempts to stimulate revascularization involved systemic delivery of 
potent regulators of angiogenesis to restore blood flow and improve patient symptoms. 
1.4.5.1 Recombinant proteins for stimulating angiogenesis 
Alongside the discovery of many of the mediators of angiogenesis, such as VEGF, FGF and 
hepatocyte growth factor (HGF), researchers initially attempted to stimulate therapeutic 
angiogenesis through the intra-arterial administration of pro-angiogenic recombinant 
proteins.167, 168 While the administration of recombinant VEGF or FGF successfully 
stimulated collateral remodeling, increased capillary density and restored hemodynamic 
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deficits in animals with unilateral hindlimb ischemia, questions were raised regarding the 
clinical applicability of recombinant protein administration in human subjects with    
PAD.168, 169  
First, due to the drastic size differences between the animals used to test the efficacy of the 
proangiogenic recombinant proteins and human subjects, an extensive scale-up and good 
manufacturing practices (GMP) overhaul of the expensive recombinant protein 
manufacturing process would be needed to achieve quantities of protein required for human 
administration. Secondly, continuous intravascular (IV) or intramuscular (IM) administration 
of proangiogenic growth factors would be needed to achieve therapeutic benefit due to the 
short plasma half-life (e.g. 33.7 minutes for VEGF) and susceptibility to degradation.170 In 
studies exploring collateral remodeling with recombinant VEGF in canine models of 
myocardial infarction, daily administration of VEGF into the coronary arteries was required 
to improve collateral coronary blood flow and intramyocardial vessel density.171 
Furthermore, IM and IV routes of administration would be unable to prevent the systemic 
effects of the growth factors and would likely lead to undesirable side effect profiles. 
1.4.5.2 Gene therapies approaches for the treatment of PAD  
To address some of the shortcomings and safety concerns with the use of recombinant 
proteins for therapeutic angiogenesis, gene therapies encoding angiogenic growth factors 
were developed. Gene therapy involves the transfer of genetic material though plasmids, viral 
vector systems or liposomal complexes for a therapeutically beneficial effect.172 Cells that 
are successfully transfected with plasmids or transduced with viral vectors demonstrate 
increased expression of the transferred gene leading to augmented expression and secretion 
of the angiogenic growth factor. Gene therapies were predicted to be a safer and more 
efficacious alternative to recombinant protein therapies due to the potential to achieve a local 
and sustained release of pro-vascular growth factors to mediate therapeutic angiogenesis.  
Similar to recombinant protein studies, researchers demonstrated that the transfection of 
individual mediators of angiogenesis, such as VEGF,173 FGF174 and HGF,175 into animals 
with surgically-induced hindlimb ischemia effectively stimulated angiogenesis, promoted 
collateral development and improved limb perfusion. Despite promising results in preclinical 
studies, gene therapies modulating VEGF, FGF or HGF expression in phase II and III 
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randomized clinical trials demonstrated minimal improvements to primary endpoints (limb 
salvage) and were deemed therapeutically ineffective in patients with CLI.176-182 It was 
believed that translational failure of these gene therapies could be attributed to issues with 
delivery of the gene to the target tissue, low gene-transfer efficacy and variable or transient 
expression of the transferred gene.183 Additionally, others have postulated that gene therapies 
targeting a single growth factor in the extremely complex angiogenic cascade, involving 
hundreds of cues from several distinct cell populations and the ECM, may not be sufficient to 
stimulate angiogenesis in the face of advanced cardiovascular pathologies.176 Thus, there 
remains an unmet need for a therapeutic strategy that stimulates angiogenesis using multiple 
angiogenic factors, is safely administered and effective at improving primary endpoints (i.e. 
amputation free survival and patient mortality) for patients with CLI. 
1.4.5.3 Cell-based therapies for the treatment of PAD 
Novel therapies harnessing the robust angiogenic secretome of adult stem cells to stimulate 
therapeutic angiogenesis have been at the forefront of regenerative medicine for CLI.184 
Historically, the use of adult stem cells for initiating therapeutic angiogenesis began with the 
discovery of EPC.98 Indeed, these cells were capable of contributing to post-natal 
neovascularization following IV injection into athymic mice with surgically-induced 
hindlimb ischemia. While the functional neovascularization capacity of the purified EPC was 
evident in the animal studies, the ‘EPC’ nomenclature given to this population was inaccurate 
due to co-expression of these markers on progenitors within the hematopoietic lineage.185  
Later studies characterizing EPC defined by Asahara et al. found that there were distinct 
hematopoietic and endothelial progenitors capable of supporting the formation of new 
vessels through angiogenic cytokine secretion and by structural vessel incorporation, 
respectively.185, 186 Although extremely rare, these cell populations predominantly reside in 
the bone marrow and can mobilize into the peripheral circulation in response to stimuli such 
as growth factors, tissue damage and hypoxia.187 Therefore, researchers postulated that both 
of these extremely rare regenerative cell populations could be harvested from easily 
accessible sources, such as peripheral blood, bone marrow and umbilical cord blood, and 
injected into damaged tissue to accelerate therapeutic neovascularization. Early 
transplantation studies in rabbits started with the autologous use of unselected mononuclear 
cells derived from the bone marrow (BM-MNC) for the treatment of surgically-induced 
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hindlimb ischemia.188 This study found that transplanted cells incorporated into the capillary 
network, induced collateral vessel formation, increased capillary density and increased limb 
perfusion relative to saline controls.188  
Based on these successes stimulating limb revascularization in animal models of CLI, the 
first randomized clinical trial involving the autologous transplantation of BM-MNC was the 
Therapeutic Angiogenesis by Cell Transplantation (TACT) trial reported in 2002.189 For 
patients with unilateral and bilateral CLI receiving autologous BM-MNC, improvements in 
ABI, TcPO2, and pain free walking time were demonstrated at the 4 week timepoint and 
sustained for up to 24 weeks. Furthermore, long term follow-up on patients receiving the 
BM-MNC showed maintained improvements in leg pain, ulcer size and pain free walking 
time at 3 years post-therapy.190  
While the therapeutic benefit of BM-MNC was demonstrated, subsequent studies claimed 
that BM-MNC were only partially effective improving patient prognosis, as amputation and 
mortality rates remained unchanged following treatment.191, 192 A meta-analysis, completed 
in 2010 by Weem et al. of 10 randomized controlled trials (RCT) exploring the 
proangiogenic and regenerative abilities of transplanted autologous mononuclear cells for 
CLI showed no improvement in amputation, survival and ulcer healing rates for trial 
participants.193 Conversely, a more recent meta-analysis including 19 RCT completed over 
the last two decades concluded that autologous MNC effectively reduced the risk of major 
amputation by 37%, improved amputation free survival by 18% and improved wound healing 
by 59%.194 Overall, the ability of unselected autologous MNC to reduce primary endpoints 
such as amputation rates and patient mortality remains controversial, and despite 
improvements in various secondary endpoints such as ABI, TcPO2 and leg pain, a successful 
phase III/IV trial for limb ischemia has remained elusive.  
Unselected BM-MNC represent an extremely heterogeneous cell population consisting 
primarily (>90%) of mature hematopoietic cells with infrequent representation by HSPC, 
EPC, and stromal cells.99 While there have been studies demonstrating the regenerative 
capacity of mature hematopoietic cell lineages, such as monocytes and macrophages, it has 
been hypothesized that BM-MNC only contain a small fraction of cells capable of effectively 
stimulating therapeutic angiogenesis.195 Further refinement of cell-based approaches using a 
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more homogenous proangiogenic cell population is warranted to bolster the therapeutic 
capabilities of injected cells and may lead to better outcomes when translated to RCT.  
Supporting this theory, cell selection using primitive cell surface markers CD34 and Flk-1 
effectively enhanced collateralization and capillarization in the ischemic limbs of mice with 
surgically induced hindlimb ischemia, leading to hemodynamic recovery and improvements 
in myofiber regeneration.196 When these findings were translated into human studies 
involving CD34+ cells derived from the blood following BM-MNC mobilization with GF-
CSF, changes in amputation rates trended towards high-dose CD34+ cell therapy versus 
saline controls but ultimately failed to reach significance (p = 0.06).197 Other studies using 
functional markers (i.e. ALDH activity) also demonstrated success stimulating limb 
vascularization and increasing perfusion in preclinical animal models of CLI when injected 
IV163. However, when translated into humans, autologous ALDHhi cells derived from bone 
marrow demonstrated modest clinical benefit in improving ABI at the 6 and 12 week 
timepoints but did not improve overall amputation rates compared to unselected BM-
MNC.198 Thus, following two decades of preclinical and clinical experimentation involving 
the use of selected and unselected MNC from the bone marrow or peripheral blood, there still 
remains a need to develop an improved cell therapy able to reduce amputation rates and 
mortality in patients with CLI.  
1.4.5.4 Limitations of cell-based revascularization strategies for PAD 
It is evident in most preclinical and clinical studies completed to date that MNC derived from 
the bone marrow, peripheral blood or umbilical blood show some therapeutic efficacy, 
despite not being able to reduce amputation rates in large RCT. While some of these 
difficulties can be attributed to the lack of large animal models with atherosclerosis-induced 
CLI to test therapeutic approaches,199 there are several fundamental limitations in current 
therapies that need to be addressed to improve the therapeutic benefit of cell therapy.  
First, the majority of proposed therapies involved the use of autologous cell populations 
where the proangiogenic fraction of the isolated cells remained extremely                           
low (<1%).188, 189, 192, 194, 197, 198 To account for these low frequencies, many studies 
compensated by using large cell dosages requiring extensive tissue harvesting. The TACT 
trial alone required 500 mL of aspirated marrow per patient; an amount that makes up almost 
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a third of the total marrow volume (1.75 L) of a 70 kg adult.200 In a meta-analysis of 37 
studies involving autologous injection of BM-MNC completed by Fadini et al., an average of 
3.56 ± 2.81 × 109 unselected MNC and 5.0 ± 1.48 × 107 CD34+ cells were injected per 
patient.201 While these methods of tissue harvesting and cell purification are feasible in 
smaller clinical trials, scaling up to millions of PAD patients would place a significant cost 
and time burden on the healthcare system.  
To address these limitations, scalable allogeneic sources of purified proangiogenic cells 
could be further developed for an ‘off-the-shelf’ solution to CLI. UCB represents an easily 
accessible and routinely discarded MNC source enriched for proangiogenic cell populations, 
as shown through the successful derivation of HSC202, EPC203 and MSC204 for downstream 
applications. The drawback to UCB is that only small volumes of blood (<100 mL) can be 
obtained from each sample. To obtain sufficient numbers of cells for therapeutic purposes, 
researchers have developed clinically relevant serum- and xeno-free ex vivo expansion 
protocols to scale up the number of cells available for injection.164, 205 Unfortunately, a caveat 
to this approach is that the cells may lose their regenerative potential during culture.164 To 
ensure effective scale-up while minimizing loss of regenerative function, several groups have 
investigated the use of pharmacological agents to try to maintain cells in their primitive 
state.158, 206 
The use of cells from an allogeneic source also addresses limitations using autologous cells 
taken from an advanced pathological environment. It is becoming more apparent that 
systemic inflammation, hyperglycemia and hyperlipidemia associated with diabetes and 
atherosclerotic cardiovascular sequelae result in dysfunction of circulating EPC via 
accelerated aging and senescence.207, 208 Furthermore, measurement of circulating EPC has 
been used as a metric for the diagnosis of vascular co-morbidity as diabetic patients with 
PAD demonstrated significant reductions in circulating EPC (i.e CD34+CD133+KDR+ cells) 
compared to non-PAD patients.208 Thus, translation of novel cell therapies involving purified 
cells from an allogeneic source may provide improved patient outcomes due to a lack of 
impairment from chronic diabetes and atherosclerosis related co-morbidities.  
Finally, many cell therapies, including those for CLI suffer from a lack of cell survival and 
retention at the ischemic site following IV- or IM-injection. In a study using IV injection of 
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BM-MNC or ALDHhi MNC into immunodeficient mice, cells were rarely found remaining in 
the ischemic tissue past day 7 post-transplantation, but were frequently detected in the bone 
marrow when analyzed by flow cytometry.165 This lack of human cell engraftment limits 
capacity of the delivered cells to exert pro-vascular paracrine effects on damaged tissues, 
which may impede functional revascularization. To account for this, many researchers are 
beginning to explore multidisciplinary approaches to improve cell engraftment and retention 
to prolong paracrine functionality of therapeutic cell populations.209 
1.5 The use of biomaterials as a cell delivery platform 
Biomaterial-based regenerative medicine approaches for the treatment CVD have been under 
investigation since the early 2000s, with early studies employing injectable biopolymers for 
cell delivery in animal models of myocardial infarction.210, 211 Since then, there has been 
growing interest in the development of novel cell delivery strategies utilizing natural (e.g. 
collagen212, hyaluronic acid213, alginate214 and decellularized tissue ECM215) and synthetic 
(e.g. polymer216 or peptide217) biomaterials to successfully stimulate therapeutic angiogenesis 
in patients with PAD. Before discussing the pros and cons associated with the use of 
biomaterials, it is important to understand the structure and function of the ECM that 
provides the native microenvironment for peripheral blood vessels. 
1.5.1 The extracellular matrix 
1.5.1.1 ECM function 
The ECM can be broadly defined as the acellular 3D compartment within human tissues that 
functions as a structural framework and provides essential biochemical and biomechanical 
cues that direct cell differentiation, proliferation, migration and survival.218 The ECM is 
composed of a complex mixture of proteins and polysaccharides that demonstrate tissue-
dependent physical and biochemical characteristics.219 The unique biochemical composition 
of the ECM in different tissues is a by-product of the dynamic and reciprocal communication 
between the cells and the matrix constituents.  
While the structure and composition of the ECM is varied among diverse tissue types in the 
body, the general functions of the ECM are similar and can be broadly classified into 4 
different categories. First, the ECM provides cells with a structural scaffolding system for 
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cell adhesion and migration.220 Second, the structural integrity of all tissues is reliant on the 
composition of the ECM, with different tissues expressing predefined frequencies of proteins 
with variable biomechanical properties in accordance with the tissue’s location and primary 
function.221 Third, the matrix microenvironment contains hundreds of bioactive cues that 
instruct cell behavior. Most prominently, cells partake in bidirectional mechano-transduction 
cell signaling through integrin proteins in the cell membrane. Integrins are heterodimeric 
proteins made up of different a and b subunits that bind to unique protein sites present in the 
ECM. Depending on the specific heterodimer bound, cells directly link their cytoskeleton to 
the surrounding matrix and activate various intracellular signaling pathways.222 Finally, ECM 
provides a dynamic environment that cells can remodel in response to developmental, 
homeostatic and pathological cues.223 How each of these functions relates to specific 
molecular and biological components of the ECM will be discussed in more detail below.      
1.5.1.2 ECM architecture and composition 
In general, within tissues, the ECM is organized into two distinct forms that differ in their 
biochemical composition and function. First, the basement membrane (BM) is a thin, fibrous 
layer of ECM proteins that acts of a point of attachment for monolayers of endothelial or 
epithelial cells and serves as a physical barrier from adjacent connective tissues. BMs 
provide structural support to cell monolayers and communicate extensively with cells in the 
adjacent stroma.224 Second, the interstitial matrix is comprised of ECM proteins that are 
heavily secreted by fibroblasts in the stroma and function to define the 3D tissue structure.225  
ECM proteins can be discriminated from one another based on their function, with large 
fibrous proteins (i.e. collagens and elastins) playing predominant structural roles and smaller 
glycoproteins (i.e. fibronectins, laminins and tenascins) exhibiting functional influences on 
cell behaviour.225 Of the structural ECM proteins, collagen is the most abundant, and acts to 
provide mechanical integrity to tissues and to facilitate cell adhesion and migration.225 There 
have been 29 different proteins identified in the collagen family to date, which can be 
categorized based on their ability to form structural fibrils (i.e. type I, II, III, V and XI) or 
sheet-like basement membranes (i.e. type IV).226 While the collagen composition differs 
between tissues, collagen types I, II and III are the most prevalent and together make up 80 - 
90% of total collagen in the body.226 Collagen possesses a high degree of stiffness and 
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functions in concert with other structural ECM proteins to provide the overall biomechanical 
properties required within tissues. In tissues that need to be able to recoil following 
stretching, such as tendons or blood vessels, collagen fibers are typically integrated with 
small amounts of elastin proteins that impart tissue elasticity.227  
While both collagen and elastin are important for the structural integrity of the ECM, other 
proteins and proteoglycans bound to the structural matrix provide cues that mediate cell 
migration, proliferation and adhesion.228 For example, fibronectin is a fibrillar protein known 
for pleiotropic effects on cell behaviour and as an important regulator of adhesion dependent 
cell growth.229 Proteoglycans represent another group of important ECM molecules that 
consist of a protein core (with the exception of hyaluronic acid) and branching 
glycosaminoglycan (GAG) chains.228 Within the interstitial space, proteoglycans and GAGs 
play a role in tissue hydration, structural ECM assembly, and modulation of cell behavior 
through regulation of cytokine and growth factor signaling.228 Other important components 
of the ECM include sequestered MMPs, cytokines and growth factors released following 
ECM remodeling, including during angiogenesis and wound healing.230 Overall, the ECM is 
an incredibly complex environment that provides precise biochemical and biophysical 
signaling to ensure proper cell differentiation, migration, proliferation and survival. By 
mimicking traits of the ECM, researchers may be able to direct cell behaviors through the 
careful design of 3D biomaterials for therapeutic intervention. 
1.5.2 Biomaterial requirements 
Optimally, engineered biomaterials should mimic the biophysical and biochemical traits of 
the native tissue target sites in the body. However, due to the highly complex nature of the 
native ECM and dynamic interactions between cellular constituents and matrix proteins, it is 
extremely difficult to recapitulate exact microenvironments found in the body. For this 
reason, bioengineers must consider the specific physical, mechanical, and chemical 
characteristics of the native tissue needed for the intended application.  
For biomaterials to be effective in cell delivery strategies for PAD, they need to facilitate 
sustained release of proangiogenic factors from transplanted cells for prolonged therapeutic 
benefit. As such, the implanted biomaterials should provide a microenvironment that 
supports cell survival and retention at the site of transplantation despite tissue ischemia and 
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degeneration.231 Importantly, biomaterials should not induce a chronic inflammatory or 
immunological response when transplanted into the host. Thus, the derivation of the 
biomaterial and all steps of the manufacturing process need to be regulated to reduce the 
retention of toxic and pathogenic substances.232 
To facilitate tissue integration, the biomaterial must be structurally and biomechanically 
compatible with the transplant site. Furthermore, scaffolds need to demonstrate architectural 
features that permit tissue remodeling and host integration, while providing mechanical 
support as regeneration progresses. Physical characteristics such as porosity and substrate 
stiffness must be fine-tuned to ensure cells are able to adhere and migrate within the 
matrix.233 Biomaterials can also be actively remodeled by host cells to permit vascularization 
within the constructs, which is necessary for the transport of essential nutrients to the 
delivered and infiltrating cell populations. Finally, while not critical to the success of the 
engineered scaffolds, functional bioactivity mediated through sequestered growth factors and 
cytokines, such as VEGF and Ang-1, may support rapid scaffold vascularization and 
contribute to cell patterning for additional therapeutic benefit.234, 235 While many engineers 
focus on the creation of synthetically derived biomaterials that recapitulate features of native 
tissues, biomaterials derived from decellularized tissues have innate bioactivity and can more 
closely replicate the native cellular microenvironment.236 This may be favorable for 
therapeutic efficacy, while remaining clinically applicable due to low immunogenicity and 
ease of production.236, 237    
1.5.3 Decellularized tissue biomaterials 
Protocols for the decellularization of intact tissues and organs have been an area of intense 
investigation in tissue engineering. The methodologies used to decellularize tissues vary 
widely among studies but generally involve a sequential process with physical (i.e. 
freeze/thaw cycles, sonication or tissue agitation), chemical (i.e. ionic solutions and 
detergents) and/or enzymatic (i.e. trypsin and nucleases) treatments.237 Intuitively, harsher 
processing steps involving the use of detergents to remove cells may result in extensive 
damage to the native ECM through reductions in GAGs and sequestered growth factors.238 
Therefore, the primary goal of the tissue decellularization process is to remove immunogenic 
cellular components from the tissue using milder reagents while retaining the overall 
composition, bioactivity and physical integrity of the native ECM as much as possible.236  
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Over the past few decades, several decellularized tissue scaffolds have been successfully 
used in pre-clinical studies and progressed to clinical trials for a wide range of clinical 
indications.239-241 To date, decellularized constructs have been derived from many tissues 
including the cornea242, esophagus243, heart valve244, blood vessels245, skin246 and skeletal 
muscle.247 While the decellularization of many of these tissues is feasible in a research 
setting where only small amounts of tissue are needed, the clinical applicability of 
biomaterials derived from human tissues that are difficult to procure (e.g. heart valve and 
cornea) remains a challenge. Many researchers have successfully derived decellularized 
tissue from widely available xenogeneic sources, selected based on the high degree of 
conservation of ECM proteins between different species.248 While these implants are 
typically well tolerated, the use of xenogeneic material in the clinical setting is complicated 
by the potential risk of xenozoonosis.249 Therefore, there is a need for human decellularized 
matrices that are abundantly available and capable of supporting integrated cells to stimulate 
in situ regeneration. 
1.5.4 Adipose tissue derived biomaterials 
Human adipose tissue (fat) is a highly-specialized connective tissue that is ubiquitously 
found throughout the body. In addition to cushioning organs and providing insulation, it also 
serves as a dynamic energy reservoir through the storage of triglycerides in adipocytes.250 
Other important cell types present in fat are adipocyte precursors, stromal cells, endothelial 
cells, smooth muscle cells and immune cells, including tissue resident macrophages.251 These 
stromal-vascular cell populations are associated with the extensive vascularization of the 
tissue needed to support adipogenesis and can contribute to the tissue structure through the 
deposition of ECM proteins.252, 253 Of these proteins, adipose tissue ECM has been found to 
be a rich source of proteins including collagen types I – VI, fibronectin and laminin, and 
contains a variety of growth factors that are associated with adipogenesis and 
angiogenesis.254, 255 For these reasons, it has been proposed that adipose tissue represents an 
abundantly available source of human ECM that has the potential to be used as a cell 
supportive scaffold for downstream soft tissue engineering and regenerative medicine 
applications.256, 257  
The successful formulation of human decellularized adipose tissue (hDAT) was first 
described by Dr. Lauren Flynn in 2010 using subcutaneous adipose tissue collected from 
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surgeries involving breast or abdominal reductions.256 The fabrication process involved an 
optimized decellularization protocol that subjected the adipose tissue to sequential physical, 
chemical and biological treatment steps, without the use of detergents. Following 
decellularization, the majority of the cellular components of native adipose tissue were 
removed, leaving a significant amount of ECM with highly conserved protein architecture.256 
In-depth macroscopic investigation of the hDAT revealed an intact 3D collagen network 
structure with biochemical and biomechanical properties similar to the native tissue.258 When 
analyzing the proteomic composition of the hDAT, collagen was found to be the most 
abundant protein (~80% of the total protein extract), with collagen 1A1, collagen 1A2 and 
collagen 3A1 being the predominant subtypes amongst the 21 collagen proteins detected.255 
Other proteins involved in the VEGF, epidermal growth factor (EGF), FGF and SDF-1 
signaling pathways were also detected.255 Following seeding with adipose-derived 
stem/stromal cells (ASCs) in vitro, it was found that the hDAT scaffolds provided a 
supportive microenvironment leading to widespread infiltration and distribution.256 When the 
ASC seeded hDAT construct was applied in vivo and subcutaneously implanted into an 
immunocompetent rat model, it demonstrated the capacity to stimulate a pro-regenerative 
immune and angiogenic response through the recruitment of pro-regenerative M2 
macrophages.259  
While the hDAT scaffolds have not been previously explored with HPCs, other studies 
involving hematopoietic stem cells cultured in porous collagen microbeads showed that the 
3D collagen microenvironment was important for expansion and preservation of 
hematopoietic stem/progenitor cell phenotype over extended periods of time.260 
Alternatively, it may be possible that the hDAT matrix could be influential in guiding 
hematopoietic differentiation towards highly regenerative lineages such as monocytes and 
macrophages. For example, studies looking at engineered matrices found that fibrillar 
constructs with varying stiffness and GAG content were instrumental in guiding monocyte 
differentiation and determining macrophage polarity.261 Furthermore, the exact role that 
adipose tissue in the bone marrow compartment plays in guiding hematopoiesis is still under 
intense investigation.262 In the marrow, adipocytes are believed to be involved in regulating 
HSC proliferation and differentiation through the secretion of factors such as adiponectin, IL-
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6 and leptin.263-265 Overall, the hDAT provides a complex ECM microenvironment with a 
multitude of structural and bioactive proteins that may directly influence seeded cells. 
1.6 Project overview 
PAD caused by the accumulation of atherosclerotic plaque in the distal extremities, affects 
over 200 million people worldwide, and costs healthcare organizations billions of dollars 
annually. Individuals with severe limb ischemia, resting pain and non-healing ulcers are 
diagnosed with the most serious form of PAD known as CLI and 30% of patients require 
lower limb amputation one year post-diagnosis. Unfortunately, many patients with advanced 
CLI are not eligible for any of the gold standard surgical revascularization techniques and 
amputation remains the only treatment option. Regenerative medicine based techniques 
aimed at stimulating new blood vessel formation using cell and gene therapies have 
demonstrated promising results in preclinical animal studies and human clinical trials. While 
many of these therapies have shown efficacy in improving blood flow in the affected limb 
and reducing pain scores, further refinement is needed to have an impact on patient 
amputation rates and mortality.  
Hematopoietic progenitor cells are rare cells that can be easily purified from umbilical cord 
blood based on the highly conserved stem cell marker, ALDH. When applied to animal 
models of CLI, HPC have shown promising pro-angiogenic paracrine function following 
intramuscular transplantation, inducing new vessel formation despite limited cell engraftment 
at the ischemic site. To improve HPC survival following administration and to prolong pro-
angiogenic paracrine functions, this project applied an interdisciplinary approach using 
naturally-derived human decellularized adipose tissue bioscaffolds as a novel, 3D cell culture 
and delivery platform. Overall, the primary goal for this study was to characterize the effect 
that hDAT had on the survival, proliferation and differentiation of seeded HPC and to 
develop an innovative cell therapy harnessing the supportive qualities of hDAT scaffolds and 
established pro-angiogenic functions of expanded HPC. 
1.7 Hypotheses 
The in vitro hypotheses for this project were that ALDHhi HPC would demonstrate 
augmented cell viability and proliferation following seeding within hDAT scaffolds 
 
 
 
31 
compared to conventional culture on tissue culture plastic (TCP). Additionally, it was 
hypothesized that HPC seeded in hDAT scaffolds would retain their primitive functional and 
cell surface phenotype when compared to suspension cultured HPC. For the in vivo objective 
of this project, it was hypothesized that ALDHhi HPC seeded in hDAT scaffolds delivered to 
the ischemic hindlimb of immunodeficient mice following FAL would result in increased 
vessel formation in situ, enhanced recovery of perfusion and improved usage of the ischemic 
limb when compared with intramuscularly injected HPC in saline. 
1.8 Objectives 
The main objectives of this Master’s project were to: 
Objective 1: Characterize the interaction of umbilical cord blood derived HPC seeded in 
hDAT scaffolds through the direct assessment of cell viability, ALDH activity, proliferation 
and cell phenotype in vitro. 
Objective 2: Assess the pro-regenerative potential of transplanted UCB-derived HPC seeded 
in hDAT scaffolds relative to HPC delivered intramuscularly, unseeded hDAT scaffolds, and 
saline alone controls in immunodeficient NOD/SCID mice with FAL-induced CLI. 
. 
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Chapter 2 
2 Materials and methods 
2.1 HPC purification and expansion 
2.1.1 Purification of ALDHhi cells from umbilical cord blood 
Cells were derived from umbilical cord blood (UCB) harvested during scheduled C-sections 
at the London Health Sciences Birthing Center in Victoria Hospital. Studies were approved 
by the Human Studies Research Ethics Board at Western University (HSREB# 12934, see 
Appendix 1). Up to 50 mL of blood was collected per sample through venipuncture of the 
umbilical vein (Figure 2.1 A). Blood was processed within 24 hours to ensure the maximum 
HPC viability.202  
UCB was lineage depleted (Lin-) through the addition of 5 µL of RosetteSep™ human 
hematopoietic progenitor cell enrichment cocktail (Stem Cell Technologies, Vancouver, BC) 
per milliliter of UCB and incubated for 45 minutes at room temperature. Following the 
incubation, UCB was diluted two-fold with sterile phosphate buffered saline (PBS, Gibco, 
Invitrogen, Carlsbad, CA) and 10 mL of the diluted UCB was carefully layered on 4 mL of 
Ficoll-Paque density gradient medium (GE Healthcare, Marlborough, MA) in 15 mL Falcon 
conical tubes (Corning Life Sciences, Corning, NY). Layered UCB was centrifuged at 450 x 
g for 20 minutes with the brake set to 0 resulting in the well-defined layer of blood plasma, 
mononuclear leukocytes, Ficoll-Paque and unwanted mature hematopoietic cells from top to 
bottom (Figure 2.1). The concentrated mononuclear cell suspension (buffy coat) was 
carefully aspirated using a Pasteur Pipette (Fisher Scientific, Hampton, NH) and placed in 50 
mL conical tubes (Corning Life Sciences, Corning, NY). Collected mononuclear cells were 
diluted 2-fold with sterile PBS containing 5% fetal bovine serum (5% FBS/PBS, 
ThermoFisher, Waltham, MA) and centrifuged at 450 x g for 7 minutes to remove residual 
plasma and Ficoll-Paque. Cells were resuspended in 5% FBS/PBS and 0.8% ammonium 
chloride (StemCell Technologies, Vancouver, BC) was added at a 1:9 ratio and incubated at 
room temperature for 8 minutes to lyse remaining red blood cells (RBC). Following RBC 
lysis, cells were centrifuged at 450 x g for 7 minutes, counted using trypan blue viability dye 
and a hemocytometer and resuspended in 1 mL of Aldefluor Assay buffer (StemCell 
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Technologies, Vancouver, BC) for every 107 cells in suspension. Cells were passed through a 
40 µm nylon mesh filter (Corning Life Sciences, Corning, NY) into a sterile 15 mL conical 
tube to remove cell clusters and 5 µL of AldeflourTM reagent, a fluorescent substrate of 
ALDH ( Stem Cell Technologies, Vancouver, BC), was added per mL of Aldefluor assay 
buffer. Cells were incubated for 30 minutes at 37 °C to facilitate the intracellular 
accumulation of the fluorescent biproduct of Aldefluor in cells with high ALDH-activity.  
Purification of progenitor cells on the basis of high ALDH activity was completed by Dr. 
Kristin Chadwick using fluorescence activated cell sorting (FACS) on the BD FACSAria™ 
III (BD Biosciences, San Jose, CA) in the London Regional Flow Cytometry Facility 
(LRFCF), Robarts Research Institute. Regions for the selection of cells with high versus low 
ALDH-activity were determined based on the fluorescent intensity of cells that received 
AldeflourTM reagent and were immediately transferred to a 15 mL conical tube containing 5 
µL of the ALDH-inhibitor, DEAB (StemCell Technologies, Vancouver, BC). 
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Figure 2.1 Objective 1 methodology and timeline for the in vitro characterization of UCB-
derived HPC seeded into hDAT scaffolds. (A) Purification and expansion protocol for UCB 
derived ALDHhi HPC. (B) Timeline for in vitro analysis of cell viability, proliferation, cell 
surface phenotype and ALDH activity for cells extracted from hDAT scaffolds, collected from 
the scaffold supernatant or cultured on TCP. (C) Representative images for all end point in 
vitro assays including cell viability, proliferation, ALDH activity and cell phenotype using 
flow cytometry. 
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2.1.2 Expansion of ALDHhi HPC  
For cell expansion prior to subsequent experiments, 1 x 105 sorted cells with high ALDH-
activity (ALDHhi) were plated on fibronectin-coated (Sigma-Aldrich, St. Louis, MO) T-25 
tissue culture plastic (TCP) flasks (Corning Life Sciences, Corning, NY) and expanded using 
optimized, serum-free and hematopoietic lineage-specific culture media X-Vivo 15 (Lonza, 
Basel, Switzerland) supplemented with 10 ng/mL of stem cell factor (SCF), Fms-related 
tyrosine kinase 3 ligand (Flt3L), and thrombopoietin (TPO, all from Life Technologies, 
Carlsbad, CA). Media was changed every 3 days. Cells were expanded for 6 days to obtain 
adequate HPC number for experiments without the loss of vascular regenerative function.164  
2.2 hDAT scaffold production  
2.2.1 Adipose tissue decellularization protocol 
Chemicals and reagents involved in hDAT scaffold production were purchased from Sigma-
Aldrich (St. Louis, MO), unless otherwise stated. hDAT scaffolds were synthesized from 
subcutaneous fat tissue harvested from patients receiving elective surgery for abdomen or 
breast reduction at London Health Sciences Centers (Cumberland Clinic, St. Joseph’s 
Hospital or University Hospital, London, ON). Human Research Ethics Board approval was 
obtained from Western University (HREB# 105426, see Appendix 3). Patient information 
including age, sex, height, weight and excision site was collected and recorded. All hDAT 
used during this project was derived from adipose tissue pooled from 5 donors. 
The decellularization protocol used throughout this project was an established, 5-day 
detergent-free process involving mechanical disruption, polar solvent extraction to remove 
lipid content, and enzymatic digestion to remove cells and cellular components, as previously 
documented in Flynn 2010.256 First, adipose tissue was transported to the lab on ice in sterile 
PBS containing 20 mg/mL bovine serum albumin (BSA). The tissue was carefully examined 
and portions of cauterized tissue and large blood vessels were removed and discarded. The 
tissue was then cut into 3 cm3 blocks to increase the surface area and placed into 100 mL of 
hypotonic buffer solution (pH 8.0) containing 10 mM Tris base, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 1% (v/v) antibiotic-antimycotic solution (ABAM, 
Gibco, Invitrogen, Carlsbad, CA) and 0.27 mM of the protease inhibitor 
phenylmethanesulphonylfluoride (PMSF).  
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The tissue tubs were placed in a -80°C freezer. Following liquid and tissue freezing, the tubs 
were removed and placed in a 37°C agitating incubator set to 120 rpm until completely 
thawed. The liquid was removed and replaced with new freezing buffer solution, including 
fresh ABAM and PMSF. This freeze/thaw cycle was repeated twice more, until a total of 3 
freeze/thaw cycles had been completed. Following the final thaw cycle, the freezing solution 
was replaced with 50 mL of an enzymatic digestion solution comprised of 0.25% Trypsin/ 
0.1% EDTA solution (Gibco, Invitrogen, Carlsbad, CA), 1% (v/v) ABAM and placed in the 
agitating incubator overnight. The next morning on day 2, the enzymatic digestion solution 
was removed and replaced with 100 mL of polar solvent solution containing 99.9% 
isopropanol, 1% (v/v) ABAM and 0.27 mM PMSF. The tissue was gently massaged and left 
in the 37°C agitating incubator for 8 hours. Polar solvent solution replacement and tissue 
massaging was repeated and the tubs were placed back into the 37°C agitating incubator 
overnight. This polar solvent solution and tissue massage process was repeated again on day 
3 and the tubs were returned to the 37°C agitating incubator overnight. On the morning of 
day 4, the tissue was rinsed three times in a solution containing 100 mL of Sorensen’s 
phosphate buffer (SPB) solution (pH 7.3, 147 g/L Na2HPO4•7H2O and 23 g/L KH2PO4), 1 
mL ABAM and 7 µL PMSF. The tissue was agitated in a 37°C incubator for 30 minutes and 
the rinsing solution was discarded between rinses. Following rinses, the tissue was placed in 
enzymatic digestion solution containing 50 mL 0.25% Trypsin/ 0.1% EDTA and 1% (v/v) 
ABAM and left in an agitating incubator at  37°C for 6 hours. The tissue was then rinsed 3 
times using the SPB rinsing solution and incubated overnight in 200 mL of SPB digest (pH 
7.3 147 g/L Na2HPO4•7H2O, 23 g/L KH2PO4 and 12g/L MgSO4•7H2O) containing 13,000 
units of type I DNase from bovine pancreas, 12.5 mg of type IIIA RNase from bovine 
pancreas, 2000 units type IV-S lipase from porcine pancreas, 2 mL ABAM and 0.27 mM 
PMSF. On the morning of day 5, the enzymatic digestion solution was replaced with 100 mL 
of polar solvent extraction solution containing 99.9% isopropanol, 1% (v/v) ABAM and 0.27 
mM PMSF and placed in an agitating 37°C incubator for 8 hours. The tissue was rinsed three 
times with SPB rinsing solution followed by 3 decontamination rinses in 70% ethanol before 
being stored at 4°C in PBS containing 1% ABAM until future use. 
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2.3 Preparation of hDAT suspension and scaffold fabrication  
To produce a uniform ECM suspension for successful hDAT porous foam scaffold 
fabrication, the Nishihara collagen solubilization methods described by F. S. Stevens were 
adapted for use with hDAT as follows (Figure 2.2).266 Stored hDAT was removed from the 
PBS solution, excess fluid was removed, and the samples were washed with PBS three times 
for 30 minutes under agitation at room temperature. Following the last wash step, the tissue 
was placed in a -20°C freezer overnight before being lyophilized for 48 hours. Following 
lyophilisation, the freeze-dried tissue was minced into 0.5 mm fragments and 75 mg was 
placed in a cryomilling chamber with two large stainless-steel milling balls. This chamber 
was submerged in liquid nitrogen for 3 minutes and subsequently milled on a Retsch Mixer 
Mill 400 (Retsch, Haan, Germany) for 3 minutes at 1800 rpm. The chamber was placed back 
into liquid nitrogen for 3 minutes and the milling/freezing procedure was repeated twice 
more for a total of 3 milling cycles.  
The finely cryomilled hDAT tissue was collected from the chambers using a round-edge 
scoopula and 1 g (dry weight) of the decellularized adipose tissue powder was digested in 
10 mL of 0.22 mM NaH2PO4 solution (pH 5.4) containing 10 mg of a-amylase (1% w/w of 
dry tissue). The liquid volume was recorded, and the samples were digested for 72 hours 
under constant agitation at room temperature. Following digestion, the samples were 
centrifuged at 1500 x g for 10 minutes and the supernatant was removed and discarded. Next, 
10 mL of 5% (w/v) NaCl solution was added to the digested tissue and the mixture was left 
to agitate for 10 minutes. The tissue was centrifuged again at 1500 x g for 10 minutes and 
was rinsed once more with 5% NaCl solution for a total of two rinses. Following the second 
rinse, the supernatant was removed and replaced with 10 mL of double-distilled water 
(ddH2O) and left to agitate for 10 minutes at room temperature. Following rinse steps with 
NaCl and ddH2O, the tissue suspension was centrifuged at 1500 x g for 7 minutes and the 
supernatant was replaced with 0.2 M acetic acid up to the volume recorded previously. The 
samples were lightly vortexed and placed on a temperature regulated incubator shaker set to 
120 rpm and 37°C overnight.  
The next day, the samples were homogenized with a Fisher Scientific Power Gen 125 hand 
held homogenizer (Fisher Scientific, Hampton, NH) using 5 second pulses at a setting of 6. 
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The solution was cooled on ice between three homogenization bursts to prevent the sample 
from over-heating. The homogenous hDAT suspension was diluted to 25 mg/mL (based on 
starting tissue mass) with 0.2 M acetic acid and 250 µL of the suspension was pipetted into 
each well of a 48 well plate, frozen in a -80°C freezer and lyophilized to form the final 
cylindrical-shaped porous foam with a diameter of 1 cm and height of 0.2 mm. The scaffolds 
were stored in 100% ethanol at 4°C until they were needed and were rehydrated through 
sequential 30 minute rinses in 100:0, 70:30, 0:100 solutions of ethanol:PBS, followed by a 60 
minute incubation in 10 mL of X-Vivo 15 supplemented with 10 ng/mL of SCF, TPO and 
Flt3L prior to cell seeding.  
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Figure 2.2 Macroscopic overview for adipose tissue decellularization and scaffold 
fabrication. (A) Freshly excised adipose tissue prior to decellularization. (B) Tissue following 
polar solvent extraction and massaging. (C) hDAT following complete decellularization 
process and rehydration with PBS. (D) hDAT following 48 hour lyophilization. (E) Finely 
minced pieces of lyophilized hDAT (F) Cryomilled hDAT prior to hDAT suspension              
(G) hDAT scaffold fabrication through lyophilization in 48-well plate (H) Final hDAT 
scaffold with a diameter of 1 cm and height of 0.2 cm. Scale bar represents 1 cm. Image 
adapted from Morissette Martin et al.2 
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2.4 HPC seeding and extraction from hDAT scaffolds 
2.4.1 HPC seeding into hDAT scaffolds 
All experiments in this project utilized the same methodologies for the effective seeding of 
HPC into hDAT scaffolds. Following 6 days of expansion, non-adherent cells were collected 
and placed in a 15 mL Falcon tube. Next, 1 mL of trypsin (TrypLE Express, Gibco, 
Invitrogen, Carlsbad, CA) was added to each T-25 flask and the flasks were incubated for 10 
minutes at 37°C to detach any remaining adherent cells. Lifted adherent cells were collected 
and added to the non-adherent fraction. Cells were centrifuged at 450 x g for 7 minutes and 
resuspended in 1 mL of supplemented X-Vivo 15 for cell counting using the Countess II 
automated cell counter (ThermoFisher Scientific, Waltham, MA). HPC were statically 
seeded into rehydrated hDAT foams at 5 x 105 cells/scaffold in a 48-well plate containing 
600 µL of supplemented X-Vivo 15 per well and cultured for up to seven days in vitro. HPC 
cultured without hDAT scaffolds were included alongside hDAT groups as TCP controls. 
2.4.2 Cell extraction from hDAT scaffolds 
For the in vitro characterization of the HPC phenotype after seeding into the hDAT scaffolds, 
flow cytometric analysis required the analyses of cells extracted from hDAT that contained 
fragments of contaminating scaffold debris. Excess scaffold debris that could not be removed 
through filtration resulted in difficulty discriminating between autofluorescent ECM 
particulates and isolated cells. Variable amounts of scaffold contamination would frequently 
lead to over- or under-representations of marker frequencies during analysis. To account for 
this, cell-specific stains were included in the viability, proliferation and monocyte / 
macrophage phenotype panels to positively select cells for accurate phenotype analysis. 
However, the ALDH and primitive cell surface marker expression panel utilized directly 
conjugated antibodies with fluorophores incompatible with fluorescent cellular dyes and 
required a centrifugation step on Ficoll-Paque to remove debris using a density gradient, 
described below.  
The TCP and supernatant samples were collected using a pipette and remaining adherent 
cells were detached using previously mentioned methods involving a short incubation with 
TrypLE expressTM. ALDH and cell surface phenotype expression was analyzed at the time of 
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seeding (day 0) and all in vitro assay analyses were performed at days 1, 3 or 7 post-seeding 
to monitor the effects of the hDAT on the HPC phenotype over time.  
2.4.2.1 Cell processing for viability, proliferation and cell surface 
marker expression analyses 
hDAT scaffolds were removed from wells using flat forceps and placed in a 5 mL round 
bottom plastic tube (Corning Life Sciences, Corning, NY) containing 1 mL of TrypLE 
ExpressTM. Cells in the scaffolds were enzymatically liberated through incubation for 15 
minutes within a water bath at 37°C. The resulting cell-ECM suspension was briefly vortexed 
to promote detachment of cells from the scaffold. Next, the entire suspension was filtered 
through a 50 µm nylon mesh filter (Sysmex, Kobe, Japan) to remove large fragments of 
scaffold ECM and rinsed twice to wash out trapped cells remaining on the filter. To 
characterize cells that did not attach directly on the scaffold, the supernatant media remaining 
in the well following scaffold removal was collected and analyzed.  
2.4.2.2 Cell processing for ALDH-activity and primitive cell surface 
marker expression analyses 
To assess ADLH-activity alongside primitive cell surface marker expression, a density 
gradient centrifugation processing step was used to separate cells from scaffold debris. 
Following 1, 3 and 7 days of culture, cells were liberated from the scaffolds following the 
same TrypLE expressTM digestion for 15-minute at 37°C. Next the cell-ECM suspension was 
carefully layered on top of 1 mL of Ficoll-Paque density gradient medium (GE Life Sciences, 
Marlborough, MA) and centrifuged at 450 x g for 20 minutes with the brake set to 0. Cells 
were collected using a Pasteur pipette at the boundary between the Ficoll-Paque and Trypsin 
layers, being careful not to disturb the ECM pellet at the bottom of the tube. Collected cells 
were filtered through a 50 µm nylon mesh filter to remove any large ECM fragments not 
filtered by the density gradient centrifugation. Cells were then centrifuged and resuspended 
in 1 mL of PBS supplemented with 5% FBS and divided among experimental tubes.  
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2.5 Cell viability, proliferation, ALDH-activity and phenotype 
analyses in vitro 
To determine if hDAT scaffolds would be an effective cell delivery vehicle, HPC viability, 
proliferation and phenotype were assessed at 1, 3 and 7 days post-seeding and compared to 
TCP controls using flow cytometry (BD™ LSR II (BD Biosciences, San Jose, CA) at the 
LRFCF. Additionally, ALDH-activity and cell surface marker expression was analyzed 
following the 6 day expansion protocol to determine the cell phenotype prior to seeding into 
hDAT (Day 0). All flow cytometric analyses were performed in a non-blinded manner. 
Samples were resuspended in 300 µL of PBS prior to the addition of the relevant cell stains 
or conjugated antibodies to ensure equal distribution of the staining agent. All flow 
cytometry data analysis was collected using the BD FACSDiva™ (BD Biosciences, San 
Jose, CA) software during cytometer operation and analyzed using FlowJo software (FlowJo 
LLC., Ashland, OR). 
2.5.1 Cell viability 
Cell survival was assessed using Calcein AM (Sigma Aldrich, St. Louis, MO) as a marker for 
cell viability, DRAQ5 (ThermoFisher Scientific, Waltham, MA) as a marker for nucleated 
cells and Sytox orange (Invitrogen, Carlsbad, CA) as a marker for non-viable cells. DRAQ5 
was used in these experiments to distinguish viable and non-viable cells from scaffold debris 
and platelets lacking cell nuclei. Cells liberated from the scaffold or unattached cells 
remaining in the supernatant, as well as TCP culture controls, were stained sequentially with 
Sytox Orange, Calcein AM and DRAQ5 for 15 minutes at 37°C and then analyzed by flow 
cytometry. Gates were established for Calcein AM and Sytox orange staining based on 
relevant fluorescence minus one (FMO) samples on each day of flow cytometry. 
2.5.2 Cell proliferation 
To quantify cell proliferation, 10 µM of 5-ethynyl-2-deoxyuridine (EdU, Invitrogen, 
Carlsbad, CA) was administered to each well 24 hours prior to analysis. HPC extracted from 
hDAT scaffolds, or collected from the supernatant, or cultured on TCP were fixed in a 10% 
formalin solution (Fisher Scientific, Hampton, NH) for 10 minutes, permeabilized in saponin 
buffer solution (Invitrogen, Carlsbad, CA) for 15 minutes and cell proliferation was assessed 
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using the Click-iT™ EdU Alexa Fluor™ 488 Imaging Kit (Invitrogen, Carlsbad, CA). Gates 
were established for EdU positive cells based on FMOs for cells cultured without EdU. 
2.5.3 ALDH Activity and Primitive Cell Surface Marker Expression  
Cell surface marker expression was characterized through conjugated antibody staining with 
1:150 BV421 CD34 (BD Biosciences, San Jose, CA), 1:150 APC CD133 (BioLegend, San 
Diego, CA) and 1:100 of PE CD38 (BD Biosciences, San Jose, CA) per tube, and incubated 
for 45 minutes at 4°C. Cells were then rinsed with 3 mL PBS and centrifuged at 450 x g for 7 
minutes to remove residual antibodies. Next, cells were resuspended in 300 µL of Aldefluor 
assay buffer (StemCell Technologies, Vancouver, BC) and 1 µL of Aldefluor was added to 
each tube prior to a 30-minute incubation at 37°C. Samples were centrifuged for 7 minutes at 
450 x g and resuspended in 300 µL fresh Aldefluor assay buffer to wash out residual 
Aldefluor reagent. To identify cells with high ALDH-activity, gates were established using 
DEAB treatment at the time of Aldefluor staining. Positive expression of each cell surface 
marker was identified through use of relevant FMOs at each timepoint. 
2.5.4 Monocyte and macrophage marker expression 
To evaluate whether hDAT scaffolds promoted the differentiation of seeded HPC, cell 
surface markers enriched on monocyte, macrophage and megakaryocyte lineages were 
analyzed. Following cell extraction from the hDAT scaffolds or TCP, samples were pelleted 
at 450 x g for 7 minutes and resuspended in 300 µL of 5% FBS/PBS. Next, CellTracker™ 
Green CMFDA Dye (Invitrogen, Carlsbad, CA) was prepared according to the 
manufacturer’s instructions and 100 µL of the 10 µM solution was added to each sample and 
all tubes were placed in a 37 °C incubator for 30 minutes to mark viable cells. Following 
incubation, samples were washed with 3 mL of 5% FBS/PBS, centrifuged at 450 x g for 7 
minutes and resuspended in 10% formalin solution for 5 minutes at room temperature. The 
cells were washed again with 3 mL of 5% FBS/PBS and centrifuged at 300 x g for 7 minutes 
before being permeabilized in saponin buffer solution for 20 minutes.  
Samples were distributed for single-stain analysis for CD14 (monocyte), CD11b 
(macrophage) and CD42b (megakaryocyte/platelet), and multi-stain analysis for CD68 
(macrophage), and CD163 (M2 macrophage). Each single stain tube received 1:150 of 
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APC/Cy7 CD14 (Biolegend, San Diego, CA), 1:150 µL of PE CD11b (Biolegend, San 
Diego, CA) or 1:150 µL of PE CD42b (Biolegend, San Diego, CA). Multi-stain tubes 
received 1:150 µL of PE CD68 (Biolegend, San Diego, CA) and 1:150 of APC CD163 
(Biolegend, San Diego, CA).  
 
Table 2.1 Antibody specifications for flow cytometry protocols 
Antibody Fluorophore Clone Catalog # Company 
Monoclonal 
mouse anti-
human CD34 
BV421 Clone 581 562577 BD Biosciences, San Jose, CA 
Monoclonal 
mouse anti-
human CD133 
APC Clone 7 372806 Biolegend, San Diego, CA 
Monoclonal 
mouse anti-
human CD38 
PE HIT2 555460 BD Biosciences, San Jose, CA 
Monoclonal 
mouse anti-
human CD14 
APC/Cy7 M5E2 301820 Biolegend, San Diego, CA 
Monoclonal 
mouse anti-
human CD11b 
PE ICRF44 301306 Biolegend, San Diego, CA 
Monoclonal 
mouse anti-
human CD42b 
PE HIP1 303906 Biolegend, San Diego, CA 
Monoclonal 
mouse anti-
human CD68 
PE Y1/82a 333808 Biolegend, San Diego, CA 
Monoclonal 
mouse anti-
human CD163 
APC GHI/61 333610 Biolegend, San Diego, CA 
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2.6 Femoral Artery Ligation and Transplantation of HPC 
seeded hDAT Scaffolds 
2.6.1 Animals 
All animal procedures used were performed in accordance with the rules and regulations set 
by the Canadian Council on Animal Care (CCAC) and were outlined in the animal use 
protocol #2015-012 (Appendix 2) approved by the Animal Care Committee at Western 
University. All in vivo experiments were performed on 8- to 10-week old NOD.CB17-
Prkdcscid/J mice (NOD/SCID mice) ordered from Jackson Laboratories (Stock number 
001303, Jackson Laboratories, Bar Harbor, ME). NOD/SCID mice were selected for the 
transfer of HPC-seeded hDAT scaffolds based on their complete lack of mature T- and B-
cells and reduced NK cell function.267 These reductions in adaptive and innate immunity 
permit human cell engraftment without xeno-rejection. For mice euthanized at day 14 post-
surgery, mice were intraperitoneal (IP) injected with 200 µg of EdU (Invitrogen, Carlsbad, 
CA) 24 hours prior to sacrifice for the labelling of proliferating cells in situ. Male and female 
NOD/SCID mice were divided among treatment groups at random. All in vivo analysis was 
collected in a non-blinded manner. 
2.6.2 Femoral Artery Ligation Surgery 
To evaluate the efficacy of hDAT scaffolds as a cell supportive delivery vehicle for expanded 
HPC compared to IM injection, day 6 expanded HPC were seeded into hDAT scaffolds (5 x 
105 cells) 24 hours prior to FAL surgery and implanted into the ischemic limb of 
immunodeficient NOD/SCID mice at the site of femoral artery ligation and excision in the 
right hindlimb (Figure 2.2A). Unseeded hDAT scaffolds were similarly implanted to serve as 
cell-free controls. Intramuscular (IM) saline injection, and mice IM-injected with HPC in 
solution were used as a hDAT scaffold-free controls. Cell doses were selected based on 
previously published experiments completed by the Hess lab.164, 165 In total, four treatment 
groups were studied: day 6 expanded HPC in hDAT scaffold, day 6 expanded HPC IM 
injected, scaffold only and saline vehicle controls. A total of 9 mice were included for each 
group. Each mouse within the HPC-seeded hDAT and IM injected HPC treatment groups 
received cells from a unique biological UCB sample. 
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To induce unilateral hind limb ischemia in the mice, femoral artery and vein ligation 
followed by excision (2 – 5 mm portion) was completed following an established  
protocol.268 Briefly, mice were anesthetized by an IP injection of 100 mg/kg ketamine and 10 
mg/kg xylazine, and maintained using 2% isoflurane (Baxter Corperation, Deerfield, IL). 
Prior to surgery, the medial side of both limbs were shaved using a sterilized electric shaver. 
Following shaving, Nair (Church & Dwight, Ewing, NJ) was applied generously from the 
feet to the hips to remove remaining hair. After 10 minutes, the Nair was removed using a 
sterile gauze pad and the region was sequentially washed using soapy water, 70% ethanol 
and chlorhexidine gluconate. Next, each mouse was positioned under a dissection 
microscope with their limbs taped down to the surface. Using forceps, the skin proximal to 
the knee joint was pinched and a scalpel was used to make an incision (2 – 3 mm) directly 
above the underlying femoral artery. Subcutaneous fat was carefully removed using forceps 
and tissue cauterizer. To expose the neurovascular bundle, the membranous fascia 
surrounding the adductor muscle was carefully removed using fine pointed forceps. The 
parallel femoral nerve was separated from the vessels using a blunt probe. Using 7-0 silk 
sutures, the femoral artery and vein were ligated at the proximal femoral artery (immediately 
distal to the bifurcation of the internal iliac artery) and distal femoral artery (proximal to the 
bifurcation into the saphenous and popliteal arteries). Sutures were positioned 3 – 5 mm apart 
with the superficial epigastric artery bifurcation present between them. The femoral artery 
and vein were carefully excised using a tissue cauterizer at sites distal to the proximal suture 
and proximal to the distal suture. Prior to incision closure, hDAT scaffolds with or without 5 
x 105 expanded HPC were transplanted over the ligation site, or 100 µL saline with or 
without 5 x 105 cultured HPC was directly injected into 2 sites on the thigh and 
gastrocnemius muscle.  
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Figure 2.3 Objective 2 methodology and timeline for the in vivo application of HPC 
delivered in hDAT scaffolds in a immunodeficient mouse model of CLI. (A) To induce 
hindlimb ischemia, NOD/SCID mice underwent unilateral femoral artery and vein ligation and 
excision and were treated with HPC-seeded hDAT scaffolds, IM injection of HPC in saline, 
scaffold only, or IM injection of saline. (B) Ischemic and non-ischemic thigh muscle sections 
were examined for CD31 vessel density and CD45 human cell engraftment. CatWalkTM gait 
analysis was used to quantify functional limb recovery through analysis of ischemic paw print 
area and intensity relative to non-ischemic limb values. RH: Right Hind Limb, LH: Left Hind 
Limb, RF: Right Front Limb, LH: Left Hind Limb 
 
 
 
48 
2.6.3 Laser Doppler Perfusion Imaging and CatWalk Gait Analysis 
To assess the recovery of limb perfusion, laser Doppler perfusion imaging (LDPI) was 
performed weekly for up to 35 days (Figure 2.1 A). Perfusion ratios (PR) were generated the 
day after surgery to ensure successful reduction in limb perfusion (PR of < 0.15 for 
ischemic/non-ischemic limbs). For limb perfusion analysis, the region of interest included the 
dorsal portion  of the hind paw that was distal to the ankle joint. For LDPI measurements at 
days 1, 7, 14, 21, 28 and 35 post-surgery, mice were anesthetically induced using 4% 
isoflurane/oxygen and maintained at 2% isoflurane/oxygen for the duration of the assay (10 
minutes). Mice were warmed for 5 minutes at 37°C prior to measuring hind limb perfusion 
using the Moor Instruments laser Doppler perfusion imager (Moor Instruments, Devon, UK). 
Ischemic limb perfusion was quantified using the Moor Instruments software and flux 
intensity within the ischemic limb was divided by the non-ischemic limb to calculate the PR.  
To assess the recovery of limb usage, CatWalkTM gait analysis (Noldus, Wageningen, 
Netherlands) was performed at days 7 and 14 in Robarts Research Institute’s integrative 
neurobehavioral facility using the CatWalk equipment and software (CatWalk 7.1, Noldus, 
Wageningen, Netherlands). Four complete runs with minimal pivoting and involving >4 
footprints per limb were collected for each mouse. Each run was analyzed individually and 
functional recovery was quantified based on the ratio of print intensity and print area for the 
ischemic versus non-ischemic hindlimbs. 
2.6.4 Histological evaluation of revascularization 
Hindlimb adductor and gastrocnemius muscles from the ischemic and control limbs were 
collected at day 14 or at day 35 and frozen in optimal cutting temperature medium (OCT, 
Fisher Scientific, Hampton, NH). Adductor muscle blocks were cryosectioned at a thickness 
of 15 µm and stored in a -80°C freezer until needed. To prepare the frozen sections for both 
immunofluorescent and colourmetric staining, tissue sections were fixed using a 10% 
formalin solution for 15 minutes before being rinsed twice with PBS for 10 minutes. To 
permeabilize the tissues, sections were incubated in 1% Triton-X detergent (Sigma-Aldrich, 
St. Louis, MO) for 20 minutes. All antibody staining was performed at room temperature. 
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2.6.4.1 Immunofluorescent staining for day 14 adductor muscles 
Permeabilized tissue sections from day 14 adductor muscles were subjected to two 10 
minutes rinses using PBS, and the sections were evaluated for human cell engraftment. First, 
all sections were incubated in 100 µL of 5% goat serum blocking agent (Vector Labs, 
Burlingame, CA) for 1 hour to reduce non-specific binding. Next, sections were covered with 
rabbit anti-human CD45 antibody (Abcam, Cambridge, UK) diluted in 5% goat serum at 
1:100 for 1 hour. Following two 10 minute washes with PBS, sections were covered with 5% 
goat serum solution containing 1:100 alexafluor 647 goat anti-rabbit secondary (Jackson 
ImmunoResearch Laboratories, Inc., Westgrove, PA) for 30 minutes. Finally, the sections 
were rinsed twice with PBS and cell nuclei were stained using 4',6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI, Invitrogen, Carlsbad, CA) according to the 
manufacturer’s specifications. Each slide was thoroughly rinsed in double-distilled water 
(ddH2O) and mounted in Vectamount aqueous mounting medium (Vector Labs, Burlingame, 
CA). Two complete sections from the surgical and non-surgical limb were analyzed for each 
animal and imaged using the Leica Aperio Versa 8 (Leica, Wetzlar, Germany) and human 
CD45+ cell engraftment was quantified using ImageJ (ImageJ software, National Institute of 
Health, Bethesda, MD). 
2.6.4.2 Colourmetric CD31 capillary density quantification 
Following tissue permeabilization and two rinses in PBS for 10 minutes, all sections were 
incubated in 100 µL of 5% goat serum blocking agent for 1 hour. Rat anti-mouse CD31 (BD 
Biosciences, San Jose, CA)  diluted 1:100 in 5% goat serum was added to cover each tissue 
section and incubated for 45 minutes. Following primary antibody incubation, tissue sections 
were rinsed twice with PBS for 10 minutes and incubated in 50 µL of 1:100 peroxidase-
labelled anti-rat secondary (Vector Labs, Burlingame, CA) for 30 minutes. Peroxidase-
labelled CD31 regions were chromogenically detected using 3,3'-diaminobenzidine (DAB, 
Vector Labs, Burlingame, CA), a chemical substrate that turns brown in regions with 
horseradish peroxidase activity. Sections were mounted using Vectamount aqueous mounting 
solution and 14 images at 3 tissue depths for each limb were acquired in a blinded fashion on 
the Olympus BX50 (Olympus, Tokyo, Japan). CD31+ cell area was quantified for each image 
and ischemic to non-ischemic CD31 positive ratios were calculated for each mouse using 
ImageJ. 
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Table 2.2 Specifications for immunohistochemistry protocols 
 CD45 CD31 
Blocking Agent PBS + 5% Goat serum PBS + 5% Goat serum 
Primary Antibody 
Rabbit anti-human monoclonal 
CD45 (Cat. Ab 40763)a 
Rat anti-mouse monoclonal 
CD31 (Cat. 550274)b 
Secondary Antibody 
Goat anti-rabbit, Alexafluor 647  
(Cat. 111-605-003)c 
Goat anti-rat, peroxidase 
labelled (Cat. Pl-9400)d  
aAbcam, Cambridge, UK bBD Biosciences, San Jose, CA cJackson Immunoresearch, 
Westgrove, PA dVector Laboratories, Burlingame, CA 
 
2.7 Statistics 
For cell viability, cell proliferation, ALDH assays and cell surface marker expression 
analyses in vitro, a two-way analysis of variance (ANOVA) was performed followed by a 
Tukey’s post hoc multiple comparisons test. For LDPI and CatWalk gait analyses, a two-way 
repeated measures ANOVA was completed followed by a Tukey’s post hoc multiple 
comparisons test. Assessment of revascularization using CD31 DAB staining was analyzed 
using a one-way ANOVA followed by a Tukey’s post hoc multiple comparisons test. All 
statistical analyses were completed using the GraphPad Prism 7 software. Outliers were 
detected using a Grubb’s test with a p < 0.05. 
 
 
 
 
 
 
 
 
 
51 
Chapter 3 
3 Results 
3.1 HPC within hDAT scaffolds demonstrated increased 
viability in vitro 
Previous experiments performed by the Hess laboratory have extensively characterized the 
regenerative capacity of fresh umbilical cord blood (UCB) ALDHhi hematopoietic progenitor 
cells (HPC) or day 6 expanded ALDHhi HPC when intramuscularly (IM) injected into the 
femoral artery ligation (FAL) mouse model of critical limb ischemia (CLI).164, 165 
Unfortunately, due to severe ischemia in the surgical limb and poor survival in muscle tissue, 
cell engraftment was rarely detected at day 7 near the site of injection.163 The central 
objective of this study was to augment cell retention near the surgical site using a cell-
supportive matrix derived from human decellularized adipose tissue (hDAT).  
To evaluate the viability of day-6 expanded HPC seeded in hDAT scaffolds in vitro, calcein 
AM and sytox orange was used to label viable and non-viable cells, respectively, and live / 
dead cells were quantified by flow cytometry over 7 days in culture. HPC seeded in hDAT 
scaffolds demonstrated significantly higher frequencies of viable (Calcein+ / Sytox-) cells at 
day 3 (84.1 ± 3.6 %, *p < 0.05) and day 7 (86.4 ± 3.4 %, *p < 0.05) compared to the cells in 
the supernatant collected from above the hDAT scaffolds (70.0 ± 6.3 % at D3 and 69.6 ± 3.4 
% at D7, Figure 3.1 A,B) and HPC cultured on TCP (70.2 ± 6.7 % at D3 and 70.7 ± 4.1 % at 
D7). Notably, while viable cell frequency decreased from day 1 through 7 for cells cultured 
on TCP (87.6 ± 1.5 % to 70.7 ± 4.1, *p < 0.05) and remaining in the supernatant (87.4 ± 1.8 
% to 69.6 ± 3.4 %, **p < 0.01), cell viability was not significantly different between 
timepoints for the cells extracted from within the hDAT scaffolds. 
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Figure 3.1 Culture in hDAT scaffolds increased HPC viability in vitro.                               
(A) Representative flow cytometry plots showing Calcein AM (viable) and Sytox orange 
(non-viable) fluorescence of cells extracted from the hDAT scaffolds, collected from the 
scaffold supernatant, or cultured on TCP at 7 days post-seeding. (B) High HPC viability 
was maintained for 7 days in hDAT scaffolds and the frequency of viable cells was increased 
at day 3 and 7 compared to cells cultured on TCP or cells collected from the scaffold 
supernatant. Data is shown as mean ± SEM (N = 7 UCB samples) and evaluated for 
statistical differences using a two-way ANOVA followed by Tukey’s post-hoc multiple 
comparisons test (*p < 0.05). 
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3.2 HPC within hDAT scaffolds demonstrated increased 
proliferation in vitro  
Next, to assess the proliferative capacity of HPC within the hDAT scaffolds, EdU 
incorporation was used to label cells that had actively divided within 24 hours prior to each 
timepoint. The frequency of proliferating cells at days 1, 3 and 7 was determined using flow 
cytometry for cells extracted from the hDAT scaffolds, remaining in the scaffold supernatant, 
or cultured on TCP. The frequency of proliferating cells was higher at day 7 for cells 
extracted from the hDAT scaffolds (52.8 ± 1.6 %) as compared to HPC cultured on TCP 
(20.3 ± 5.4 %, *p < 0.05, Figure 3.2 A,B). Cell proliferation was equivalent when comparing 
the HPC extracted from the hDAT scaffolds to those collected from the scaffold supernatant, 
suggesting that the presence of the scaffolds contributed to proliferation for both populations. 
When evaluating differences in HPC proliferation over time, both TCP and supernatant HPC 
experienced sequential decreases in the frequency of proliferating cells at day 1 (73.9 ± 4.0 % 
and 62.6 ± 8.9 %) compared to day 3 (33.8 ± 9.43 % and 43.1 ± 8.6 %) and day 7 (20.3 ± 5.4 
% and 43.0 ± 10.3 %), respectively (Figure 3.2 C). Interestingly, cells extracted from the 
hDAT scaffolds demonstrated no significant decrease in the frequency of cell proliferation 
over the 7-day time course, indicating HPC expansion was maintained for 7 days in vitro. 
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Figure 3.2 Culture in hDAT scaffolds maintained HPC proliferation in vitro. (A) 
Representative flow cytometry plots demonstrating the frequency of EdU-labelled cells 
extracted from hDAT scaffolds, remaining in the scaffold supernatant, or cultured on TCP 
at day 7 post-seeding. (B) The frequency of proliferating cells was increased at day 7 for 
cells cultured in hDAT scaffolds compared to cells cultured on TCP (*p < 0.05). Although 
HPC cultured on TCP (***p < 0.001) and HPC collected from the scaffold supernatant        
(*p < 0.05) showed decreased proliferation frequencies at day 3 and 7 compared to day 1, 
HPC cultured in hDAT showed no significant changes in the frequency of proliferating cells 
between the time points studied. Data is shown as mean ± SEM (N = 5 UCB samples) and 
evaluated for statistical significance using a two-way ANOVA followed by Tukey’s post-
hoc multiple comparisons test. 
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3.3 Culture in hDAT scaffolds did not affect primitive cell 
surface marker frequency  
In order to evaluate changes in the primitive HPC phenotype after culture in hDAT scaffolds, 
multi-parametric flow cytometry was performed on HPC to detect several primitive cell 
surface markers (CD34, CD133, CD38) at the time of seeding and after 1, 3 and 7 days of 
culture. At the time of HPC seeding, the frequency of day-6 expanded HPC demonstrating 
primitive cell surface phenotypes (CD34+CD38- 12.7 ± 1.7 %, CD34+CD133+ 10.9 ± 1.6 %) 
were similar to previously-documented values collected by the Hess Lab.164, 206 Cells 
extracted from the hDAT scaffolds, remaining in the scaffold supernatant, or cultured on 
TCP demonstrated an equivalent frequency of CD34+CD38- cells over the 7-day time course 
(Figure 3.3 A,C). Similar to CD34+CD38- HPC frequencies, no significant differences were 
observed in the frequency of CD34+CD133+ cells between treatment groups at each 
timepoint, but the majority of values remained below frequencies reported at day 0 (Figure 
3.3 B,D). Collectively, these data suggest primitive HPC phenotype was not affected by in 
vitro culture in the hDAT scaffolds compared to conventional TCP culture methodology. 
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Figure 3.3 Cells cultured in hDAT scaffolds and on TCP showed similar frequencies of 
primitive phenotype. (A) Representative flow cytometry plots demonstrating the frequency 
of CD34+CD38- HPC at day 0 and after 7 days of culture for cells extracted from the hDAT 
scaffolds, remaining in the scaffold supernatant, or on TCP. (B) Representative flow cytometry 
plots demonstrating the frequency of CD34+CD133+ HPC day 0 and after 7 days culture for 
cells extracted from the hDAT scaffolds, collected from the scaffold supernatant, or on TCP. 
(C) The frequency of CD34+CD38- cells was equivalent between all treatment groups at each 
timepoint. (D) The frequency of CD34+CD133+ HPC was equivalent between all treatment 
groups at each timepoint. Dashed lines represent values recorded at day 0. Data is represented 
as mean ± SEM (N = 4 UCB samples) and analyses for statistical significance was performed 
using two-way ANOVA followed by a Tukey’s post-hoc multiple comparisons test (*p < 0.05). 
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3.4 Culture in hDAT scaffolds stimulated an increase in cells 
with high aldehyde dehydrogenase activity  
HPC cultured in hDAT scaffolds were also assessed for retention of a functional progenitor 
phenotype through quantification of aldehyde dehydrogenase (ALDH) activity using the 
AldefluorTM Assay kit. ALDH is a conserved self-protective enzyme that is highly expressed 
by hematopoietic progenitor cells and has been found to play an important role in 
maintaining the balance between hematopoietic differentiation and self-renewal.158 
Following 6 days of expansion, the frequency of ALDHhi HPC was 11.8 ± 2.3 % (Figure 3.4 
C). Following 7 days of culture, HPC extracted from the hDAT scaffolds (34.5 ± 8.5, p = 
0.06), or HPC collected from the scaffold supernatant (30.9 ± 0.8 %, ***p < 0.001), showed 
an increase in the frequency of cells with high ALDH-activity compared to cells cultured on 
TCP (1.6 ± 0.3 %). In assessing each treatment group over time, the cells collected from the 
supernatant demonstrated an increase in the frequency of ALDHhi cells at day 7 (30.9 ± 0.8 
%, **p < 0.01), compared baseline, as well as day 1 (13.7 ± 1.7 %) and day 3 (5.5 ± 1.8 %, 
Figure 3.4 C). In contrast, cells cultured on TCP demonstrated a significant decrease in the 
frequency of cells with high ALDH-activity at day 3 (2.9 ± 0.8 % **p < 0.01) and 7 (1.6 ± 
0.3 %, *p < 0.05) relative to day 1 (8.0 ± 1.2 %) (Figure 3.4 C).  
To evaluate if the increased frequency of HPC with high ALDH-activity correlated with an 
increase in the frequency of HPC expressing primitive cell surface markers, CD34 expression 
was analyzed in the ALDHhi cell population in each treatment group. ALDHhi  HPC extracted 
from the hDAT scaffolds showed reduced frequency of CD34 expression as early as 3 days 
after seeding (11.6 ± 1.6 %, *p < 0.05), and at day 7 (6.8 ± 2.1%, *p < 0.05) relative to day 0 
(33.3 ± 0.8 %, Figure 3.4 D). A similar pattern of decreased frequency of CD34 expression 
was observed in the ALDHhi HPC collected from the scaffold supernatant. In contrast, 
ALDHhi HPC cultured on TCP did not show altered frequency of CD34 expression over time.  
Further, the frequency of CD34+ cells in the ALDHhi population was higher in the TCP 
cultured cells at day 7 (40.2 ± 2.2 %) as compared to cells extracted from the hDAT scaffolds 
(6.8 ± 2.1 %, ***p < 0.001) and cells collected from the scaffold supernatant (5.5 ± 1.1 %, 
***p < 0.001, Figure 3.4 D). Taken together, these data suggest that hDAT scaffolds 
increased the frequency of ALDHhi cells remaining in the supernatant, but these cells showed 
reduced frequency of expression of the primitive cell surface marker CD34.  
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Figure 3.4 HPC collected from the supernatant showed increased ALDH activity in 
vitro, with reduced frequency of the primitive cell surface marker CD34 in the ALDHhi 
population. (A) Representative flow cytometry plots showing the gating strategy used to 
determine cells with high ALDH activity using the ALDH inhibitor, DEAB.                               
(B) Representative flow cytometry plots showing the frequency of ALDHhi cells extracted 
from hDAT scaffolds or collected from the scaffold supernatant, or cultured on TCP at day 
7 post-seeding. (C) The frequency of cells with high ALDH activity was increased at day 7 
for cells extracted from the hDAT (p = 0.06) and collected from the supernatant                 
(***p < 0.001), compared to cells cultured on TCP. (D) Cells extracted from the hDAT and 
supernatant showed decreased CD34 expression in the ALDHhi population at day 7 
compared to cells cultured on TCP (***p < 0.001). Dashed lines represent values recorded 
at day 0. Data is represented as mean ± SEM (N = 4 UCB samples) and statistical analysis 
was performed using two way ANOVA with a Tukey’s post-hoc multiple comparisons test 
(***p < 0.001). 
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3.5 Culture in hDAT scaffolds augments expression of 
monocyte/macrophage lineage markers in HPC  
As UCB-derived ALDHhi cells possess the capacity to differentiate into multiple myeloid 
lineages,164, 269 differentiation towards the monocyte, macrophage, and megakaryocyte / 
platelet lineages was probed to assess whether culture in hDAT scaffolds modulated HPC 
differentiation.270 At day 7 post-seeding, the frequency of CD14+ cells in the population 
extracted from the hDAT scaffolds (33.1 ± 2.0 %) was increased compared to the cells 
collected from the scaffold supernatant (19.2 ± 3.0 %, *p < 0.05) or HPC cultured on TCP 
(4.3 ± 1.4 %, ***p<0.001, Figure 3.5 A,B). The CD14+ cell frequency was also significantly 
different between the scaffold supernatant population and the TCP culture group at 7 days 
(*p < 0.05). Similar to CD14 expression, CD11b expression was also increased in the cells 
extracted from the hDAT scaffolds (34.0 ± 3.9 %, **p < 0.01) and scaffold supernatant (29.6 
± 4.2 %, *p < 0.05) compared to HPC cultured on TCP (4.0 ± 1.4 %, Figure 3.5 A,C).  
Previous studies from our lab have demonstrated that HPC cultured on TCP under the same 
media conditions differentiate preferentially towards the megakaryocyte lineage.206 In the 
current study, the frequency of CD42b+ cells was significantly increased at day 3 for cells 
cultured on TCP (35.7 ± 4.1 %) compared to day 1 TCP (9.7 ± 1.2 %, *p < 0.05) and day 3 
supernatant cells (16.1 ± 3.7 %, *p < 0.05). Positive events for T-lymphocyte (CD3, CD8) or 
B-lymphocyte (CD19) lineages were <1% at all timepoints in both hDAT and TCP cultures, 
suggesting limited differentiation toward lymphoid lineages. This data suggests that culturing 
in the presence of the hDAT scaffolds may have directed HPC differentiation towards the 
monocyte/macrophage lineage.   
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Figure 3.5 Culture in hDAT scaffolds results in enhanced expression of 
monocyte/macrophage lineage markers. (A) Representative flow cytometry plots displaying 
the frequency of CD14, CD11b and CD42b labelled cells at day 0 and after 7 days of culture for 
cell extracted from the hDAT scaffolds, collected from the scaffold supernatant, or on TCP. (B) 
The frequency of CD14+ cells was increased in cells extracted from the scaffold relative to cells 
collected from the scaffold supernatant (*p < 0.05) or cultured on TCP (***p < 0.001) at day 7. 
Cells collected from the scaffold supernatant showed increased CD14+ frequency relative to 
TCP (*p < 0.05) at 7 days. (C) Cells extracted from the scaffolds (**p < 0.01) and collected 
from the scaffold supernatant (*p < 0.05) showed increased CD11b+ frequency relative to cells 
cultured on TCP at 7 days. (D) The frequency of CD42b+ cells was increased at day 3 in the 
population cultured on TCP relative to TCP at day 1 (*p < 0.05) and the scaffold supernatant 
population at day 3 (*p < 0.05). Dashed lines represent values recorded at day 0. Data is 
represented as mean ± SEM (N = 4 UCB samples) and statistical analyses were performed using 
two-way ANOVA with a Tukey’s post-hoc multiple comparisons test (*p < 0.05, **p < 0.01, 
***p < 0.001).  
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3.6 HPC cultured on hDAT scaffolds show upregulated CD163 
expression after 7 days  
Following the observation that culture in hDAT scaffolds promoted the expression of 
markers associated with the monocyte/macrophage lineage, HPC were further analyzed for 
CD68, which is enriched on macrophages,271 and CD163, which is commonly used as a 
marker of M2 macrophage polarization that is associated with tissue remodeling and pro-
vascular function.272 CD68 expression increased over time, with a significant difference 
between the frequency of expression at day 7 as compared to day 1 for all groups (Figure 3.6 
C). 
Based on elevated expression of both macrophage markers CD68 and CD11b at day 7, 
expression of CD163 was evaluated to determine the potential polarization toward tissue 
remodeling M2 macrophages. At day 7 post-seeding, there was increased CD163 expression 
for cells extracted from the hDAT scaffolds (23.6 ± 3.0 %) and collected from the scaffold 
supernatant (20.9 ± 2.6 %) as compared to cells cultured on TCP (1.7 ± 0.4 %, ***p<0.001). 
Taken together, these results suggest that culturing in the hDAT scaffolds may have 
upregulated cell surface markers commonly found on macrophages with an M2-like 
macrophage phenotype.  
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Figure 3.6 Culture in hDAT promotes CD163+ cell frequency for seeded HPC.                  
(A) Representative flow cytometry plots displaying the relative frequency of CD68+ cells at 
day 0 and after 7 days of culture in populations extracted from hDAT scaffolds, collected from 
the scaffold supernatant, or cultured on TCP. (B) Representative flow cytometry plots 
showing the frequency of CD163+ cells after 7 days of culture in each of the culturing 
methods. (C) Cells extracted from the scaffold demonstrated increased frequency of CD68+ 
cells at day 7 compared to day 3 (*p < 0.05) and day 1 (*p < 0.05). Cells collected from the 
scaffold supernatant showed a stepwise increase of CD68+ expression from day 1 to day 3 and 
to day 7 (*p < 0.05). Cells cultured on TCP demonstrated increased CD68+ frequency at day 
7 relative to day 1 (*p < 0.05). (D) Cells extracted from the hDAT scaffolds and remaining in 
the supernatant had increased CD163+ cell frequencies compared to cells cultured on TCP. 
Dashed line represents values recorded at day 0. Data is represented as mean ± SEM (N = 4 
UCB samples) and statistical analyses were performed using two way ANOVA with a 
Tukey’s post-hoc multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001). 
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3.7 Mice treated with HPC delivered in hDAT scaffolds 
showed accelerated recovery of limb perfusion 
The Hess lab has previously demonstrated that fresh UCB ALDHhi cells and day-6 expanded 
HPC have the capacity to accelerate the recovery of perfusion in mice with femoral artery 
ligation-induced critical limb ischemia (CLI).164, 165 Following unilateral hindlimb femoral 
artery ligation (FAL), non-obese diabetic/severe combined immunodeficient (NOD/SCID) 
mice transplanted with HPC-seeded hDAT scaffolds demonstrated an accelerated recovery in 
distal hindlimb perfusion. In this group, laser Doppler perfusion imaging (LDPI) ratios 
between the ischemic and non-ischemic hindlimbs started at 0.13 ± 0.04 at day 1 and 
increased to 0.72 ± 0.13 at day 35 (Figure 3.7 A,B). Similarly, mice receiving an 
intramuscular (IM) injection of 5 x 105 day-6 expanded HPC in saline initially showed 
accelerated recovery of perfusion at day 7 (0.37 ± 0.15) and day 14 (0.60 ± 0.14). However, 
the perfusion ratios decreased to 0.47 ± 0.11 at day 21, before normalizing at 0.54 ± 0.18 at 
day 35. Control mice receiving IM injection of saline started with a perfusion ratio of 0.10 ± 
0.03 at day 1 and attained a maximal perfusion ratio of 0.49 ± 0.14 at day 35 (Figure 3.7 
A,B). Finally, mice transplanted with hDAT scaffolds without HPC demonstrated perfusion 
recovery similar to saline injected mice with perfusion ratios of 0.11 ± 0.04 at day 1 and 0.48 
± 0.13 at day 35. Overall blood perfusion recovery, evaluated using area under curve (AUC) 
quantification, demonstrated significantly increased perfusion recovery after transplantation 
of HPC in hDAT (2.77 ± 0.09) compared to mice IM injected with HPC (2.23 ± 0.12, 
*p<0.05) or saline (1.82 ± 0.12, ***p < 0.001), or transplanted with hDAT scaffold without 
HPC (1.58 ± 0.12, ***p < 0.001). Collectively, these data indicate that HPC delivered in 
hDAT scaffolds were capable of stimulating accelerated limb perfusion recovery at early 
timepoints and sustaining elevated perfusion up until day 35. 
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Figure 3.7 Mice treated with HPC seeded in hDAT scaffolds showed increased limb 
perfusion following femoral artery and vein ligation and excision. (A) Representative LDPI 
images showing restoration of limb perfusion following FAL surgery and treatment with HPC-
seeded hDAT scaffolds,  IM injection of HPC in saline, scaffold only, or IM injection of saline. 
(B) Both HPC-seeded hDAT scaffolds and IM-injected HPC accelerated the recovery of limb 
perfusion to day 14. HPC-seeded scaffolds showed increased perfusion ratios to day 35 (*p < 
0.05, **p < 0.01. ***p < 0.001, HPC in hDAT vs. Scaffold only). (C) Mice transplanted with 
HPC in hDAT experienced greater recovery of limb perfusion, as measured by area under curve 
(AUC), relative to mice receiving IM HPC (*p < 0.05), scaffold only (***p < 0.001) and saline 
(***p < 0.001). Mice treated with HPC via IM injection in saline demonstrated increased AUC 
relative to mice transplanted with the hDAT scaffold only (**p < 0.01). Data represented as 
mean ± SEM from 9 mice / group (n = 9) treated with 9 UCB samples (N = 9) and statistical 
significance was evaluated using a two-way repeated measures ANOVA, followed by a 
Tukey’s post-hoc multiple comparisons test. 
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3.8 Mice treated with HPC seeded hDAT showed improved 
early limb use compared to saline injected mice  
Similar to previous studies by our lab164, mice transplanted with HPC delivered IM or seeded 
in hDAT scaffolds demonstrated increased ischemic limb use at day 7 post-transplantation 
relative to the saline control group (Figure 3.8). Paw print intensity was evaluated using the 
CatWalkTM gait analysis system to determine the weight bearing capacity of the surgical limb 
compared to the contralateral hind limb. Paw print intensity ratios were higher at day 7 in 
mice transplanted with HPC-seeded in hDAT (0.88 ± 0.03) compared to mice that received 
an IM injection of saline (0.67 ± 0.11, *p < 0.05). No significant differences were observed 
between treatment groups at day 14 (Figure 3.8 B). The ratio of paw print area comparing the 
ischemic and non-ischemic footprint was also evaluated as a measure of limb dexterity 
during locomotion. Comparing treatment groups, paw print area ratio was increased at day 7 
in mice transplanted with HPC in hDAT (0.57 ± 0.18, *p < 0.05) and IM HPC (0.67 ± 0.03, 
*p < 0.05) compared to mice that received IM injection of saline (0.13 ± 0.05). Thus, 
improvements in two metrics of functional limb use were observed after HPC transplantation 
in hDAT scaffolds, suggesting improved perfusion correlated with improved limb usage.  
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Figure 3.8 Mice treated with HPC delivered in hDAT scaffolds showed accelerated 
recovery of limb use compared to mice IM injected with saline. (A) Representative 
CatWalkTM gait analysis images following limb print identification at day 7 post-surgery. (B) 
Paw print intensity ratio was increased at day 7 in mice transplanted with HPC in hDAT 
relative to mice that received an IM injection of saline (*p < 0.05). No differences were seen 
at day 14. (C) Paw print area ratio was increased at day 7 in mice transplanted with HPC in 
hDAT and IM HPC compared to mice that received an IM injection of saline (*p < 0.05). For 
the paw print area data, three data points (IM HPC at day 7, PBS at day 7 and 14) were 
excluded from the data set following outlier detection by the Grubb’s test with a p < 0.05. 
Data represented as mean ± SEM from 5 mice / group (n = 5) treated with 5 UCB samples 
(N = 5) and statistical significance was evaluated using a two-way repeated measures 
ANOVA with a Tukey’s post-hoc multiple comparisons test. 
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3.9 Mice treated with HPC delivered in hDAT scaffolds 
showed increased intramuscular capillary density in the 
ischemic thigh  
Previous studies from the Hess lab have reported that various cell populations derived from 
UCB stimulated increased CD31+ vessel density.164, 165, 206 To further investigate the 
mechanisms of vascular recovery in mice receiving HPC in hDAT scaffolds, adductor 
muscles (thigh) were collected at day 35 and CD31+ vessel area within the ischemic and non-
ischemic limbs was quantified by histomorphometry. Mice transplanted with scaffold only 
(0.52 ± 0.05) or injected with saline (0.52 ± 0.04) demonstrated a significant reduction in  
relative CD31+ staining in the ischemic limb relative to the non-ischemic limb at day 35 
(Figure 3.9 B). In contrast, mice transplanted with HPC in hDAT (0.91 ± 0.18, ***p < 0.001) 
demonstrated significantly increased relative CD31+ area compared to the scaffold alone 
group (0.52 ± 0.05). Similarly, mice IM-injected with HPC (0.73 ± 0.19, *p < 0.05) 
demonstrated significantly increased relative CD31+ area compared to saline controls (0.52 ± 
0.04) (Figure 3.9 B). When evaluating human cell engraftment through immunofluorescent 
analysis of human CD45, no human cells were detected in the thigh muscle of mice 
sacrificed at day 14 post FAL surgery (Data not shown). These data suggest that HPC 
delivered in hDAT scaffolds or injected IM augmented CD31+ vessel density in the ischemic 
limb following FAL. 
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Figure 3.9 Mice treated with HPC delivered in hDAT scaffolds showed enhanced 
intramuscular CD31 expression in the ischemic thigh. (A) Representative adductor muscle 
sections stained for CD31 and quantified based on positive pixel counts in mice treated with 
HPC-seeded hDAT, scaffold only, IM injection of HPC in saline, or saline alone at day 35 post-
transplantation. (B) Average CD31+ area ratio of ischemic : non-ischemic adductor muscles of 
mice was increased in mice receiving HPC in hDAT (***p < 0.001) and IM HPC (*p < 0.05) 
compared to scaffold only and saline controls. Data represented as mean ± SEM from 9 mice / 
group (n = 9) treated with 9 UCB samples (N = 9) and statistical significance was evaluated using 
a two-way repeated measures ANOVA, with a Tukey’s post-hoc multiple comparisons test. (*p 
< 0.05, ***p < 0.001). 
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Chapter 4 
4 Discussion  
While there has been an intense and ongoing collaborative effort between physicians and 
researchers to develop an effective therapy for critical limb ischemia (CLI), a cellular therapy 
with the ability to meaningfully reduce patient amputation and mortality rates has remained 
elusive. The Hess lab has extensively documented the revascularization potential of 
intramuscularly (IM) injected human umbilical cord blood (UCB) derived hematopoietic 
progenitor cells (HPC) in immunodeficient mouse models of CLI,165 and has developed an 
optimized serum-free expansion protocol to augment regenerative ALDHhi cell numbers 
while preserving vascular regenerative functions.164 Unfortunately, due to the creation of a 
severely ischemic microenvironment following femoral artery ligation (FAL) surgery and the 
predisposition of HPC to migrate to the bone marrow, cell viability and engraftment at the 
site of transplantation have been limited.163, 165 As a result, decellularized tissue constructs 
have been explored as a delivery platform to enhance cell retention, due to ease of 
production, innate bioactivity and biochemical composition that closely resembles native 
tissue.237 Notably, human decellularized adipose tissue (hDAT) represents an easily 
accessible source of scaffolding material with retained architecture and composition 
important for promoting cellular attachment and angiogenesis.259, 273 In the work presented in 
this thesis, delivery strategies using cell-supportive hDAT-derived bioscaffolds were 
explored as a means to augment cell viability and prolong the regenerative paracrine 
secretions of seeded human umbilical cord blood-derived HPC in the ischemic limb of 
immunodeficient mice with unilateral FAL.  
HPC maintenance, expansion, proliferation and differentiation are guided by a complex set of 
microenvironmental cues in the bone marrow niche including chemokines, cytokines, 
structural proteins, growth factors, oxygen tension and mechanical forces.274 While the use of 
a decellularized tissue scaffold is unlikely to recapitulate all of these signals inherent to the 
hematopoietic compartment, hDAT has been shown to be a rich source of structural proteins 
and sequestered growth factors also present in endosteal regions of the bone marrow.255 
Previous studies by the Flynn lab have comprehensively characterized the proteomic 
composition of hDAT-derived scaffolds using mass spectrometry screening techniques and 
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identified many relevant structural and bioactive proteins present in the matrix.255 Notably, 
the hDAT proteome was found to be primarily composed (>80%) of structural proteins (i.e. 
collagen and elastin), glycoproteins and proteoglycans, with a smaller amount of growth 
factors and cytokines that have been implicated in signaling pathways critical for 
hematopoietic stem cell (HSC) survival and expansion.275 Therefore, hDAT contains 
conserved components that may contribute towards guiding hematopoiesis and maintaining 
the HPC pool. 
In an effort to characterize the impact of the complex microenvironment of the hDAT 
scaffolds on the seeded cells and evaluate their applicability as a platform for HPC 
transplantation, flow cytometry assays were performed at multiple timepoints to quantify the 
survival, proliferation and differentiation of HPC cultured and extracted from within the 
hDAT scaffolds relative to the HPC in suspension in the supernatant above the scaffolds, or 
HPC cultured on traditional tissue culture plastic (TCP). Cell viability and proliferation were 
evaluated to ensure that the scaffolds demonstrated supportive qualities that permitted HPC 
infiltration and long-term growth. Interestingly, the studies revealed that cells cultured in 
hDAT scaffolds demonstrated increased cell viability and a greater abundance of 
proliferating cells compared to cells cultured on TCP. Thus, conducive biophysical and/or 
biochemical stimuli were present in the matrix promoting HPC adhesion and cell division. 
While it is unclear what specific stimuli facilitated increased cell viability and proliferation, 
other studies modelling the endosteal region of bone marrow using 3D collagen gels also 
found that CD34+ HPC migrated successfully into the collagen scaffolds and exhibited an 
increased frequency of proliferated cells compared to cells grown using conventional culture 
techniques.276 Furthermore, this study also demonstrated that increased proliferation was not 
limited to cells that directly seeded in the collagen gels but were also observed for HPC 
found in suspension above the collagen.276 These findings were also observed in our study 
after 7 days of culture with the hDAT scaffolds, suggesting collagen plays an important role 
in HPC proliferation. Matrix-induced cell proliferation may be crucial for future translation 
of human HPC-seeded hDAT scaffolds, as continued proliferation may promote increased 
cell numbers within the scaffold to offset the low seeding efficiency of HPC grown in 
suspension above the matrix.  
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Another important variable related to cell survival and proliferation within the hDAT 
scaffolds is the maintenance of the progenitor phenotype or guidance of differentiation 
towards mature hematopoietic lineages. Historically, more primitive hematopoietic cells with 
self-renewal capacity have been identified by their cell surface marker expression¾with 
CD34+CD38- and CD34+CD133+ cells demonstrating increased long-term hematopoietic 
repopulation capacity in immunodeficient mice.134, 140 In order to evaluate how the increased 
proliferation impacted HPC phenotype after culture in the hDAT scaffolds, primitive cell 
surface marker expression was analyzed through the flow cytometric quantification of 
CD34+CD38- or CD34+CD133+ expression at the time of seeding and at day 1, 3 and 7 for 
cells extracted from the hDAT scaffolds, collected the scaffold supernatant, or cultured on 
TCP. Although no significant differences in CD34+CD38- or CD34+CD133+ frequencies 
were observed for HPC on all culturing conditions, cells maintained consistent progenitor 
cell surface marker expression across all timepoints, suggesting retention of progenitor cell 
populations. 
In order to identify and functionally characterize progenitor cells in the hDAT scaffold, high 
ALDH-activity was evaluated due to its conserved role as a self-protective enzyme in 
multiple progenitor cell lineages.133 Surprisingly, cells extracted from within the hDAT 
scaffolds showed a >3 fold increase in the frequency of cells with high ALDH activity at 7 
days post-seeding, while a general decline was observed for the cells cultured on TCP. These 
data taken alone suggested an increased progenitor cell frequency of cells cultured within the 
hDAT scaffolds, but primitive hematopoietic cell surface marker expression remained 
equivalent over all timepoints for cells extracted from the hDAT or collected from the 
scaffold supernatant. Results published by Leisten et al. also demonstrated no significant 
difference in CD34+CD38- frequency of cells cultured on collagen scaffolds compared to 
conventional TCP culture.276 Therefore, significantly increased ALDH-activity at day 7 
within the scaffold and supernatant groups without a concomitant increase primitive cell 
surface marker expression suggested that although ALDH expression was upregulated in 
response to factors within the scaffold, primitive cell surface marker expression did not 
correlate with high ALDH-activity. For cells cultured on TCP, the ALDHhi cell population 
showed elevated CD34 co-expression across all timepoints, suggesting the well-defined 
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correlation between ALDH-activity and CD34 expression was preserved in the absence of 
hDAT.142  
One explanation for an increased frequency of cells with high ALDH-activity may be that 
increased oxidative stress was placed on cells in contact with the scaffold due to increased 
HPC activation and observed degradation of the scaffolds throughout extended culture.277 In 
addition, it was also possible that seeded HPC may have differentiated towards a mature 
hematopoietic cell population with elevated ALDH activity. In the seminal study by Storms 
et al. that used the Aldefluor assay to identify cells with high ALDH activity, UCB was 
found to have two populations of ALDHhi cells with distinct Aldefluor fluorescent intensity 
peaks and side scatter (SSC) properties.142 While cells that expressed brighter Aldefluor 
fluorescence and higher SSC properties were suspected to be monocytes based on the co-
expression of CD14, cells that demonstrated high Aldefluor fluorescence and low SSC 
properties were both phenotypically and functionally representative of primitive HPC.142 
Likewise, previous work by the Hess lab demonstrated that cells within the 
monocyte/macrophage lineage, characterized by the co-expression of the early myeloid 
markers CD33 and CD14, typically had elevated ADLH-activity and could be separated from 
the more primitive CD34+CD38- cells using SSC properties.163 In the current work, ALDHhi 
cells extracted from the hDAT scaffold or remaining in the supernatant qualitatively 
exhibited higher SSC relative to ALDHhi TCP cells, thus suggesting that a large proportion of 
seeded HPC may have differentiated towards the monocyte lineage.  
This project attempted to broadly characterize how hDAT scaffolds influenced HPC 
differentiation following extended culture using cell surface markers enriched on various 
mature hematopoietic cell lineages. Previous studies have demonstrated that freshly-sorted 
ALDHhi UCB primarily consists of early myeloid cells133, 165 that progressively lose 
progenitor cell phenotype and selectively differentiate towards the megakaryocyte/platelet 
lineage over time when cultured traditionally on TCP.206 Megakaryocytes, are large cells (50 
– 100 µm) that can be identified by upregulated expression of the megakaryocyte lineage-
specific cell surface markers CD41 (Integrin alpha-IIb) and CD42 (glycoprotein 1b).278 
Megakaryocytes are typically found in bone marrow and release cytoplasmic fragments 
(mature platelets) into the circulation that function in the clotting cascade and participate in 
wound repair following tissue injury.279 The megakaryocyte lineage is relevant to this project 
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as megakaryocyte enriched cell populations derived from UCB have shown regenerative 
efficacy when intramuscularly (IM) injected into immunodeficient mice with FAL-induced 
CLI.206 When evaluating acquisition of megakaryocyte cell surface markers, HPC retained 
similar frequencies of CD42b expression across timepoints, independent of the culturing 
methodology. This data suggests that either CD42b+ cells migrated directly into the hDAT 
and/or some HPC present in the scaffold differentiated towards the megakaryocyte lineage at 
a rate equal to TCP. While the presence of megakaryocytes in the hDAT may be a due to 
thrombopoietin (TPO) and fms-like tyrosine kinase 3 ligand (Flt-3L) present in the 
supplemented media and not factors intrinsic to the hDAT, it is notable that the matrix was 
able to harbour large cells capable of promoting angiogenesis and participating in wound 
healing processes. 
Based on the increased frequency of cells with high ALDH-activity at day 7 that did not co-
express the primitive hematopoietic marker CD34, we next investigated whether cells within 
the hDAT scaffold were demonstrating markers of differentiation towards the 
monocyte/macrophage lineages. Mononuclear phagocytes consists of monocytes, 
macrophages and dendritic cells that function to maintain steady-state tissue homeostasis by 
generating an immune reaction in response to infection or tissue inflammation.280 While it 
has been recently found that the majority of tissue resident macrophages are present before 
birth and maintained throughout adulthood,281 circulating monocytes can be recruited to sites 
of infection and inflammation as a secondary response to accelerate tissue repair.280 
Monocytes are derived from hematopoietic stem cell precursors in the bone marrow and are 
released into circulation where they play a role in both innate and adaptive immunity.282 
They are typically thought to consist of a heterogenous population of cells divided into 3 
main subsets based on the differential expression of the cell surface markers CD14 and 
CD16.283 Cells with high CD14 and low CD16 expression represent a population of classical 
inflammatory monocytes that ultimately give rise to non-classical CD14-CD16+ monocytes 
through an intermediate CD14+CD16+ stage.283 Each monocyte subset demonstrates a unique 
morphology, gene expression profile and function, but have all shown the capacity to 
differentiate into macrophages and dendritic cells.284, 285 Due to the essential role that 
mononuclear phagocytes play in mediating tissue repair and regeneration17 it is of great 
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importance to evaluate whether hDAT promoted HPC differentiation towards these cell 
populations. 
CD14 was selected as a marker of differentiation towards the monocyte lineage due to its 
expression in the initial steps in monocyte development and because classical CD14+CD16- 
monocytes comprise ~85% of the total monocyte pool in the peripheral blood.286 Similarly, 
CD11b was selected for its overlapping expression on mature myeloid cells of the monocyte, 
macrophage and granulocyte lineages.287 Studies in the Hess lab have previously used these 
markers to evaluate monocyte and macrophage differentiation of expanded HPC.164, 206 Flow 
cytometric analysis of CD14 and CD11b expression suggested that cells cultured within the 
hDAT scaffolds or remaining in the supernatant demonstrated potential differentiation 
towards the monocyte lineage with increased frequencies of CD14+ and CD11b+ cells at day 
7, compared to cells cultured on TCP. Additionally, increased CD14 and CD11b expression 
was only demonstrated at day 7 of culture in the hDAT scaffolds, suggesting that extended 
culture in the hDAT was necessary to mediate the upregulation of markers enriched in the  
monocyte/macrophage lineage. Interestingly, emergence of CD14+ and CD11b+ cells at day 7 
of hDAT culture coincided with observed degradation of the hDAT scaffolds. Similar studies 
completed by Ariganello et al. evaluating the impact of decellularized bovine pericardium 
(DBP) on macrophage differentiation and polarization found that monocyte-derived 
macrophages seeded on DBP had increased matrix metalloproteinase-2 (MMP-2) and matrix 
metalloproteinase-9 (MMP-9) activity, as measured by zymography, compared to cells 
cultured on TCP.288 While the present study did not evaluate the proteins that hDAT-seeded 
HPC secreted, it was evident that cells were degrading the matrix within 7 days of culture. 
This indicated that there were seeded cells with high proteolytic activity that could actively 
remodel or degrade the hDAT matrix. 
To further evaluate HPC differentiation following culture within hDAT scaffolds, the 
frequency of cells expressing the cell surface markers CD68 and CD163 were also examined 
based on their utility broadly identifying functionally distinct subsets of macrophages.289, 290 
Macrophages are believed to exist on a phenotypic spectrum, traditionally defined by 
“classically-activated” M1 macrophages and “alternatively-activated” M2 macrophages on 
opposing ends, but it is now recognized that there is a complex array of macrophage 
phenotypes involved in different aspects of tissue repair and regeneration.281, 285 While M1-
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like macrophages are believed to regulate the immune response through pro-inflammatory 
cytokine release, M2-like macrophage subtypes are characterized by their capacity to 
remodel the extracellular matrix (ECM) and resolve tissue inflammation.291 CD68 has been 
referred to as a ‘pan-macrophage marker’ due to its relative abundance on both M1 and M2 
macrophage subpopulations, with very low expression on basophils, neutrophils and 
lymphocytes.271, 292 Cells extracted from the hDAT, collected from the scaffold supernatant, 
or cultured on TCP, all demonstrated increased CD68+ cell frequencies compared to day 1, 
suggesting minimal influence of the hDAT on CD68 expression. While this was initially 
surprising based on the increased CD14 and CD11b expression on HPC in the hDAT, 
previous studies evaluating macrophage differentiation on DBP also demonstrated increased 
CD68 protein expression at day 7 and 14 for both TCP and matrix cultured cells.288  
Within the M2 macrophage spectrum, further characterization has identified three main 
subsets (M2a, M2b and M2c) of M2 macrophages that participate in wound healing and 
tissue repair.290 Based on the potent angiogenic capabilities and increased phagocytic 
capacity of M2c macrophages,290, 293, 294 CD163 expression was evaluated in these studies to 
identify cells potentially polarized towards an M2c-like macrophage phenotype.290 CD163 is 
a transmembrane glycoprotein primarily found on subsets of human tissue-resident 
macrophages, but can also be detected to a lesser extent on circulating peripheral blood 
monocytes.295, 296 CD163 is part of the scavenger receptor cysteine-rich superfamily and 
functions by binding a broad range of ligands for host defense, red blood cell homeostasis 
and regulation of inflammation.297 Indeed, HPC extracted from the hDAT scaffolds or 
isolated from the scaffold supernatant demonstrated increased frequencies of CD163+ cells at 
day 7 compared to cells cultured on TCP, suggesting potential differentiation towards an 
M2c-like monocyte/macrophage phenotype. While the mechanisms guiding the 
differentiation response remain unclear, it appeared that the hDAT scaffolds promoted 
differentiation of the HPC towards mononuclear myeloid cell lineages capable of remodeling 
the hDAT matrix. Of the M2 macrophage subsets, the M2c subset demonstrate high 
expression and secretion of enzymes such as MMP-9 that contribute to matrix remodeling 
and stimulating angiogenesis.290 Differentiation towards the monocyte/macrophage lineage is 
highly relevant to the biomaterial field as many developed matrices have attempted to 
modulate the host immune system through the recruitment of monocytes and macrophages 
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for tissue regeneration.298 Furthermore, these cell populations are relevant when translating to 
in vivo experiments, as monocytes and macrophages have previously demonstrated important 
roles in angiogenesis, revascularization and tissue repair.299 By engineering a matrix with the 
capacity to guide HPC differentiation towards proangiogenic cell populations, the delivery of 
potent regenerative stimuli to regions of ischemia may facilitate tissue repair and augment 
blood vessel regeneration.    
Previous studies in the Hess lab have thoroughly characterized the ability of fresh or day-6 
expanded ALDHhi HPC derived from UCB to stimulate revascularization in immunodeficient 
mice with surgically-induced hind-limb ischemia.164, 165 This project attempted to improve 
HPC viability at the site of transplantation and prolong the pro-angiogenic paracrine function 
of HPC using a cell-supportive delivery strategy within hDAT implants. It was found that 
transplantation of HPC-seeded hDAT scaffolds in immunodeficient mice with acute 
unilateral hindlimb ischemia resulted in accelerated perfusion recovery compared to PBS-
injected or unseeded scaffold implantation, with significantly augmented perfusion observed 
as early as day 7 post-transplantation. Notably, while mice treated with an IM injection of 
HPC also demonstrated accelerated recovery in perfusion of the ischemic limb until day 14, 
only mice treated with the HPC-seeded in hDAT maintained elevated perfusion out to day 
35. These data suggested that mice receiving an IM injection of HPC received similar 
regenerative stimuli at early timepoints, but ultimately plateaued earlier in recovery. Only 
mice transplanted with HPC seeded in hDAT demonstrated sustained perfusion, eluding to a 
more potent revascularization capacity and/or sustained regenerative effect. Further analysis 
evaluating the area under the curve (AUC) for each treatment condition was performed to 
gain insight on the total perfusion recovery over the 35 days following surgery. Of the 
treatment conditions, HPC seeded in hDAT demonstrated an increased AUC compared to IM 
injected HPC, unseeded hDAT scaffolds and IM injected saline, suggesting that total 
perfusion recovery over the 35 day was improved. Overall, HPC seeded in hDAT scaffolds 
demonstrated the capacity to improve the recovery trajectory and total perfusion over time in 
immunodeficient mice following unilateral FAL.  
Next, to corelate improved perfusion recovery with functional limb use, CatWalk gait 
analysis was performed at day 7 and 14 post-surgery. Paw print intensity and area were 
selected as criteria to evaluate the weight bearing capacity of the limb and paw dexterity, 
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respectively. Previous studies by the Hess lab have demonstrated that mice IM injected with 
day-6 expanded HPC had improved paw print intensity at day 7 following FAL.164 No other 
metrics of functional recovery were reported.164 In the present study, mice transplanted with 
HPC seeded in hDAT scaffolds and those IM injected with HPC had increased paw print area 
and values compared to mice IM injected with saline. However, only mice transplanted with 
HPC seeded in hDAT demonstrated increased paw print intensity compared to those 
receiving an IM injection of saline. This indicated that while both cell treatment groups were 
effective in improving metrics of limb dexterity, only mice transplanted with HPC in hDAT 
were capable in improving the weight bearing capacity of the surgical limb compared to 
saline controls. It is important to note however, that mice transplanted with unseeded hDAT 
scaffolds demonstrated a similar recovery of functional limb use compared to HPC seeded 
hDAT and IM injected HPC treatment groups. While these improvements in limb use were 
unexpected based on decreased recovery of limb perfusion and CD31+ vessel density, the 
CatWalk gait analysis assay may not be sensitive enough to record smaller differences 
between treatment groups and further experiments involving more N values should be 
performed. Overall, these data suggest that HPC delivered in the hDAT scaffolds or injected 
IM were successful in delivering angiogenic stimuli capable of improving early functional 
limb use when compared to mice injected with saline in relevant surgically induced animal 
models of CLI.  
In an attempt to identify the underlying mechanism of perfusion and functional recovery, 
immunohistochemical analysis was completed to evaluate CD31+ vessel density. CD31 
(PECAM-1) is a cell surface marker found on endothelial cells that is commonly used to 
identify small vessels in histological sections.300 When looking at the response at 35 days 
after transplantation, the CD31+ vessel density within the thigh muscles of mice transplanted 
with HPC seeded in hDAT scaffolds and those IM injected HPC were significantly increased 
compared to the scaffold only or IM-saline injection groups. These finding suggest that HPC 
were able to secrete paracrine factors that increased CD31+ vessel density and corelated with 
improved limb perfusion and functional limb use. While it is unknown what angiogenic 
stimuli was secreted by the HPC to mediate these changes in CD31+ vessel density, other 
studies analyzing the gene expression of HPC cultured on collagen gels found that genes 
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encoding the potent angiogenic cytokines IL-8, CXCL2 and HGF were upregulated on HPC 
following culture on collagen.301  
Finally, the ability of the hDAT scaffolds to retain HPC at the site of transplantation and 
promote engraftment into the ischemic tissue was evaluated by immunofluorescent staining 
for human-specific CD45. CD45 is a transmembrane cell surface marker found on all 
nucleated human hematopoietic cell lineages and was used to evaluate human cell 
engraftment in the ischemic thigh muscle.302 When attempting to evaluate HPC retention at 
day 14, it was found that hDAT scaffolds seeded with HPC had degraded rapidly and were 
undetectable at the site of transplantation. This was most likely due to the proteolytic activity 
of HPC seeded into the matrix as scaffolds were typically found intact in mice that were 
transplanted with hDAT without HPC. Additionally, previous studies completed by the Flynn 
lab have shown that hDAT scaffolds seeded with or without adipose-derived stromal cells are 
detectable up to 12 weeks after surgery when implanted into immunocompetent rats.259 When 
evaluating HPC engraftment into the ischemic tissue, no CD45+ human cells were detected at 
day 14 in the thigh sections of mice transplanted with HPC seeded in hDAT scaffolds or IM 
injected with HPC. Notably, this two week post-surgery evaluation of human cell 
engraftment exceeds the maximum point of detection in previously conducted studies 
evaluating human cell engraftment of IM injected HPC (<7 days).165 Overall, these studies 
supported the use of HPC seeded hDAT scaffolds for promoting the revascularization of the 
ischemic limb of mice following FAL. However, future studies need to be completed at 
earlier timepoints (7 and 10 days) to more accurately assess the cell retentive and 
engraftment qualities of the hDAT scaffolds. 
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Chapter 5 
5 Conclusions and future directions 
5.1 Summary of findings 
In objective 1, this project sought to characterize the interaction between the human 
umbilical cord blood (UCB)-derived hematopoietic progenitor cells (HPC) and decellularized 
adipose tissue (hDAT) scaffolds. HPC were expanded for 6 days following purification based 
on high ALDH-activity, seeded into hDAT scaffolds, and cell viability, proliferation and 
phenotype were analyzed at day 1, 3 and 7 by flow cytometry. Compared to HPC grown on 
TCP, HPC seeded in the hDAT scaffolds showed an increased cell viability as early as day 3 
that was sustained over the 7-day culture period. Interestingly, while cells remaining in the 
scaffold supernatant or cultured in suspension on TCP demonstrated decreasing cell viability 
across 7 days of culture, HPC extracted from the hDAT showed maintained cell viability 
across timepoints. Similarly, the hDAT scaffolds also supported the growth of seeded HPC, 
with increased frequency of proliferating cells at day 7 for HPC cultured on hDAT compared 
to cells cultured on TCP. Furthermore, HPC extracted from hDAT scaffolds demonstrated 
sustained frequencies of proliferation over the 7 days of culture while cells remaining in the 
supernatant and cultured on TCP demonstrated decreases from day 1 to 7. Therefore, these 
results confirmed hDAT supported HPC survival and stimulated proliferation compared to 
traditional suspension culture on TCP.  
Next, cell phenotype was evaluated through the flow cytometric analysis of the co-expression 
of primitive cell surface markers and ALDH activity. The cell surface markers CD34, CD133 
and CD38 were first examined based on previous evidence supporting the enrichment of 
NOD/SCID repopulating cells within CD34+CD38- and CD34+CD133+ fractions of UCB.134, 
140 Aldehyde dehydrogenase (ALDH) was selected due to its conserved role as a self-
protective enzyme within many stem cell lineages and high correlation with CD34 and 
CD133-expressing HPC.133, 142 HPC extracted from hDAT scaffolds, collected from the 
scaffold supernatant or cultured on TCP each demonstrated a low and equivalent frequency 
of CD34+CD38- and CD34+CD133+ cells throughout 7 days of culture, with the exception of 
a decreased frequency of CD34+CD133+ between days 1 and 7 for cells remaining in the 
supernatant. Looking at the frequency of cells with high ALDH-activity, cells remaining in 
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the supernatant showed an increased frequency of ALDHhi cells at day 7 compared to day 1, 
and an increased frequency of ALDHhi cells at day 7 compared to cells cultured on TCP at 
day 7. HPC cultured on hDAT trended towards an increased frequency of ALDHhi cells 
compared to day 1 values (p = 0.06) and when compared to cells cultured on TCP for 7 days 
(p = 0.07). When the ALDHhi cells were evaluated for the co-expression of the primitive cell 
surface marker CD34, cells cultured on hDAT scaffolds or remaining in the supernatant 
demonstrated a reduced frequency of ALDHhiCD34+ cells, while cells cultured on TCP 
retained high levels of ALDH and CD34 co-expression. These data indicated that the 
increased frequency of cells with high ALDH-activity was independent of primitive cell 
phenotype, and suggested that HPC may have differentiated into mature myeloid cells with 
elevated ALDH-activity.142, 163 
To evaluate how culture in hDAT scaffolds influenced HPC differentiation, cell surface 
marker expression associated with the monocyte, macrophage and megakaryocyte (platelet) 
lineages was analyzed using CD14, CD11b and CD42b expression, respectively.279, 286, 287 
Culture of HPC in hDAT scaffolds augmented HPC differentiation towards the 
monocyte/macrophage lineage with both CD14 and CD11b expression increased at day 7 
compared to cells cultured on TCP. Interestingly, cells cultured in hDAT demonstrated the 
greatest enrichment of CD14+ cells, suggesting that the scaffolds had instructive effects in 
promoting monocyte/macrophage differentiation. When evaluating the frequency of cells 
with megakaryocyte marker CD42b, only cells cultured in suspension on TCP showed 
increased CD42 expression from day 1 to 3. No other changes in CD42b frequencies were 
observed, indicating megakaryocytes were maintained at all timepoints for all culturing 
methodologies.  
Following the observations that the frequency of CD14 and CD11b were increased for cells 
extracted from the hDAT or collected from the scaffold supernatant, the expression of the 
cell surface markers CD68 and CD163 was analyzed based on their common use as 
indicators of macrophage differentiation and M2c macrophage polarization, respectively.292, 
295 Interestingly, all groups demonstrated increased CD68 expression at day 7 compared to 
day 1, indicating that culture itself rather than the exposure to hDAT was influential in 
driving CD68 expression. CD163+ cell frequencies were increased at day 7 for cells cultured 
in hDAT scaffolds and remaining in the supernatant. Taken together, these data suggest that 
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HPC cultured in the hDAT scaffolds or remaining in the supernatant show upregulation of 
markers enriched on the macrophage lineage, with increased frequencies of CD163 as a 
marker of M2c-like macrophage polarization.   
For objective 2, in vivo analyses were performed to assess the regenerative capacity of HPC 
seeded in hDAT scaffolds in immunodeficient non-obese diabetic/severe combined immune 
deficient (NOD/SCID) mice following femoral artery and vein ligation and excision. Herein, 
it was demonstrated that day-6 expanded ALDHhi HPC seeded within decellularized adipose 
scaffolds facilitated an accelerated recovery in distal hind-limb perfusion following FAL 
surgery. Improved perfusion was sustained until the end of the assay at day 35. When 
evaluating the capacity of HPC delivered within hDAT scaffolds for improving functional 
metrics of limb use, treatment with the cell-seeded scaffold was shown to increase surgical 
limb paw print intensity and area compared to mice IM injected with saline alone. To 
evaluate the underlying mechanisms of recovery in functional limb use and hind-limb 
perfusion, CD31 vessel area of the ischemic and non-ischemic thighs were evaluated at day 
35. Mice that were transplanted with HPC-seeded hDAT scaffolds or IM injected with day-6 
expanded HPC demonstrated increased CD31+ vessel area compared to mice transplanted 
with hDAT alone or IM injected with saline. When assessing human cell engraftment at day 
14 through human-specific CD45 immunohistochemical analysis, no human CD45+ cells 
were detected in the ischemic thighs of  either cell treatment group at day 14, suggesting that 
long-term retention was not required for observed improvements. 
5.2 Limitations and future recommendations 
The current study attempted to quantitatively characterize the interaction between the hDAT 
scaffolds and UCB-derived HPC over 7 days of in vitro culture and offered support for the 
use of the cell-seeded matrix in promoting in vivo revascularization in surgically induced 
animal models of CLI. Future studies assessing HPC behaviour within hDAT matrix and 
more fully evaluating the mechanisms of vascular regeneration within in vivo models of CLI 
need to be completed for a better understanding of the applicability of hDAT scaffolds for 
HPC delivery. Additionally, other cell delivery strategies harnessing injectable hDAT 
microcarriers could be explored with seeded HPC for a more clinical translatable therapy.303 
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Although the characterization of the viability, proliferation and cell phenotype of HPC 
seeded in the hDAT were thorough and highly quantitative, all of the in vitro assays were 
performed using flow cytometry and thus relied on cell frequencies for interpretation. While 
these analyses were effective in evaluating the proportion of cells positive for each marker 
within each culture condition, the total number of cells seeded and present in each scaffold 
remained unknown. Future studies will need to be completed to evaluate the magnitude of 
HPC attachment and infiltration into the hDAT scaffolds so that these values can be directly 
compared with the quantity of cells present in the supernatant or cultured on TCP. 
Immunohistochemistry has proven to be an effective tool in evaluating cell density within 
many other biomaterial studies and could be employed alongside flow cytometric analysis to 
provide further insight on cell behaviour within the hDAT matrix.259, 304 In particular, 
measures of cell viability, proliferation and cell phenotype could be repeated using 
fluorescent microscopy analyses using CellTracker green CMFDA dye,305 Click-iT EdU cell 
proliferation assay,306 and/or antibodies specific for cell surface markers indicative of cell 
phenotype (i.e. CD34, CD38, CD133, ALDH1A1, CD14, CD11b, CD163, CD206), 
respectively. By pairing the EdU and cell surface marker IHC assays together, information 
on what cell phenotype is proliferating could be evaluated. Although these analyses may be 
less quantitative than flow cytometry, they could be combined with stereology to offer 
quantitative insight on the spatial distribution of seeded HPC and the maturation of 
hematopoietic progeny within the hDAT scaffold. Alternatively, fluorescent flow cytometry 
counting beads could be used to obtain an absolute cell number of cells present in the 
scaffold following enzymatic digestion.307 
It is important to note that many of the cell surface markers employed in this study are not 
exclusive to a specific cell population, but generally provide an indication of differentiation 
towards a particular cell lineage. For example, while CD14, CD11b and CD68 are useful 
markers to broadly evaluate the induction of monocytopoiesis within hDAT scaffolds, it is 
difficult to draw firm conclusions on what specific cell types are present in the matrix 
because the markers detected may also be present on other myeloid populations, such as 
granulocytes.287, 308 Therefore, future studies could use additional myeloid markers in unison 
with the ones selected in this project to give a more in-depth understanding of the cell 
populations present in the hDAT scaffold. For example, flow cytometry panels involving 
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CD66b and CD15 alongside CD11b, CD14, CD68, and CD16 could be developed for a better 
interpretation of the frequency of granulocyte and monocyte cell differentiation, 
respectively.309, 310 For the megakaryocyte lineage, CD41 in unison with CD42 and CD38 
expression could be used to identify more primitive CD41+CD42- megakaryoblasts before the 
upregulation of CD42 and CD38 during megakaryocyte maturation.206 Finally, while T- 
(CD3 and CD8) and B-lymphocyte (CD19) induction was not demonstrated in the hDAT 
scaffolds, other lymphocyte populations such as natural killer (NK) cells, remain to be tested. 
Similar studies evaluating HPC differentiation in collagen scaffolds found that CD56, a 
marker representative of human NK cells, was upregulated in cells in the suspension above 
the matrix and on TCP.276 While they reported reduced expression of CD56 on HPC cultured 
in collagen, it still may be important to evaluate if hDAT is able to induce differentiation 
towards a non-myeloid lineage. 
Another important question that arose following the observation that hDAT promoted the 
upregulation of cell surface markers commonly enriched in the monocyte/macrophage 
lineage was whether the hDAT was capable of directing macrophage polarization to a pro-
regenerative phenotype. This study selected CD163 for its enrichment on macrophages with 
M2c polarization that play a prominent role in ECM remodeling and wound healing.295 
Similar to the issues arising with the use of CD14 and CD11b, CD163 on its own does not 
give a conclusive representation of what cells are present in the matrix, due to it being 
present on multiple macrophage populations.311 Future studies fully examining multiple 
markers of macrophage polarization through flow cytometry and IHC could be utilized for a 
more complete characterization of the macrophage subsets present in the matrix. Cell surface 
markers such as CD80, CD64 and/or CD86, and CD206, CD200R and/or CD163 could be 
examined in unison with CD68 for a more accurate portrayal of the frequency of M1 and M2 
macrophages, respectively.290, 295, 312  
While the updated flow cytometry panels would provide a more complete overview of 
hematopoietic lineages present by cell surface marker expression, assays measuring the 
functional differentiation capacity of cells cultured in the hDAT remain to be performed. 
Clonogenic assays could be employed to evaluate the differentiation potential of cells 
extracted from the hDAT, remaining in the supernatant or cultured on TCP through 
quantitative measurement of colony formation with morphology indicative of erythrocytes 
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(BFU‐E), granulocytes (CFU‐G), macrophages (CFU‐M), granulocytes/macrophages (CFU‐
GM), or mixed (CFU‐Mixed) hematopoietic cells.313 Previous studies by the Hess lab 
analyzing the hematopoietic colony formation of UCB-derived fresh ALDHhi HPC and HPC 
cultured for 6 or 9 days on TCP found that the frequency of total hematopoietic colony 
formation was decreased with extended culture. Furthermore, CFU-G and CFU-M frequency 
was decreased at 6 and 9 days of culture, indicating a reduction in myeloid precursors over 
culture.164 With upregulation of cell surface markers commonly enriched on monocyte and 
granulocyte populations following culture in hDAT, it would be interesting to evaluate the 
colony forming capacity of HPC after culture on hDAT compared to HPC cultured on TCP. 
Further work also needs to be performed in vivo. Studies need to be completed evaluating the 
degradation of the hDAT scaffold and the capacity to support HPC engraftment at the site of 
transplantation at earlier timepoints. In previous studies involving IM injection of HPC into 
the thigh muscle of mice following FAL, human cells were rarely detected past 7 days post-
injection.164 Future studies should be designed to carefully assess human cell engraftment 
using the cell tracking NOD/SCID/mucopolysaccharidosis type VII (MPSVII) mouse model. 
NOD/SCID/MPSVII mice are deficient in beta-glucoronidase (GUSB) activity allowing for 
the detection of human cells with ubiquitously expressed GUSB activity at single cell 
sensitivity.314 Previous studies using the MPSVII mouse have detected individual human 
cells in the thigh tissue, with the added benefit of being able to co-stain GUSB activity with 
vessel markers such as von-Willebrand factor (vWF).165 Additionally, detailed in situ 
analysis of endothelial cell proliferation within the thigh muscle surrounding the implantation 
site could be assessed following EdU injection prior to euthanasia and staining using 
fluorescent antibodies targeting the murine vessel marker, CD31.164 
Finally, different methodologies evaluating hind limb perfusion and blood flow dynamics in 
the ischemic limb could be developed to confirm the laser Doppler perfusion imaging data. 
In collaboration with Dr. James Lacefield at Robarts Research Institute, novel imaging 
modalities such as power Doppler and contrast enhanced ultrasound could be used to gain 
further insight on the collateral vessel formation within the ischemic limb for further 
detailing of the underlying mechanisms of vascular recovery.315 These ultrasound imaging 
modalities have been successful in quantifying blood flow dynamics to tumours implanted in 
the mammary fat pad of mice in a breast cancer xenograft model.315 Preliminary application 
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of power Doppler ultrasound on the ischemic and non-ischemic limbs are shown in 
Supplementary Figure 1, where small vessels are clearly visible following a post scan 
filtration algorithm. Altogether, these future investigations will more accurately evaluate 
HPC behavior within the hDAT scaffolds and help clarify the underlying mechanisms of 
perfusion recovery and improved functional limb use.   
5.3 Conclusion 
With the rising prevalence of PAD in the global population, there remains a large number of 
CLI patients who are ineligible for traditional surgical revascularization and require an 
effective therapy that can stimulate new blood vessel growth and improve patient 
outcomes.59 Previous studies evaluating the regenerative potential of expanded umbilical 
cord blood-derived hematopoietic progenitor cells found that intramuscularly-injected cells 
were capable of restoring limb perfusion in a surgical model mouse model of CLI, but 
demonstrated poor cell viability and engraftment at the ischemic site in mice.164 These 
multidisciplinary studies aimed to provide pre-clinical proof-of-concept for an improved 
cellular therapy strategy for CLI using a cell-supportive matrix derived from human 
decellularized adipose tissue. hDAT was shown to promote the viability and proliferation of 
seeded HPC, and had cell-instructive effects on HPC differentiation, with increased 
expression of cell surface markers associated with the monocyte/macrophage lineages. When 
translated in vivo, HPC seeded hDAT scaffolds were shown to promote revascularization in 
an established animal model of CLI and correlated with improvements in perfusion, limb use 
and small vessel density. Altogether, the present work supports the potential use of hDAT 
scaffolds as a cell delivery platform for UCB-derived HPC for therapeutic applications 
requiring revascularization and vessel regeneration. 
 
 
 
 
 
 
 
 
89 
References 
1. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nature medicine, 
2000. 6(4): p. 389. 
2. Martin, P.M., et al., Decellularized adipose tissue scaffolds for soft tissue 
regeneration and adipose-derived stem/stromal cell delivery, in Adipose-Derived 
Stem Cells. 2018, Springer. p. 53-71. 
3. Pugsley, M. and R. Tabrizchi, The vascular system: An overview of structure and 
function. Journal of pharmacological and toxicological methods, 2000. 44(2): p. 333-
340. 
4. Semenza, G.L., Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of 
blood vessel formation and remodeling. Journal of cellular biochemistry, 2007. 
102(4): p. 840-847. 
5. Gutterman, D.D., Adventitia-dependent influences on vascular function. American 
Journal of Physiology-Heart and Circulatory Physiology, 1999. 277(4): p. H1265-
H1272. 
6. Betz, E., et al., Proliferation of smooth muscle cells in the inner and outer layers of 
the tunica media of arteries: an in vitro study. Journal of cellular physiology, 1991. 
147(3): p. 385-395. 
7. Schwartz, S.M., M.W. Majesky, and C.E. Murry, The intima: development and 
monoclonal responses to injury. Atherosclerosis, 1995. 118: p. S125-S140. 
8. Rhodin, J.A., The ultrastructure of mammalian arterioles and precapillary sphincters. 
Journal of ultrastructure research, 1967. 18(1-2): p. 181-223. 
9. Hashizume, H., et al., Openings between defective endothelial cells explain tumor 
vessel leakiness. The American journal of pathology, 2000. 156(4): p. 1363-1380. 
10. Palmer, R.M., A. Ferrige, and S. Moncada, Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature, 1987. 327(6122): 
p. 524. 
11. Palmer, R.M., D. Ashton, and S. Moncada, Vascular endothelial cells synthesize 
nitric oxide from L-arginine. Nature, 1988. 333(6174): p. 664. 
12. Min, J.-K., et al., TNF-related activation-induced cytokine enhances leukocyte 
adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor 
and protein kinase C-dependent NF-κB activation in endothelial cells. The Journal of 
Immunology, 2005. 175(1): p. 531-540. 
13. Navab, M., et al., Monocyte migration into the subendothelial space of a coculture of 
adult human aortic endothelial and smooth muscle cells. The Journal of clinical 
investigation, 1988. 82(6): p. 1853-1863. 
N=7 
* = p<0.05 
 
 
 
90 
14. Gerhardt, T. and K. Ley, Monocyte trafficking across the vessel wall. Cardiovascular 
research, 2015. 107(3): p. 321-330. 
15. Danese, S., E. Dejana, and C. Fiocchi, Immune regulation by microvascular 
endothelial cells: directing innate and adaptive immunity, coagulation, and 
inflammation. The Journal of Immunology, 2007. 178(10): p. 6017-6022. 
16. Yona, S. and S. Jung, Monocytes: subsets, origins, fates and functions. Current 
opinion in hematology, 2010. 17(1): p. 53-59. 
17. Arnold, L., et al., Inflammatory monocytes recruited after skeletal muscle injury 
switch into antiinflammatory macrophages to support myogenesis. Journal of 
Experimental Medicine, 2007. 204(5): p. 1057-1069. 
18. Nahrendorf, M., et al., The healing myocardium sequentially mobilizes two monocyte 
subsets with divergent and complementary functions. Journal of Experimental 
Medicine, 2007. 204(12): p. 3037-3047. 
19. Aird, W.C., Endothelial cell heterogeneity. Cold Spring Harbor perspectives in 
medicine, 2012. 2(1): p. a006429. 
20. Simionescu, M., N. Simionescu, and G.E. Palade, Segmental differentiations of cell 
junctions in the vascular endothelium. Arteries and veins. The Journal of cell biology, 
1976. 68(3): p. 705-723. 
21. Langille, B.L. and S.L. Adamson, Relationship between blood flow direction and 
endothelial cell orientation at arterial branch sites in rabbits and mice. Circulation 
Research, 1981. 48(4): p. 481-488. 
22. Haefliger, J.-A., P. Nicod, and P. Meda, Contribution of connexins to the function of 
the vascular wall. Cardiovascular research, 2004. 62(2): p. 345-356. 
23. Lilly, B., We have contact: endothelial cell-smooth muscle cell interactions. 
Physiology, 2014. 29(4): p. 234-241. 
24. Fraisl, P., et al., Regulation of angiogenesis by oxygen and metabolism. 
Developmental cell, 2009. 16(2): p. 167-179. 
25. Hirschi, K.K. and P.A. D'Amore, Pericytes in the microvasculature. Cardiovascular 
research, 1996. 32(4): p. 687-698. 
26. Hall, C.N., et al., Capillary pericytes regulate cerebral blood flow in health and 
disease. Nature, 2014. 508(7494): p. 55. 
27. Andrejecsk, J.W., et al., Paracrine exchanges of molecular signals between alginate-
encapsulated pericytes and freely suspended endothelial cells within a 3D protein gel. 
Biomaterials, 2013. 34(35): p. 8899-8908. 
28. Aird, W.C., Phenotypic heterogeneity of the endothelium: I. Structure, function, and 
mechanisms. Circulation research, 2007. 100(2): p. 158-173. 
 
 
 
91 
29. Paulson, K.E., et al., Resident intimal dendritic cells accumulate lipid and contribute 
to the initiation of atherosclerosis. Circulation research, 2010. 106(2): p. 383-390. 
30. Benjamin, E.J., et al., Heart disease and stroke statistics-2018 update: a report from 
the American Heart Association. Circulation, 2018. 137(12): p. e67. 
31. Mendis, S., et al., Global atlas on cardiovascular disease prevention and control. 
2011: Geneva: World Health Organization. 
32. McAloon, C.J., et al., The changing face of cardiovascular disease 2000–2012: An 
analysis of the world health organisation global health estimates data. International 
journal of cardiology, 2016. 224: p. 256-264. 
33. Trogdon, J.G., et al., The economic burden of chronic cardiovascular disease for 
major insurers. Health promotion practice, 2007. 8(3): p. 234-242. 
34. Heidenreich, P.A., et al., Forecasting the future of cardiovascular disease in the 
United States: a policy statement from the American Heart Association. Circulation, 
2011. 123(8): p. 933-944. 
35. Frostegård, J., Immunity, atherosclerosis and cardiovascular disease. BMC medicine, 
2013. 11(1): p. 117. 
36. Dai, G., et al., Distinct endothelial phenotypes evoked by arterial waveforms derived 
from atherosclerosis-susceptible and-resistant regions of human vasculature. 
Proceedings of the National Academy of Sciences, 2004. 101(41): p. 14871-14876. 
37. Heo, K.-S., K. Fujiwara, and J.-i. Abe, Shear stress and atherosclerosis. Molecules 
and cells, 2014. 37(6): p. 435. 
38. Tabas, I., K.J. Williams, and J. Borén, Subendothelial lipoprotein retention as the 
initiating process in atherosclerosis: update and therapeutic implications. Circulation, 
2007. 116(16): p. 1832-1844. 
39. Camejo, G., et al., Characterization and properties of a lipoprotein-complexing 
proteoglycan from human aorta. Atherosclerosis, 1980. 35(3): p. 307-320. 
40. Weber, C. and H. Noels, Atherosclerosis: current pathogenesis and therapeutic 
options. Nature medicine, 2011. 17(11): p. 1410. 
41. Mestas, J. and K. Ley, Monocyte-endothelial cell interactions in the development of 
atherosclerosis. Trends in cardiovascular medicine, 2008. 18(6): p. 228-232. 
42. Boyle, J.J., P.L. Weissberg, and M.R. Bennett, Tumor necrosis factor-α promotes 
macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine 
mechanisms. Arteriosclerosis, thrombosis, and vascular biology, 2003. 23(9): p. 
1553-1558. 
43. Tabas, I., Macrophage death and defective inflammation resolution in atherosclerosis. 
Nature Reviews Immunology, 2010. 10(1): p. 36. 
 
 
 
92 
44. Fowkes, F.G., et al., Comparison of global estimates of prevalence and risk factors 
for peripheral artery disease in 2000 and 2010: a systematic review and analysis. 
Lancet, 2013. 382(9901): p. 1329-40. 
45. Criqui, M.H. and V. Aboyans, Epidemiology of peripheral artery disease. Circulation 
research, 2015. 116(9): p. 1509-1526. 
46. Margolis, J., J.J. Barron, and W.D. Grochulski, Health care resources and costs for 
treating peripheral artery disease in a managed care population: results from analysis 
of administrative claims data. Journal of Managed Care Pharmacy, 2005. 11(9): p. 
727-734. 
47. Walden, R., et al., Distribution and symmetry of arteriosclerotic lesions of the lower 
extremities: an arteriographic study of 200 limbs. Cardiovascular and interventional 
radiology, 1985. 8(4): p. 180-182. 
48. Garcia, L.A., Epidemiology and pathophysiology of lower extremity peripheral 
arterial disease. Journal of endovascular therapy, 2006. 13(2_suppl): p. II-3-II-9. 
49. Coats, P. and R. Wadsworth, Marriage of resistance and conduit arteries breeds 
critical limb ischemia. American Journal of Physiology-Heart and Circulatory 
Physiology, 2005. 288(3): p. H1044-H1050. 
50. Lowe, G., Pathophysiology of critical leg ischaemia, in Critical leg ischaemia. 1990, 
Springer. p. 17-38. 
51. Ten, V.S. and D.J. Pinsky, Endothelial response to hypoxia: physiologic adaptation 
and pathologic dysfunction. Current opinion in critical care, 2002. 8(3): p. 242-250. 
52. Shreeniwas, R., et al., Hypoxia-mediated induction of endothelial cell interleukin-1 
alpha. An autocrine mechanism promoting expression of leukocyte adhesion 
molecules on the vessel surface. The Journal of clinical investigation, 1992. 90(6): p. 
2333-2339. 
53. Ha, D.M., et al., Transforming growth factor-beta 1 produced by vascular smooth 
muscle cells predicts fibrosis in the gastrocnemius of patients with peripheral artery 
disease. Journal of translational medicine, 2016. 14(1): p. 39. 
54. Pipinos, I.I., et al., Mitochondrial defects and oxidative damage in patients with 
peripheral arterial disease. Free Radical Biology and Medicine, 2006. 41(2): p. 262-
269. 
55. McDermott, M.M., Lower extremity manifestations of peripheral artery disease: the 
pathophysiologic and functional implications of leg ischemia. Circulation research, 
2015. 116(9): p. 1540-1550. 
56. McDermott, M.M., et al., Leg symptoms in peripheral arterial disease: associated 
clinical characteristics and functional impairment. Jama, 2001. 286(13): p. 1599-
1606. 
 
 
 
93 
57. Varu, V.N., M.E. Hogg, and M.R. Kibbe, Critical limb ischemia. Journal of vascular 
surgery, 2010. 51(1): p. 230-241. 
58. Uccioli, L., et al., Critical limb ischemia: current challenges and future prospects. 
Vascular health and risk management, 2018. 14: p. 63. 
59. Teraa, M., et al., Critical limb ischemia: current trends and future directions. Journal 
of the American Heart Association, 2016. 5(2): p. e002938. 
60. Dabrh, A.M.A., et al., The natural history of untreated severe or critical limb 
ischemia. Journal of vascular surgery, 2015. 62(6): p. 1642-1651. e3. 
61. Sprengers, R.W., et al., Quality of life in patients with no-option critical limb 
ischemia underlines the need for new effective treatment. Journal of vascular 
surgery, 2010. 52(4): p. 843-849. e1. 
62. Jude, E.B., et al., Peripheral arterial disease in diabetic and nondiabetic patients: a 
comparison of severity and outcome. Diabetes care, 2001. 24(8): p. 1433-1437. 
63. Mozaffarian, D., et al., Heart disease and stroke statistics-2016 update a report from 
the American Heart Association. Circulation, 2016. 133(4): p. e38-e48. 
64. Belch, J.J., et al., Critical issues in peripheral arterial disease detection and 
management: a call to action. Archives of internal medicine, 2003. 163(8): p. 884-
892. 
65. Norgren, L., et al., Inter-society consensus for the management of peripheral arterial 
disease (TASC II). Journal of vascular surgery, 2007. 45(1): p. S5-S67. 
66. Iida, O., et al., Prognostic impact of revascularization in poor-risk patients with 
critical limb ischemia: the PRIORITY registry (Poor-Risk Patients With and Without 
Revascularization Therapy for Critical Limb Ischemia). JACC: Cardiovascular 
Interventions, 2017. 10(11): p. 1147-1157. 
67. Iida, O., et al., Three-year outcomes of surgical versus endovascular revascularization 
for critical limb ischemia: the SPINACH Study (Surgical Reconstruction Versus 
Peripheral Intervention in Patients With Critical Limb Ischemia). Circulation: 
Cardiovascular Interventions, 2017. 10(12): p. e005531. 
68. Adam, D., et al., Bypass versus angioplasty in severe ischaemia of the leg (BASIL): 
multicentre, randomised controlled trial. Lancet (London, England), 2005. 366(9501): 
p. 1925-1934. 
69. Jones, W.S., et al., Comparative effectiveness of endovascular and surgical 
revascularization for patients with peripheral artery disease and critical limb 
ischemia: systematic review of revascularization in critical limb ischemia. American 
heart journal, 2014. 167(4): p. 489-498. e7. 
 
 
 
94 
70. Conte, M.S., Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and 
the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. 
Journal of vascular surgery, 2010. 51(5): p. 69S-75S. 
71. Bertele, V., et al., Clinical outcome and its predictors in 1560 patients with critical leg 
ischaemia. European journal of vascular and endovascular surgery, 1999. 18(5): p. 
401-410. 
72. Lu, D., et al., Comparison of bone marrow mesenchymal stem cells with bone 
marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia 
and foot ulcer: a double-blind, randomized, controlled trial. Diabetes research and 
clinical practice, 2011. 92(1): p. 26-36. 
73. Pries, A.R., B. Reglin, and T.W. Secomb, Remodeling of blood vessels: responses of 
diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension, 
2005. 46(4): p. 725-731. 
74. Folkman, J., Tumor angiogenesis: therapeutic implications. New england journal of 
medicine, 1971. 285(21): p. 1182-1186. 
75. Caduff, J., L. Fischer, and P.H. Burri, Scanning electron microscope study of the 
developing microvasculature in the postnatal rat lung. The Anatomical Record, 1986. 
216(2): p. 154-164. 
76. Burri, P.H., R. Hlushchuk, and V. Djonov, Intussusceptive angiogenesis: its 
emergence, its characteristics, and its significance. Developmental dynamics: an 
official publication of the American Association of Anatomists, 2004. 231(3): p. 474-
488. 
77. Buschmann, I. and W. Schaper, The pathophysiology of the collateral circulation 
(arteriogenesis). The Journal of pathology, 2000. 190(3): p. 338-342. 
78. Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS 
heterodimer regulated by cellular O2 tension. Proceedings of the national academy of 
sciences, 1995. 92(12): p. 5510-5514. 
79. Schofield, C.J. and P.J. Ratcliffe, Signalling hypoxia by HIF hydroxylases. 
Biochemical and biophysical research communications, 2005. 338(1): p. 617-626. 
80. Dvorak, H.F., et al., Vascular permeability factor/vascular endothelial growth factor, 
microvascular hyperpermeability, and angiogenesis. The American journal of 
pathology, 1995. 146(5): p. 1029. 
81. Detmar, M., et al., Hypoxia regulates the expression of vascular permeability 
factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human 
skin. Journal of Investigative Dermatology, 1997. 108(3): p. 263-268. 
82. Thurston, G., et al., Angiopoietin-1 protects the adult vasculature against plasma 
leakage. Nature medicine, 2000. 6(4): p. 460. 
 
 
 
95 
83. Maisonpierre, P.C., et al., Angiopoietin-2, a natural antagonist for Tie2 that disrupts 
in vivo angiogenesis. Science, 1997. 277(5322): p. 55-60. 
84. Muramatsu, M., et al., Chymase as a Proangiogenic Factor a possible involvement of 
chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. 
Journal of Biological Chemistry, 2000. 275(8): p. 5545-5552. 
85. Poupard, N., et al., Assessment of heparanase-mediated angiogenesis using 
microvascular endothelial cells: Identification of λ-Carrageenan derivative as a potent 
anti angiogenic agent. Marine drugs, 2017. 15(5): p. 134. 
86. Rundhaug, J.E., Matrix metalloproteinases and angiogenesis. Journal of cellular and 
molecular medicine, 2005. 9(2): p. 267-285. 
87. Kalluri, R., Angiogenesis: Basement membranes: structure, assembly and role in 
tumour angiogenesis. Nature Reviews Cancer, 2003. 3(6): p. 422. 
88. Carmeliet, P., Fibroblast growth factor-1 stimulates branching and survival of 
myocardial arteries: a goal for therapeutic angiogenesis? 2000, Am Heart Assoc. 
89. Gerhardt, H., et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell 
filopodia. The Journal of cell biology, 2003. 161(6): p. 1163-1177. 
90. Blanco, R. and H. Gerhardt, VEGF and Notch in tip and stalk cell selection. Cold 
Spring Harbor perspectives in medicine, 2013. 3(1): p. a006569. 
91. Ilan, N., et al., PECAM-1 (CD31) functions as a reservoir for and a modulator of 
tyrosine-phosphorylated beta-catenin. J Cell Sci, 1999. 112(18): p. 3005-3014. 
92. Corada, M., et al., Vascular endothelial–cadherin is an important determinant of 
microvascular integrity in vivo. Proceedings of the National Academy of Sciences, 
1999. 96(17): p. 9815-9820. 
93. Lindahl, P., et al., Endothelial–perivascular cell signaling in vascular development: 
lessons from knockout mice. Current opinion in lipidology, 1998. 9(5): p. 407-411. 
94. Augustin, H.G., et al., Control of vascular morphogenesis and homeostasis through 
the angiopoietin–Tie system. Nature reviews Molecular cell biology, 2009. 10(3): p. 
165. 
95. Risau, W. and I. Flamme, Vasculogenesis. Annual review of cell and developmental 
biology, 1995. 11(1): p. 73-91. 
96. Abdulla, R.-i., G. Blew, and M. Holterman, Cardiovascular embryology. Pediatric 
cardiology, 2004. 25(3): p. 191-200. 
97. Marcelo, K.L., L.C. Goldie, and K.K. Hirschi, Regulation of endothelial cell 
differentiation and specification. Circulation research, 2013. 112(9): p. 1272-1287. 
 
 
 
96 
98. Asahara, T., et al., Isolation of putative progenitor endothelial cells for angiogenesis. 
Science, 1997. 275(5302): p. 964-966. 
99. Asahara, T., et al., Bone marrow origin of endothelial progenitor cells responsible for 
postnatal vasculogenesis in physiological and pathological neovascularization. 
Circulation research, 1999. 85(3): p. 221-228. 
100. Asahara, T., et al., VEGF contributes to postnatal neovascularization by mobilizing 
bone marrow‐derived endothelial progenitor cells. The EMBO journal, 1999. 18(14): 
p. 3964-3972. 
101. Peichev, M., et al., Expression of VEGFR-2 and AC133 by circulating human CD34+ 
cells identifies a population of functional endothelial precursors. Blood, 2000. 95(3): 
p. 952-958. 
102. Balaji, S., et al., The role of endothelial progenitor cells in postnatal vasculogenesis: 
implications for therapeutic neovascularization and wound healing. Advances in 
wound care, 2013. 2(6): p. 283-295. 
103. Yoder, M.C., et al., Redefining endothelial progenitor cells via clonal analysis and 
hematopoietic stem/progenitor cell principals. Blood, 2007. 109(5): p. 1801-1809. 
104. Helisch, A. and W. Schaper, Arteriogenesis the development and growth of collateral 
arteries. Microcirculation, 2003. 10(1): p. 83-97. 
105. Longland, C., The collateral circulation of the limb: Arris and Gale lecture delivered 
at the Royal College of Surgeons of England on 4th February, 1953. Annals of the 
Royal College of Surgeons of England, 1953. 13(3): p. 161. 
106. Schaper, W. and I. Buschmann, Arteriogenesis, the good and bad of it. 
Cardiovascular research, 1999. 43(4): p. 835-837. 
107. Schaper, W., Collateral circulation. Basic research in cardiology, 2009. 104(1): p. 5-
21. 
108. Shyy, Y.-J., et al., Fluid shear stress induces a biphasic response of human monocyte 
chemotactic protein 1 gene expression in vascular endothelium. Proceedings of the 
National Academy of Sciences, 1994. 91(11): p. 4678-4682. 
109. Scholz, D., et al., Ultrastructure and molecular histology of rabbit hind-limb collateral 
artery growth (arteriogenesis). Virchows Archiv, 2000. 436(3): p. 257-270. 
110. Hoefer, I.E., et al., Direct evidence for tumor necrosis factor-α signaling in 
arteriogenesis. Circulation, 2002. 105(14): p. 1639-1641. 
111. Conway, E.M., D. Collen, and P. Carmeliet, Molecular mechanisms of blood vessel 
growth. Cardiovascular research, 2001. 49(3): p. 507-521. 
 
 
 
97 
112. Cai, W.-J., et al., Remodeling of the adventitia during coronary arteriogenesis. 
American Journal of Physiology-Heart and Circulatory Physiology, 2003. 284(1): p. 
H31-H40. 
113. Wolf, C., et al., Vascular remodeling and altered protein expression during growth of 
coronary collateral arteries. Journal of molecular and cellular cardiology, 1998. 
30(11): p. 2291-2305. 
114. Heuslein, J.L., et al., Mechanisms of amplified arteriogenesis in collateral artery 
segments exposed to reversed flow direction. Arteriosclerosis, thrombosis, and 
vascular biology, 2015. 35(11): p. 2354-2365. 
115. Till, J.E. and E.A. McCulloch, A direct measurement of the radiation sensitivity of 
normal mouse bone marrow cells. Radiation research, 1961. 14(2): p. 213-222. 
116. Siminovitch, L., E.A. McCulloch, and J.E. Till, The distribution of colony‐forming 
cells among spleen colonies. Journal of Cellular and Comparative Physiology, 1963. 
62(3): p. 327-336. 
117. Till, J.E., E.A. McCulloch, and L. Siminovitch, A stochastic model of stem cell 
proliferation, based on the growth of spleen colony-forming cells. Proceedings of the 
National Academy of Sciences of the United States of America, 1964. 51(1): p. 29. 
118. Jagannathan-Bogdan, M. and L.I. Zon, Hematopoiesis. Development, 2013. 140(12): 
p. 2463-2467. 
119. Haar, J.L. and G.A. Ackerman, A phase and electron microscopic study of 
vasculogenesis and erythropoiesis in the yolk sac of the mouse. The Anatomical 
Record, 1971. 170(2): p. 199-223. 
120. Paik, E.J. and L.I. Zon, Hematopoietic development in the zebrafish. International 
Journal of Developmental Biology, 2010. 54(6-7): p. 1127-1137. 
121. Palis, J., et al., Development of erythroid and myeloid progenitors in the yolk sac and 
embryo proper of the mouse. Development, 1999. 126(22): p. 5073-5084. 
122. Morrison, S.J. and D.T. Scadden, The bone marrow niche for haematopoietic stem 
cells. Nature, 2014. 505(7483): p. 327. 
123. Kiel, M.J., et al., SLAM family receptors distinguish hematopoietic stem and 
progenitor cells and reveal endothelial niches for stem cells. Cell, 2005. 121(7): p. 
1109-1121. 
124. Sugiyama, T., et al., Maintenance of the hematopoietic stem cell pool by CXCL12-
CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 2006. 
25(6): p. 977-988. 
 
 
 
98 
125. Wilson, N.K., et al., Combined single-cell functional and gene expression analysis 
resolves heterogeneity within stem cell populations. Cell stem cell, 2015. 16(6): p. 
712-724. 
126. Busch, K., et al., Fundamental properties of unperturbed haematopoiesis from stem 
cells in vivo. Nature, 2015. 518(7540): p. 542. 
127. Hawkins, C., et al., Profound lymphopenia and bacteraemia. Internal medicine 
journal, 2006. 36(6): p. 385-388. 
128. Baldridge, M.T., et al., Quiescent haematopoietic stem cells are activated by IFN-γ in 
response to chronic infection. Nature, 2010. 465(7299): p. 793. 
129. Hodgson, G. and T. Bradley, Properties of haematopoietic stem cells surviving 5-
fluorouracil treatment: evidence for a pre-CFU-S cell? Nature, 1979. 281(5730): p. 
381. 
130. Visser, J., et al., Isolation of murine pluripotent hemopoietic stem cells. Journal of 
Experimental Medicine, 1984. 159(6): p. 1576-1590. 
131. Köhler, G. and C. Milstein, Continuous cultures of fused cells secreting antibody of 
predefined specificity. nature, 1975. 256(5517): p. 495. 
132. Spangrude, G.J., S. Heimfeld, and I.L. Weissman, Purification and characterization of 
mouse hematopoietic stem cells. Science, 1988. 241(4861): p. 58-62. 
133. Hess, D.A., et al., Functional characterization of highly purified human hematopoietic 
repopulating cells isolated according to aldehyde dehydrogenase activity. Blood, 
2004. 104(6): p. 1648-1655. 
134. Bhatia, M., et al., Purification of primitive human hematopoietic cells capable of 
repopulating immune-deficient mice. Proceedings of the national academy of 
Sciences, 1997. 94(10): p. 5320-5325. 
135. Aiuti, A., et al., The chemokine SDF-1 is a chemoattractant for human CD34+ 
hematopoietic progenitor cells and provides a new mechanism to explain the 
mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental 
Medicine, 1997. 185(1): p. 111-120. 
136. Civin, C.I., et al., Antigenic analysis of hematopoiesis. III. A hematopoietic 
progenitor cell surface antigen defined by a monoclonal antibody raised against KG-
1a cells. The Journal of Immunology, 1984. 133(1): p. 157-165. 
137. Murray, L., et al., Enrichment of human hematopoietic stem cell activity in the 
CD34+ Thy-1+ Lin-subpopulation from mobilized peripheral blood. Blood, 1995. 
85(2): p. 368-378. 
 
 
 
99 
138. Baum, C.M., et al., Isolation of a candidate human hematopoietic stem-cell 
population. Proceedings of the National Academy of Sciences, 1992. 89(7): p. 2804-
2808. 
139. Lansdorp, P., H. Sutherland, and C. Eaves, Selective expression of CD45 isoforms on 
functional subpopulations of CD34+ hemopoietic cells from human bone marrow. 
Journal of Experimental Medicine, 1990. 172(1): p. 363-366. 
140. Hess, D.A., et al., Selection based on CD133 and high aldehyde dehydrogenase 
activity isolates long-term reconstituting human hematopoietic stem cells. Blood, 
2006. 107(5): p. 2162-2169. 
141. Anjos-Afonso, F., et al., CD34− cells at the apex of the human hematopoietic stem 
cell hierarchy have distinctive cellular and molecular signatures. Cell stem cell, 2013. 
13(2): p. 161-174. 
142. Storms, R.W., et al., Isolation of primitive human hematopoietic progenitors on the 
basis of aldehyde dehydrogenase activity. Proceedings of the National Academy of 
Sciences, 1999. 96(16): p. 9118-9123. 
143. Black, W.J., et al., Human aldehyde dehydrogenase genes: alternatively-spliced 
transcriptional variants and their suggested nomenclature. Pharmacogenetics and 
genomics, 2009. 19(11): p. 893. 
144. Stewart, M.J., K. Malek, and D.W. Crabb, Distribution of messenger RNAs for 
aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 
5 in human tissues. Journal of investigative medicine: the official publication of the 
American Federation for Clinical Research, 1996. 44(2): p. 42-46. 
145. Marchitti, S.A., et al., Non-P450 aldehyde oxidizing enzymes: the aldehyde 
dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology, 2008. 
4(6): p. 697-720. 
146. LoPachin, R.M. and T. Gavin, Molecular mechanisms of aldehyde toxicity: a 
chemical perspective. Chemical research in toxicology, 2014. 27(7): p. 1081-1091. 
147. Faroon, O., et al., Acrolein environmental levels and potential for human exposure. 
Toxicology and Industrial Health, 2008. 24(8): p. 543-564. 
148. Abraham, K., et al., Toxicology and risk assessment of acrolein in food. Molecular 
nutrition & food research, 2011. 55(9): p. 1277-1290. 
149. Vasiliou, V., A. Pappa, and T. Estey, Role of human aldehyde dehydrogenases in 
endobiotic and xenobiotic metabolism. Drug metabolism reviews, 2004. 36(2): p. 
279-299. 
150. Croker, A.K., et al., High aldehyde dehydrogenase and expression of cancer stem cell 
markers selects for breast cancer cells with enhanced malignant and metastatic ability. 
Journal of cellular and molecular medicine, 2009. 13(8b): p. 2236-2252. 
 
 
 
100 
151. Burger, P.E., et al., High aldehyde dehydrogenase activity: a novel functional marker 
of murine prostate stem/progenitor cells. Stem Cells, 2009. 27(9): p. 2220-2228. 
152. Corti, S., et al., Identification of a primitive brain–derived neural stem cell population 
based on aldehyde dehydrogenase activity. Stem cells, 2006. 24(4): p. 975-985. 
153. Ginestier, C., et al., ALDH1 is a marker of normal and malignant human mammary 
stem cells and a predictor of poor clinical outcome. Cell stem cell, 2007. 1(5): p. 555-
567. 
154. Sladek, N.E., Aldehyde dehydrogenase-mediated cellular relative insensitivity to the 
oxazaphosphorines. Current pharmaceutical design, 1999. 5: p. 607-626. 
155. Muramoto, G.G., et al., Inhibition of aldehyde dehydrogenase expands hematopoietic 
stem cells with radioprotective capacity. Stem cells, 2010. 28(3): p. 523-534. 
156. Simandi, Z., et al., Activation of retinoic acid receptor signaling coordinates lineage 
commitment of spontaneously differentiating mouse embryonic stem cells in 
embryoid bodies. FEBS letters, 2010. 584(14): p. 3123-3130. 
157. Duester, G., F.A. Mic, and A. Molotkov, Cytosolic retinoid dehydrogenases govern 
ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific 
metabolism to retinoic acid. Chemico-biological interactions, 2003. 143: p. 201-210. 
158. Chute, J.P., et al., Inhibition of aldehyde dehydrogenase and retinoid signaling 
induces the expansion of human hematopoietic stem cells. Proceedings of the 
National Academy of Sciences, 2006. 103(31): p. 11707-11712. 
159. Kastan, M.B., et al., Direct demonstration of elevated aldehyde dehydrogenase in 
human hematopoietic progenitor cells. Blood, 1990. 75(10): p. 1947-1950. 
160. Jones, R.J., et al., Assessment of aldehyde dehydrogenase in viable cells. Blood, 
1995. 85(10): p. 2742-2746. 
161. Zhou, P., et al., Human progenitor cells with high aldehyde dehydrogenase activity 
efficiently engraft into damaged liver in a novel model. Hepatology, 2009. 49(6): p. 
1992-2000. 
162. Sondergaard, C.S., et al., Human cord blood progenitors with high aldehyde 
dehydrogenase activity improve vascular density in a model of acute myocardial 
infarction. Journal of translational medicine, 2010. 8(1): p. 24. 
163. Capoccia, B.J., et al., Revascularization of ischemic limbs after transplantation of 
human bone marrow cells with high aldehyde dehydrogenase activity. Blood, 2009. 
113(21): p. 5340-5351. 
164. Putman, D.M., et al., Expansion of umbilical cord blood aldehyde dehydrogenase 
expressing cells generates myeloid progenitor cells that stimulate limb 
revascularization. Stem cells translational medicine, 2017. 6(7): p. 1607-1619. 
 
 
 
101 
165. Putman, D.M., et al., Umbilical cord blood‐derived aldehyde dehydrogenase‐
expressing progenitor cells promote recovery from acute ischemic injury. Stem cells, 
2012. 30(10): p. 2248-2260. 
166. Gentry, T., et al., Simultaneous isolation of human BM hematopoietic, endothelial 
and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase 
activity: implications for cell therapy. Cytotherapy, 2007. 9(3): p. 259-274. 
167. Takeshita, S., et al., Therapeutic angiogenesis. A single intraarterial bolus of vascular 
endothelial growth factor augments revascularization in a rabbit ischemic hind limb 
model. The Journal of clinical investigation, 1994. 93(2): p. 662-670. 
168. Baffour, R., et al., Enhanced angiogenesis and growth of collaterals by in vivo 
administration of recombinant basic fibroblast growth factor in a rabbit model of 
acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. 
Journal of vascular surgery, 1992. 16(2): p. 181-191. 
169. Isner, J.M., et al., Arterial gene therapy for therapeutic angiogenesis in patients with 
peripheral artery disease. Circulation, 1995. 91(11): p. 2687-2692. 
170. Eppler, S.M., et al., A target‐mediated model to describe the pharmacokinetics and 
hemodynamic effects of recombinant human vascular endothelial growth factor in 
humans. Clinical Pharmacology & Therapeutics, 2002. 72(1): p. 20-32. 
171. Banai, S., et al., Angiogenic-induced enhancement of collateral blood flow to 
ischemic myocardium by vascular endothelial growth factor in dogs. Circulation, 
1994. 89(5): p. 2183-2189. 
172. Ylä-Herttuala, S. and J.F. Martin, Cardiovascular gene therapy. The Lancet, 2000. 
355(9199): p. 213-222. 
173. Gowdak, L.H.W., et al., Adenovirus-mediated VEGF121 gene transfer stimulates 
angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after 
induction of ischemia. Circulation, 2000. 102(5): p. 565-571. 
174. Tabata, H., M. Silver, and J.M. Isner, Arterial gene transfer of acidic fibroblast 
growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in 
use of naked DNA. Cardiovascular research, 1997. 35(3): p. 470-479. 
175. Taniyama, Y., et al., Therapeutic angiogenesis induced by human hepatocyte growth 
factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment 
of peripheral arterial disease. Gene therapy, 2001. 8(3): p. 181. 
176. Miao, Y.-L., et al., Clinical effectiveness of gene therapy on critical limb ischemia: a 
meta-analysis of 5 randomized controlled clinical trials. Vascular and endovascular 
surgery, 2014. 48(5-6): p. 372-377. 
 
 
 
102 
177. De Haro, J., et al., Meta-analysis of randomized, controlled clinical trials in 
angiogenesis: gene and cell therapy in peripheral arterial disease. Heart and vessels, 
2009. 24(5): p. 321-328. 
178. Kusumanto, Y., et al., Treatment with intramuscular vascular endothelial growth 
factor gene compared with placebo for patients with diabetes mellitus and critical 
limb ischemia: a double-blind randomized trial. Human gene therapy, 2006. 17(6): p. 
683-691. 
179. Rajagopalan, S., et al., Regional angiogenesis with vascular endothelial growth factor 
in peripheral arterial disease: a phase II randomized, double-blind, controlled study of 
adenoviral delivery of vascular endothelial growth factor 121 in patients with 
disabling intermittent claudication. Circulation, 2003. 108(16): p. 1933-1938. 
180. Nikol, S., et al., Therapeutic angiogenesis with intramuscular NV1FGF improves 
amputation-free survival in patients with critical limb ischemia. Molecular Therapy, 
2008. 16(5): p. 972-978. 
181. Belch, J., et al., Effect of fibroblast growth factor NV1FGF on amputation and death: 
a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. The 
Lancet, 2011. 377(9781): p. 1929-1937. 
182. Powell, R.J., et al., Safety and efficacy of patient specific intramuscular injection of 
HGF plasmid gene therapy on limb perfusion and wound healing in patients with 
ischemic lower extremity ulceration: results of the HGF-0205 trial. Journal of 
vascular surgery, 2010. 52(6): p. 1525-1530. 
183. Ylä-Herttuala, S., Vascular gene transfer. Current opinion in lipidology, 1997. 8(2): 
p. 72-76. 
184. Satija, N.K., et al., Mesenchymal stem cell‐based therapy: a new paradigm in 
regenerative medicine. Journal of cellular and molecular medicine, 2009. 13(11‐12): 
p. 4385-4402. 
185. Hirschi, K.K., D.A. Ingram, and M.C. Yoder, Assessing identity, phenotype, and fate 
of endothelial progenitor cells. Arteriosclerosis, thrombosis, and vascular biology, 
2008. 28(9): p. 1584-1595. 
186. Case, J., et al., Human CD34+ AC133+ VEGFR-2+ cells are not endothelial 
progenitor cells but distinct, primitive hematopoietic progenitors. Experimental 
hematology, 2007. 35(7): p. 1109-1118. 
187. Takahashi, T., et al., Ischemia-and cytokine-induced mobilization of bone marrow-
derived endothelial progenitor cells for neovascularization. Nature medicine, 1999. 
5(4): p. 434. 
188. Shintani, S., et al., Augmentation of postnatal neovascularization with autologous 
bone marrow transplantation. Circulation, 2001. 103(6): p. 897-903. 
 
 
 
103 
189. Tateishi-Yuyama, E., et al., Therapeutic angiogenesis for patients with limb 
ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a 
randomised controlled trial. The Lancet, 2002. 360(9331): p. 427-435. 
190. Matoba, S., et al., Long-term clinical outcome after intramuscular implantation of 
bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation 
[TACT] trial) in patients with chronic limb ischemia. American heart journal, 2008. 
156(5): p. 1010-1018. 
191. Benoit, E., et al., The role of amputation as an outcome measure in cellular therapy 
for critical limb ischemia: implications for clinical trial design. Journal of 
translational medicine, 2011. 9(1): p. 165. 
192. Li, M., et al., Autologous bone marrow mononuclear cells transplant in patients with 
critical leg ischemia: preliminary clinical results. Exp Clin Transplant, 2013. 11(5): p. 
435-439. 
193. Weem, S.P., et al., Bone marrow derived cell therapy in critical limb ischemia: a 
meta-analysis of randomized placebo controlled trials. European Journal of Vascular 
and Endovascular Surgery, 2015. 50(6): p. 775-783. 
194. Rigato, M., M. Monami, and G.P. Fadini, Autologous cell therapy for peripheral 
arterial disease: systematic review and meta-analysis of randomized, nonrandomized, 
and noncontrolled studies. Circulation research, 2017. 120(8): p. 1326-1340. 
195. Urbich, C., et al., Relevance of monocytic features for neovascularization capacity of 
circulating endothelial progenitor cells. Circulation, 2003. 108(20): p. 2511-2516. 
196. Madeddu, P., et al., Transplantation of low dose CD34+ KDR+ cells promotes 
vascular and muscular regeneration in ischemic limbs. The FASEB Journal, 2004. 
18(14): p. 1737-1739. 
197. Losordo, D.W., et al., A randomized, controlled pilot study of autologous CD34+ cell 
therapy for critical limb ischemia. Circulation: Cardiovascular Interventions, 2012. 
5(6): p. 821-830. 
198. Perin, E.C., et al., A randomized, controlled study of autologous therapy with bone 
marrow–derived aldehyde dehydrogenase bright cells in patients with critical limb 
ischemia. Catheterization and Cardiovascular Interventions, 2011. 78(7): p. 1060-
1067. 
199. Krishna, S.M., S.M. Omer, and J. Golledge, Evaluation of the clinical relevance and 
limitations of current pre-clinical models of peripheral artery disease. Clinical 
science, 2016. 130(3): p. 127-150. 
200. Hassan, H. and M. El-Sheemy, Adult bone-marrow stem cells and their potential in 
medicine. Journal of the Royal Society of Medicine, 2004. 97(10): p. 465-471. 
 
 
 
104 
201. Fadini, G.P., C. Agostini, and A. Avogaro, Autologous stem cell therapy for 
peripheral arterial disease: meta-analysis and systematic review of the literature. 
Atherosclerosis, 2010. 209(1): p. 10-17. 
202. Broxmeyer, H.E., et al., Human umbilical cord blood as a potential source of 
transplantable hematopoietic stem/progenitor cells. Proceedings of the National 
Academy of Sciences, 1989. 86(10): p. 3828-3832. 
203. Ingram, D.A., et al., Identification of a novel hierarchy of endothelial progenitor cells 
using human peripheral and umbilical cord blood. Blood, 2004. 104(9): p. 2752-2760. 
204. Roura, S., et al., Human umbilical cord blood-derived mesenchymal stem cells 
promote vascular growth in vivo. PloS one, 2012. 7(11): p. e49447. 
205. Pineault, N. and A. Abu-Khader, Advances in umbilical cord blood stem cell 
expansion and clinical translation. Experimental hematology, 2015. 43(7): p. 498-513. 
206. Cooper, T.T., et al., Inhibition of Aldehyde Dehydrogenase‐Activity Expands 
Multipotent Myeloid Progenitor Cells with Vascular Regenerative Function. Stem 
Cells, 2018. 36(5): p. 723-736. 
207. Heeschen, C., et al., Profoundly reduced neovascularization capacity of bone marrow 
mononuclear cells derived from patients with chronic ischemic heart disease. 
Circulation, 2004. 109(13): p. 1615-1622. 
208. Fadini, G.P., et al., Number and function of endothelial progenitor cells as a marker 
of severity for diabetic vasculopathy. Arteriosclerosis, thrombosis, and vascular 
biology, 2006. 26(9): p. 2140-2146. 
209. Ungerleider, J.L. and K.L. Christman, Concise review: injectable biomaterials for the 
treatment of myocardial infarction and peripheral artery disease: translational 
challenges and progress. Stem cells translational medicine, 2014. 3(9): p. 1090-1099. 
210. Christman, K.L., et al., Injectable fibrin scaffold improves cell transplant survival, 
reduces infarct expansion, and induces neovasculature formation in ischemic 
myocardium. Journal of the American College of Cardiology, 2004. 44(3): p. 654-
660. 
211. Christman, K.L., et al., Fibrin glue alone and skeletal myoblasts in a fibrin scaffold 
preserve cardiac function after myocardial infarction. Tissue engineering, 2004. 10(3-
4): p. 403-409. 
212. Wang, J., et al., A cellular delivery system fabricated with autologous BMSCs and 
collagen scaffold enhances angiogenesis and perfusion in ischemic hind limb. Journal 
of Biomedical Materials Research Part A, 2012. 100(6): p. 1438-1447. 
213. Tang, Z.C., et al., The enhancement of endothelial cell therapy for angiogenesis in 
hindlimb ischemia using hyaluronan. Biomaterials, 2011. 32(1): p. 75-86. 
 
 
 
105 
214. Ruvinov, E., J. Leor, and S. Cohen, The effects of controlled HGF delivery from an 
affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a 
hindlimb ischemia model. Biomaterials, 2010. 31(16): p. 4573-4582. 
215. Ungerleider, J., et al., Fabrication and characterization of injectable hydrogels derived 
from decellularized skeletal and cardiac muscle. Methods, 2015. 84: p. 53-59. 
216. Chen, R.R., et al., Spatio–temporal VEGF and PDGF delivery patterns blood vessel 
formation and maturation. Pharmaceutical research, 2007. 24(2): p. 258-264. 
217. Kim, J.H., et al., Stem cell recruitment and angiogenesis of neuropeptide substance P 
coupled with self-assembling peptide nanofiber in a mouse hind limb ischemia model. 
Biomaterials, 2013. 34(6): p. 1657-1668. 
218. Hynes, R.O., The extracellular matrix: not just pretty fibrils. Science, 2009. 
326(5957): p. 1216-1219. 
219. Schlie-Wolter, S., A. Ngezahayo, and B.N. Chichkov, The selective role of ECM 
components on cell adhesion, morphology, proliferation and communication in vitro. 
Experimental cell research, 2013. 319(10): p. 1553-1561. 
220. Werb, Z., ECM and cell surface proteolysis: regulating cellular ecology. Cell, 1997. 
91(4): p. 439-442. 
221. Elster, S.K. and E.L. Lowry, Collagen content of guinea pig tissues. Proceedings of 
the Society for Experimental Biology and Medicine, 1950. 75(1): p. 127-129. 
222. Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. cell, 2002. 
110(6): p. 673-687. 
223. Bonnans, C., J. Chou, and Z. Werb, Remodelling the extracellular matrix in 
development and disease. Nature reviews Molecular cell biology, 2014. 15(12): p. 
786. 
224. LeBleu, V.S., B. MacDonald, and R. Kalluri, Structure and function of basement 
membranes. Experimental biology and medicine, 2007. 232(9): p. 1121-1129. 
225. Kular, J.K., S. Basu, and R.I. Sharma, The extracellular matrix: structure, 
composition, age-related differences, tools for analysis and applications for tissue 
engineering. Journal of tissue engineering, 2014. 5: p. 2041731414557112. 
226. Sorushanova, A., et al., The collagen suprafamily: from biosynthesis to advanced 
biomaterial development. Advanced Materials, 2019. 31(1): p. 1801651. 
227. Boland, E.D., et al., Electrospinning collagen and elastin: preliminary vascular tissue 
engineering. Front Biosci, 2004. 9(2): p. 1422-1432. 
228. Schaefer, L. and R.M. Schaefer, Proteoglycans: from structural compounds to 
signaling molecules. Cell and tissue research, 2010. 339(1): p. 237. 
 
 
 
106 
229. Sottile, J., D.C. Hocking, and K.J. Langenbach, Fibronectin polymerization stimulates 
cell growth by RGD-dependent and-independent mechanisms. Journal of cell science, 
2000. 113(23): p. 4287-4299. 
230. Schultz, G.S. and A. Wysocki, Interactions between extracellular matrix and growth 
factors in wound healing. Wound repair and regeneration, 2009. 17(2): p. 153-162. 
231. Silva, E.A., et al., Material-based deployment enhances efficacy of endothelial 
progenitor cells. Proceedings of the National Academy of Sciences, 2008. 105(38): p. 
14347-14352. 
232. Hussein, K.H., et al., Biocompatibility evaluation of tissue-engineered decellularized 
scaffolds for biomedical application. Materials Science and Engineering: C, 2016. 
67: p. 766-778. 
233. Discher, D.E., P. Janmey, and Y.-l. Wang, Tissue cells feel and respond to the 
stiffness of their substrate. Science, 2005. 310(5751): p. 1139-1143. 
234. Chiu, L.L. and M. Radisic, Scaffolds with covalently immobilized VEGF and 
Angiopoietin-1 for vascularization of engineered tissues. Biomaterials, 2010. 31(2): 
p. 226-241. 
235. Laschke, M., et al., Incorporation of growth factor containing Matrigel promotes 
vascularization of porous PLGA scaffolds. Journal of Biomedical Materials Research 
Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for 
Biomaterials, and The Australian Society for Biomaterials and the Korean Society for 
Biomaterials, 2008. 85(2): p. 397-407. 
236. Crapo, P.M., T.W. Gilbert, and S.F. Badylak, An overview of tissue and whole organ 
decellularization processes. Biomaterials, 2011. 32(12): p. 3233-3243. 
237. Gilpin, A. and Y. Yang, Decellularization strategies for regenerative medicine: from 
processing techniques to applications. BioMed research international, 2017. 2017. 
238. Woods, T. and P.F. Gratzer, Effectiveness of three extraction techniques in the 
development of a decellularized bone–anterior cruciate ligament–bone graft. 
Biomaterials, 2005. 26(35): p. 7339-7349. 
239. Chen, F., J.J. Yoo, and A. Atala, Acellular collagen matrix as a possible “off the 
shelf” biomaterial for urethral repair. Urology, 1999. 54(3): p. 407-410. 
240. Dellgren, G., et al., The extended Biocor stentless aortic bioprosthesis: early clinical 
experience. Scandinavian Cardiovascular Journal, 1999. 33(5): p. 259-264. 
241. Kolker, A.R., et al., Multilayer reconstruction of abdominal wall defects with 
acellular dermal allograft (AlloDerm) and component separation. Annals of plastic 
surgery, 2005. 55(1): p. 36-42. 
 
 
 
107 
242. Oh, J.Y., et al., Processing porcine cornea for biomedical applications. Tissue 
Engineering Part C: Methods, 2009. 15(4): p. 635-645. 
243. Totonelli, G., et al., Detergent enzymatic treatment for the development of a natural 
acellular matrix for oesophageal regeneration. Pediatric surgery international, 2013. 
29(1): p. 87-95. 
244. Syedain, Z., et al., 6-Month aortic valve implantation of an off-the-shelf tissue-
engineered valve in sheep. Biomaterials, 2015. 73: p. 175-184. 
245. Funamoto, S., et al., The use of high-hydrostatic pressure treatment to decellularize 
blood vessels. Biomaterials, 2010. 31(13): p. 3590-3595. 
246. Chen, R.-N., et al., Process development of an acellular dermal matrix (ADM) for 
biomedical applications. Biomaterials, 2004. 25(13): p. 2679-2686. 
247. Borschel, G.H., R.G. Dennis, and W.M. Kuzon Jr, Contractile skeletal muscle tissue-
engineered on an acellular scaffold. Plastic and reconstructive surgery, 2004. 113(2): 
p. 595-602. 
248. Bernard, M.P., et al., Nucleotide sequences of complementary deoxyribonucleic acids 
for the pro. alpha. 1 chain of human type I procollagen. Statistical evaluation of 
structures that are conserved during evolution. Biochemistry, 1983. 22(22): p. 5213-
5223. 
249. Patience, C., Y. Takeuchi, and R.A. Weiss, Infection of human cells by an 
endogenous retrovirus of pigs. Nature medicine, 1997. 3(3): p. 282. 
250. Ahmadian, M., et al., Triacylglycerol metabolism in adipose tissue. Future lipidology, 
2007. 2(2): p. 229-237. 
251. Albright, A.L. and J.S. Stern, Adipose tissue. Encyclopedia of sports medicine and 
science, 1998. 10: p. 1998. 
252. Nishimura, S., et al., Adipogenesis in obesity requires close interplay between 
differentiating adipocytes, stromal cells, and blood vessels. Diabetes, 2007. 56(6): p. 
1517-1526. 
253. Mariman, E.C. and P. Wang, Adipocyte extracellular matrix composition, dynamics 
and role in obesity. Cellular and molecular life sciences, 2010. 67(8): p. 1277-1292. 
254. Nakajima, I., et al., Adipose tissue extracellular matrix: newly organized by 
adipocytes during differentiation. Differentiation, 1998. 63(4): p. 193-200. 
255. Kuljanin, M., et al., Collagenase treatment enhances proteomic coverage of low-
abundance proteins in decellularized matrix bioscaffolds. Biomaterials, 2017. 144: p. 
130-143. 
 
 
 
108 
256. Flynn, L., The use of decellularized adipose tissue to provide an inductive 
microenvironment for the adipogenic differentiation of human adipose-derived stem 
cells. Biomaterials, 2010. 31(17): p. 4715-4724. 
257. Brown, B.N., et al., Comparison of three methods for the derivation of a biologic 
scaffold composed of adipose tissue extracellular matrix. Tissue Engineering Part C: 
Methods, 2011. 17(4): p. 411-421. 
258. Omidi, E., et al., Characterization and assessment of hyperelastic and elastic 
properties of decellularized human adipose tissues. Journal of biomechanics, 2014. 
47(15): p. 3657-3663. 
259. Han, T.T.Y., et al., Adipose-derived stromal cells mediate in vivo adipogenesis, 
angiogenesis and inflammation in decellularized adipose tissue bioscaffolds. 
Biomaterials, 2015. 72: p. 125-137. 
260. Kim, H.-S., et al., Ex Vivo Expansion of Human Umbilical Cord Blood CD34+ Cells 
in a Collagen Bead—Containing 3-Dimensional Culture System. International 
journal of hematology, 2003. 78(2): p. 126-132. 
261. Friedemann, M., et al., Instructing human macrophage polarization by stiffness and 
glycosaminoglycan functionalization in 3D collagen networks. Advanced healthcare 
materials, 2017. 6(7): p. 1600967. 
262. Wang, H., Y. Leng, and Y. Gong, Bone marrow fat and hematopoiesis. Frontiers in 
endocrinology, 2018. 9. 
263. Laharrague, P., et al., High expression of leptin by human bone marrow adipocytes in 
primary culture. The FASEB Journal, 1998. 12(9): p. 747-752. 
264. DiMascio, L., et al., Identification of adiponectin as a novel hemopoietic stem cell 
growth factor. The Journal of Immunology, 2007. 178(6): p. 3511-3520. 
265. Poloni, A., et al., Molecular and functional characterization of human bone marrow 
adipocytes. Experimental hematology, 2013. 41(6): p. 558-566. e2. 
266. Steven, F., Nishihara Technique for the Solubilization of Collagen: Application to the 
Preparation of Soluble Collagens from Normal and Rheumatoid Connective Tissue. 
Annals of the rheumatic diseases, 1964. 23(4): p. 300. 
267. Shultz, L.D., et al., Multiple defects in innate and adaptive immunologic function in 
NOD/LtSz-scid mice. The Journal of Immunology, 1995. 154(1): p. 180-191. 
268. Niiyama, H., et al., Murine model of hindlimb ischemia. JoVE (Journal of Visualized 
Experiments), 2009(23): p. e1035. 
269. Seneviratne, A.K., et al., Expanded hematopoietic progenitor cells reselected for high 
aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells, 
2016. 34(4): p. 873-887. 
 
 
 
109 
270. Lim, W.F., et al., Hematopoietic cell differentiation from embryonic and induced 
pluripotent stem cells. Stem cell research & therapy, 2013. 4(3): p. 71. 
271. Pulford, K.A., et al., Distribution of the CD68 macrophage/myeloid associated 
antigen. International immunology, 1990. 2(10): p. 973-980. 
272. Spiller, K.L., et al., Sequential delivery of immunomodulatory cytokines to facilitate 
the M1-to-M2 transition of macrophages and enhance vascularization of bone 
scaffolds. Biomaterials, 2015. 37: p. 194-207. 
273. Yu, C., et al., Porous decellularized adipose tissue foams for soft tissue regeneration. 
Biomaterials, 2013. 34(13): p. 3290-3302. 
274. Wang, L.D. and A.J. Wagers, Dynamic niches in the origination and differentiation of 
haematopoietic stem cells. Nature reviews Molecular cell biology, 2011. 12(10): p. 
643. 
275. Choi, J.S., B.P. Mahadik, and B.A. Harley, Engineering the hematopoietic stem cell 
niche: Frontiers in biomaterial science. Biotechnology journal, 2015. 10(10): p. 1529-
1545. 
276. Leisten, I., et al., 3D co-culture of hematopoietic stem and progenitor cells and 
mesenchymal stem cells in collagen scaffolds as a model of the hematopoietic niche. 
Biomaterials, 2012. 33(6): p. 1736-1747. 
277. Singh, S., et al., Aldehyde dehydrogenases in cellular responses to 
oxidative/electrophilicstress. Free radical biology and medicine, 2013. 56: p. 89-101. 
278. Psaila, B., et al., Single-cell profiling of human megakaryocyte-erythroid progenitors 
identifies distinct megakaryocyte and erythroid differentiation pathways. Genome 
biology, 2016. 17(1): p. 83. 
279. Deutsch, V.R. and A. Tomer, Megakaryocyte development and platelet production. 
British journal of haematology, 2006. 134(5): p. 453-466. 
280. Shi, C. and E.G. Pamer, Monocyte recruitment during infection and inflammation. 
Nature reviews immunology, 2011. 11(11): p. 762. 
281. Davies, L.C., et al., Tissue-resident macrophages. Nature immunology, 2013. 14(10): 
p. 986. 
282. Geissmann, F., S. Jung, and D.R. Littman, Blood monocytes consist of two principal 
subsets with distinct migratory properties. Immunity, 2003. 19(1): p. 71-82. 
283. Passlick, B., D. Flieger, and H. Ziegler-Heitbrock, Identification and characterization 
of a novel monocyte subpopulation in human peripheral blood. Blood, 1989. 74(7): p. 
2527-2534. 
 
 
 
110 
284. Wong, K.L., et al., Gene expression profiling reveals the defining features of the 
classical, intermediate, and nonclassical human monocyte subsets. Blood, 2011. 
118(5): p. e16-e31. 
285. Wynn, T.A. and K.M. Vannella, Macrophages in tissue repair, regeneration, and 
fibrosis. Immunity, 2016. 44(3): p. 450-462. 
286. Montanari, M., et al., Correlation between differentiation plasticity and mRNA 
expression profiling of CD34+-derived CD14− and CD14+ human normal myeloid 
precursors. Cell death and differentiation, 2005. 12(12): p. 1588. 
287. Rosmarin, A.G., et al., Differential expression of CD11b/CD18 (Mo1) and 
myeloperoxidase genes during myeloid differentiation. Blood, 1989. 73(1): p. 131-
136. 
288. Ariganello, M.B., et al., Macrophage differentiation and polarization on a 
decellularized pericardial biomaterial. Biomaterials, 2011. 32(2): p. 439-449. 
289. Allavena, P., et al., IL‐10 prevents the differentiation of monocytes to dendritic cells 
but promotes their maturation to macrophages. European journal of immunology, 
1998. 28(1): p. 359-369. 
290. Spiller, K.L., et al., The role of macrophage phenotype in vascularization of tissue 
engineering scaffolds. Biomaterials, 2014. 35(15): p. 4477-4488. 
291. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage 
activation. Nature reviews immunology, 2008. 8(12): p. 958. 
292. Falini, B., et al., PG-M1: a new monoclonal antibody directed against a fixative-
resistant epitope on the macrophage-restricted form of the CD68 molecule. The 
American journal of pathology, 1993. 142(5): p. 1359. 
293. Jetten, N., et al., Anti-inflammatory M2, but not pro-inflammatory M1 macrophages 
promote angiogenesis in vivo. Angiogenesis, 2014. 17(1): p. 109-118. 
294. Zizzo, G., et al., Efficient clearance of early apoptotic cells by human macrophages 
requires M2c polarization and MerTK induction. The Journal of Immunology, 2012. 
189(7): p. 3508-3520. 
295. Ambarus, C.A., et al., Systematic validation of specific phenotypic markers for in 
vitro polarized human macrophages. Journal of immunological methods, 2012. 375(1-
2): p. 196-206. 
296. Philippidis, P., et al., Hemoglobin scavenger receptor CD163 mediates interleukin-10 
release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage 
responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass 
surgery. Circulation research, 2004. 94(1): p. 119-126. 
 
 
 
111 
297. Fabriek, B.O., et al., The macrophage scavenger receptor CD163 functions as an 
innate immune sensor for bacteria. Blood, 2009. 113(4): p. 887-892. 
298. Krieger, J., et al., Spatially localized recruitment of anti-inflammatory monocytes by 
SDF-1α-releasing hydrogels enhances microvascular network remodeling. 
Biomaterials, 2016. 77: p. 280-290. 
299. Das, A., et al., Monocyte and macrophage plasticity in tissue repair and regeneration. 
The American journal of pathology, 2015. 185(10): p. 2596-2606. 
300. Hellingman, A.A., et al., Variations in surgical procedures for hind limb ischaemia 
mouse models result in differences in collateral formation. European Journal of 
Vascular and Endovascular Surgery, 2010. 40(6): p. 796-803. 
301. Oswald, J., et al., Gene‐expression profiling of CD34+ hematopoietic cells expanded 
in a collagen I matrix. Stem Cells, 2006. 24(3): p. 494-500. 
302. Woodford-Thomas, T. and M. Thomas. The leukocyte common antigen, CD45 and 
other protein tyrosine phosphatases in hematopoietic cells. in Seminars in cell 
biology. 1993. Elsevier. 
303. Turner, A.E., et al., The performance of decellularized adipose tissue microcarriers as 
an inductive substrate for human adipose-derived stem cells. Biomaterials, 2012. 
33(18): p. 4490-4499. 
304. Higgins, D.M., et al., Localized immunosuppressive environment in the foreign body 
response to implanted biomaterials. The American journal of pathology, 2009. 
175(1): p. 161-170. 
305. Elliott, J.T., A. Tona, and A.L. Plant, Comparison of reagents for shape analysis of 
fixed cells by automated fluorescence microscopy. Cytometry Part A: The Journal of 
the International Society for Analytical Cytology, 2003. 52(2): p. 90-100. 
306. Anderson, S.B., et al., The performance of human mesenchymal stem cells 
encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials, 2011. 
32(14): p. 3564-3574. 
307. Keeney, M., et al., Single platform flow cytometric absolute CD34+ cell counts based 
on the ISHAGE guidelines. Cytometry: The Journal of the International Society for 
Analytical Cytology, 1998. 34(2): p. 61-70. 
308. Ziegler-Heitbrock, H. and R. Ulevitch, CD14: cell surface receptor and differentiation 
marker. Immunology today, 1993. 14(3): p. 121-125. 
309. Torsteinsdottir, I., et al., Enhanced expression of integrins and CD66b on peripheral 
blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect 
of glucocorticoids. Scandinavian journal of immunology, 1999. 50(4): p. 433-439. 
 
 
 
112 
310. Tao, W., et al., Comparative proteomic analysis of human CD34+ stem/progenitor 
cells and mature CD15+ myeloid cells. Stem Cells, 2004. 22(6): p. 1003-1014. 
311. Barros, M.H.M., et al., Macrophage polarisation: an immunohistochemical approach 
for identifying M1 and M2 macrophages. PloS one, 2013. 8(11): p. e80908. 
312. Sousa, S., et al., Human breast cancer cells educate macrophages toward the M2 
activation status. Breast Cancer Research, 2015. 17(1): p. 101. 
313. Sarma, N.J., A. Takeda, and N.R. Yaseen, Colony forming cell (CFC) assay for 
human hematopoietic cells. JoVE (Journal of Visualized Experiments), 2010(46): p. 
e2195. 
314. Birkenmeier, E., et al., Murine mucopolysaccharidosis type VII. Characterization of a 
mouse with beta-glucuronidase deficiency. The Journal of clinical investigation, 
1989. 83(4): p. 1258-1266. 
315. Lowerison, M.R., et al., Improved linear contrast-enhanced ultrasound imaging via 
analysis of first-order speckle statistics. IEEE transactions on ultrasonics, 
ferroelectrics, and frequency control, 2016. 63(9): p. 1409-1421. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
A 
C B 
Appendix. 1 Supplementary Figures 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Preliminary images highlighting the utility of power doppler 
ultrasound at day 35 post FAL surgery. Images were taken in collaboration with Mahsa 
Bataghva Shahbaz of Dr. James Lacefield’s lab and analyzed with a currently under-
development filtration algorithm used to reduce clutter and emphasize microvascular blood 
flow. (A) Representative images of blood flow detected using power doppler ultrasound prior 
to any post-scan filtration algorithms. (B) Vasculature detected in the non-surgical leg of mice 
following ultrasound data filtration algorithm developed by Mahsa. (C) Vasculature detected 
in the surgical leg of mice following ultrasound data filtration. Relevant vasculature signal 
highlighted by white arrows. 
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